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This dissertation is composed of five chapters and describes my Ph.D. studies aimed at the 
synthesis and biochemical evaluation of multifunction acetylcholinesterase (AChE) 
inhibitor hybrids for treatment of Alzheimer’s disease (AD). Chapter 1 serves as an 
introduction to AD and describes the scope of the disease, its pathological hallmarks, and 
current treatments. Chapter 2 describes two series of tacrine- and 6-chlorotacrine-
mefenamic acid hybrids. Several compounds that showed remarkable inhibition of AChE 
were identified from these series (Bornstein, J. J.; Eckroat, T. J.; Houghton, J. L.; Jones, 
C. K.; Green, K. D.; Garneau-Tsodikova, S. Med Chem Commun 2011, 2, 406-412.). 
Chapter 3 investigates the role of linker moieties in bifunctional tacrine hybrids through 
the synthesis of 6-chlorotacrine analogs and comparison to 6-chlortacrine-mefenamic acid 
hybrids in AChE inhibition assays (Eckroat, T. J.; Green, K. D.; Reed, R. A.; Bornstein, 
J. J.; Garneau-Tsodikova, S. Bioorg Med Chem 2013, 21, 3614-3623.). Chapter 4 describes 
the synthesis of a novel 6-chlorotacrine-metal-A modulator hybrid. In addition to strong 
inhibition of AChE and BChE under various conditions, this compound showed the ability 
to interact with metal ions involved in AD, control metal-free and metal-induced A 
aggregate assembly, and disaggregate preformed metal-free and metal-associated A 
aggregates (Kochi, A.*; Eckroat, T. J.*; Green, K. D.; Mayhoub, A. S.; Lim, M. H.; 
Garneau-Tsodikova, S. Chem Sci 2013, 4, 4137-4145. *Denotes equal contribution.). 
Chapter 5 suggests various future directions for these projects.
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Alzheimer’s disease (AD) places a significant and dramatically increasing burden on 
society. While pathological hallmarks of this neurodegenerative disorder are known, the 
exact cause remains unclear. Acetylcholinesterase inhibitors (AChEis) may help with 
cognitive symptoms, but they are incapable of reversing disease progression. The 
multifunctional hybrid approach towards new AD treatments aims to combine two 
molecules, one of which is usually an AChEi, with beneficial properties for AD into a 
single chemical entity showing enhanced properties and capable of attacking multiple 
facets of the disease. Using this approach, several such hybrids were synthesized and 
characterized biochemically.  
 
Tacrine was the first AChEi approved for the treatment of AD. Mefenamic acid is a non-
steroidal anti-inflammatory drug capable of inactivating AChE through radicals generated 
in the presence of reactive oxygen species (ROS). Various tacrine- and 6-chlorotacrine-
mefenamic acid hybrids were synthesized. Several were potent AChEis with low 
nanomolar IC50 values under standard conditions and in the presence ROS, the most potent 
being 13m (IC50 = 0.418 ± 0.025 nM, ROS IC50 = 0.009 ± 0.003 nM). Compared to tacrine, 
13m exhibited >100-fold increase in potency under standard conditions and >20,000-fold 
increase in the presence of ROS.  
 
Subsequent studies investigated the role of the linker and the need for covalent linkage of 
mefenamic acid in regards to AChE inhibition. Results suggest the mefenamic acid moiety 
in an amine-linked tacrine-mefenamic acid hybrid may not contribute to AChE inhibition 
under standard conditions, and the linker moiety alone may be responsible for the increase 
in potency. However, in the presence of ROS, there may be some advantage to amine-




Additionally, 6-chlorotacrine-metal-amyloid- modulator hybrid 19 was synthesized. 19 
displayed potent inhibition of AChE (IC50 = 2.37 ± 0.29 nM) and butyrylcholinesterase 
(IC50 = 2.01 ± 0.12 nM). Inhibition was largely retained in the presence of ROS, Cu
2+/Zn2+, 
and amyloid- (A). 19 showed remarkable multifunctionality through interaction with 
Cu2+/Zn2+, control of metal-free and metal-induced A aggregate assembly, and 
disaggregation of preformed metal-free and metal-associated A aggregates. A particularly 
promising compound, 19 represents one of the few tacrine hybrids designed to specifically 






Alzheimer’s disease (AD): background, epidemiology, pathological hallmarks, 
current treatments, and the multifunctional approach to treatment 
 
1.1. Background and epidemiology of AD 
Despite the fact that it has been over 100 years since the progressive, neurodegenerative 
disorder known as Alzheimer’s disease (AD) was first formally described in the scientific 
literature, there is still much we do not know about this devastating disease. The exact 
cause and sequence of events leading to disease onset and progression has eluded 
researchers despite the identification of numerous factors that are known to play a role. 
Current pharmacological treatments for AD may offer some relief from the well-known 
cognitive symptoms. However, research efforts to develop a drug that is able to halt or 
reverse disease progression remain ongoing. The burden that AD places on humanity, in 
terms of sheer number of people affected, is at its highest level ever and only expected to 
get worse. Clearly, research into understanding and treating the AD problem is an 
important endeavor, and this dissertation describes one approach.   
 
AD is named for the German neuropathologist and clinician, Alois Alzheimer (b. 1864 d. 
1915), who first reported on the disease.1 Alzheimer’s clinical work with dementia patient 
Auguste Deter, and subsequent post mortem examination of her brain and spinal cord 
tissues, led to his 1906 lecture in which he described his findings on the disease that now 
bears his name. Alzheimer’s initial report included a symptomatic description of cognitive 
failures, as well as descriptions and drawings of senile plaques (SPs) and neurofibrillary 
tangles (NFTs). The official eponym “Alzheimer’s disease” was first applied in a textbook 
by psychiatrist Emil Kraepelin in 1910, but research into understanding causes, symptoms, 
and treatments has only gained momentum over the last 30 years.1,2 Today, the SPs and 
2 
 
NFTs first described by Alois Alzheimer are well recognized by doctors and researchers 
as pathological hallmarks of AD and potential targets for therapeutic intervention. 
 
Over a century has passed since Alzheimer’s initial report, and the scope of the disease has 
grown immensely. Consider that, in the United States alone, AD is estimated to affect a 
total of 5.2 million Americans, 96% of which are age 65 and older. Put another way, one 
in nine people age 65 and older suffer from AD, a prevalence that jumps to one in three 
when considering the population age 85 and older. By the year 2050, it is expected that 
nearly 1 million new cases of AD will be diagnosed annually, and the total number of 
people age 65 and older suffering from AD is projected to approach 14 million.2 Globally, 
it is estimated that over 24 million people are suffering from AD.3 
 
AD represents the 6th 
leading cause of death 
across all ages in the 
United States. Based 
on preliminary data, 
the Centers for 
Disease Control and 
Prevention (CDC) 
listed AD as the 
underlying cause of 
death for 84,691 
people in 2011.4 However, many people die after being diagnosed with and experiencing 
complications from AD, but other acute conditions (e.g. pneumonia), not AD, may be listed 
as the primary cause of death. Thus, the true number of deaths caused by AD is probably 
higher than the listed value. In addition, while this number is currently still well behind the 
numbers listed for other leading causes of death such as heart disease and cancer (both well 
over 500,000 people), it will likely grow significantly as the incidence of AD increases in 
the coming decades.2,4 It should also be noted that AD showed a 68% increase in the 
number of deaths caused between the years 2000 and 2010 (Fig. 1.1). This is a dramatic 
 
Fig. 1.1. Percentage changes in selected causes of death from 2000-2010.  
Reproduced from ref. 2.  
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increase, especially when compared to the percentage changes in other selected causes of 
death such as heart disease, stroke, prostate cancer, breast cancer, and human 
immunodeficiency virus (HIV), which showed decreases ranging from 2-42%.2 
 
Age is the single biggest risk factor for developing AD, as the disease is seen primarily in 
individuals age 65 and over.2,3,5 In fact, the dramatic projected rise in the incidence of AD 
can most likely be attributed to the ever increasing age of the population. For example, the 
average life expectancy at birth for someone born in 1900 was approximately 49 years, but 
for someone born in 2008 it was approximately 78 years.6 Other risk factors for developing 
AD have been identified including cerebrovascular disease, diabetes, obesity, 
hypertension, dyslipidemia, depression, smoking, traumatic head injury, genetics, and 
family history.2,3 
 
Symptoms of AD can be divided into three primary groups: (1) cognitive failures, (2) 
psychiatric and behavioral disturbances, and (3) difficulties in performing tasks of daily 
living.2,5 Cognitive failures include things such as memory loss, language difficulties, and 
challenges in planning or solving problems. This group of symptoms, in particular the 
ability to remember new information, is usually the first to appear. The second group 
includes symptoms such as agitation, depression, and hallucinations. The third group of 
symptoms is the most severe, usually occurring in advanced stages of the disease, and 
prevents patients from being able to perform tasks such as eating, bathing, or dressing 
without assistance. It can also prevent those suffering from AD from being able to 
recognize family members or even speak. The progression from mild AD to severe AD 
varies between individual cases, but it is generally on the timescale of years.5 
 
Postmortem histopathological examination of brain tissue is currently the only way to 
firmly confirm AD.7 In view of the limited accessibility to living brain and other central 
nervous system (CNS) tissues, AD is currently diagnosed by the patient’s primary care 
physician, and the process typically involves a mental state assessment through cognitive 
tests, physical and neurological examination, examination of family, medical, and 
psychiatric history, as well as interviews with the patient and family members or other 
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close individuals.2,5,7 These diagnostic tools are problematic, especially in the early stages 
of the disease, due to the lack absolute sensitivity and accuracy. Therefore, as pathological 
hallmarks such as amyloid- (A) plaques (see section 1.2) precede the onset of dementia 
and cognitive decline in AD patients by years or even decades, their detection by nuclear 
imaging techniques such as positron emission tomography (PET) or single-photon 
emission computed tomography (SPECT) represents a promising new presymptomatic 
diagnostic tool for AD.8-12 
 
1.2. Pathological hallmarks of AD 
Billions of neurons are found in a healthy adult brain. These neurons are interconnected 
through an even greater number of synapses. Synapses are specialized junctions in which 
information flows in chemical pulses from a releasing neuron to a detecting neuron. The 
chemical flow of information is carried out by neurotransmitters (e.g. acetylcholine (ACh), 
dopamine, serotonin, glycine, opioid peptides). The interconnectivity of neurons through 
synapses and neurotransmitters is the biochemical basis of memories, emotions, thoughts, 
sensations, movements and skills. AD, through various mechanisms, leads to 
malfunctioning neurons and synapses.2 
 
In general, AD is characterized by significant neurodegeneration and neuronal atrophy in 
the brain. Several specific pathological hallmarks of AD have been identified, and they 
include decreased cholinergic neurons and ACh levels, plaques caused by aggregation of 
the Aβ peptide, NFTs associated with irregular phosphorylation of the tau protein, 
inflammation and increased oxidative stress from reactive oxygen species (ROS), and 
dyshomeostasis of metal ions such as Cu2+ and Zn2+.2,13-21 Observation of these hallmarks 
has led to several hypotheses in attempts to explain the underlying cause of the disease. 
However, the exact cause and timeframe of events leading to AD remains unknown, and it 
is likely multifactorial and involves a complex array of factors. 
   
ACh is known to play a role in learning and memory,22-24 and the reduction of activity at 
cholinergic neurons in the brains of AD patients has been known for some time.25,26 These 
facts led to the cholinergic hypothesis of AD, first proposed in 1982, in which cholinergic 
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deficit was seen as the primary cause of the disease. Although it has been met with some 
skepticism, the cholinergic hypothesis remains important in understanding AD today, and 
it has led to various treatments for AD (see section 1.3) aimed at restoring the cholinergic 
deficit.15,27-29  
 
 Two enzymes play major roles in controlling 
brain ACh levels: choline acetyltransferase 
(ChAT) and acetylcholinesterase (AChE) 
(Fig. 1.2). ChAT catalyzes the synthesis of 
ACh from choline and acetyl-CoA, and levels of ChAT can be decreased by as much as 
90% in individuals with severe AD when compared to normal.30 AChE catalyzes the 
hydrolysis of ACh to choline and acetate, and its action is important for terminating 
synaptic transmission mediated by ACh. Butyrylcholinesterase (BChE), a related enzyme, 
is capable of catalyzing the same reaction. Of note, BChE levels are known to increase in 
AD patients, which may further exacerbate the problems caused by decreased ChAT 
levels.30 Structurally, AChE is known to contain features that include a peripheral anionic 
site (PAS) near the exterior of the enzyme at the entrance of a gorge that leads to the 
catalytic active site (CAS) in the interior of the enzyme. The CAS contains the catalytic 
triad of serine, histidine, and glutamate that is responsible for the enzymatic reaction. The 
gorge leading to the CAS is about 20 Å long and lined with conserved aromatic amino acid 
residues. The PAS near the exterior of the enzyme also consists largely of aromatic 
residues, and it is thought to serve as a low affinity binding site to concentrate ACh at the 
gorge opening.31-33 Interestingly, the PAS also plays a role in promoting the aggregation of 
A peptides, another hallmark of AD.34-37 
 
A is a peptide processed from the amyloid precursor protein (APP) by -secretase and -
secretase enzymes.38 The presence and possible role A peptide aggregates in AD is well 
characterized in the literature, and the accumulation of extracellular A plaques and A 
oligomers is thought be essential for AD (the amyloid hypothesis of AD) as these 
aggregates interfere with communication between neurons and contribute to neuronal 
death, possibly through oxidative stress and mitochondrial dysfunction.2,13,39-43 The 
 
Fig. 1.2. Biochemical reactions catalyzed by 
ChAT and AChE. 
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amyloid hypothesis of AD is supported by the fact that most common genetic mutations 
leading to AD are related to A processing. Mutations in genes encoding APP and 
presenilin 1/2 (part of -secretase) are responsible for early-onset autosomal dominant AD, 
while the apolipoprotein E 4 allele is a major risk factor for late-onset AD.13,17,44,45 Metal 
ions, such as Cu2+ and Zn2+, are known to interact with A peptides, promote their 
aggregation, and increase neurotoxicity.19,21,46-51 In addition, through their interaction with 
A, these metal ions may lead to the production of ROS which, along with inflammatory 
responses, have also been implicated in the onset and progression of AD.19,52-57  
 
Although not relevant to the work presented in subsequent chapters of this dissertation, a 
brief mention of tau pathology related to AD is warranted. Tau is a protein associated with 
microtubules that interacts with the neuronal cytoskeleton to help facilitate intracellular 
signaling processes. In a hyperphosphorylated state, tau can aggregate to form intracellular 
NFTs leading to microtubule dissociation, compromised axonal transport, and diminished 
synaptic function, and there is evidence that tau may act synergistically with A to produce 
neuronal dysfunction.13,58 
 
1.3. Current treatments for AD 
Current pharmacological therapies for AD are 
largely centered on AChE inhibitors 
(AChEis), which aim to decrease the rate of 
synaptic ACh decomposition leading to 
increased cholinergic transmission and 
improved cognitive function.  Four out of the 
five drugs approved by the FDA for the 
treatment of AD (tacrine, donepezil, 
rivastigmine, and galantamine) are AChEis 
(Fig. 1.3), with the outlier being an N-methyl-D-aspartate receptor (NMDAR) antagonist 
(memantine). Although these have had moderate success, they only treat symptoms of AD, 
and, while symptomatic treatment is beneficial, it leaves much to be desired and offers little 
 
Fig. 1.3. Structures of FDA approved AD drugs. 
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hope for reducing projected cases of AD as AChEis are incapable of directly halting or 
reversing disease progression.59  
 
Tacrine was the first AChEi approved for AD in 1993 for mild to moderate AD,60 and it is 
known to be a potent inhibitor of BChE in addition to AChE. While still used widely for 
research purposes, tacrine is no longer used clinically because of poor pharmacokinetics 
that requires dosing four times a day and numerous side effects.61 The most severe side 
effect was hepatotoxicity, most likely caused by metabolism to a hydroxylated analog 
followed by additional metabolism to a reactive quinone-like compound.62,63 
 
Donepezil, which is marketed under the trade name Aricept®, is the most commonly 
prescribed AChEi for AD as it accounts for over 50% of the entire sales market of drugs 
for AD and is used in more than 75 countries and regions worldwide.64 In the United States, 
studies have shown that over 60% of patients being treated with an AChEi for AD received 
donepezil while the remainder was nearly evenly split between those receiving galantamine 
and rivastigmine.65 Donepezil was first approved by the FDA in 1996 for the treatment of 
mild to moderate AD.66 Additionally, in 2007, it was approved for severe AD making it 
the only AChEi approved for the entire clinical spectrum of the disease.67,68 Compared to 
its predecessor tacrine, donepezil shows a better pharmacological profile by exhibiting 
better oral bioavailability, longer duration of action, and fewer adverse events in patients. 
In particular, donepezil shows significantly less hepatotoxicity.62,64 Overall, despite some 
controversy, numerous clinical studies in recent years have shown that donepezil is 
effective for the treatment of AD.69-75 
 
Rivastigmine and galantamine were approved by the FDA for mild to moderate AD in 2000 
and 2001, respectively. Both show better pharmacological profiles than tacrine, similar to 
that of donepezil.61 Memantine was approved in 2003 for the treatment of moderate to 
severe AD. As an NMDAR antagonist, memantine works by partially protecting neurons 
from toxicity due to excessive glutamate release,76 and evidence shows that memantine 




1.4. Multifunctional approach for treatment of AD 
As mentioned above, current treatments for AD only address symptoms and are incapable 
of directly halting or reversing disease progression. This clearly indicates the need for new 
and improved therapeutics. In addition to offering improved treatment, the development of 
new and improved therapeutics for the treatment of AD can offer tools to aid in the 
understanding of the complex biochemical events surrounding the development and 
progression of AD. The work described in this dissertation employs a hybrid strategy 
towards the development of new therapeutics for AD relying on chemically linking a 
known AChEi with another compound capable of exerting other properties which are 
beneficial to the treatment of AD to create a bifunctional or multifunctional hybrid 
compound. This allows one hybrid to attack multiple facets of the disease at once. As 
evidenced through numerous examples in the literature, this has been a popular strategy 
over the past 15-20 years.32,80-93 
 
Although the use of tacrine has been severely limited since its inception due to 
hepatotoxicity, it is often the AChEi of choice for designing multifunctional hybrids due 
to its AChE inhibitory properties and the ease at which synthetic derivatives such as the 9-
chloro derivative,88 which is susceptible to nucleophilic substitution for generating linked 
compounds, can be generated. By linking tacrine with another compound to create a 
multifunctional hybrid, it is possible to not only increase potency towards AChE inhibition 
but to also attack the multifactorial nature of AD. For example, a heptylene-linked tacrine 
dimer was shown to be 150-fold more potent than tacrine. This large increase in potency 
was likely due to the fact that the compound was capable of simultaneously binding to the 
CAS and PAS of the enzyme.32,80 As another example, tacrine-8-hydroxyquinoline hybrids 
were shown to be potent inhibitors of AChE and antioxidants with low cell toxicity and the 
ability to complex copper ions, as well as the predicted ability to be able to disrupt AChE-
mediated Aβ aggregation. The best compound from this series showed a remarkable 700-
fold greater potency towards human AChE than tacrine.81 Other examples will be discussed 




Specifically, this dissertation describes the synthesis and biochemical evaluation of novel 
AChEi-ROS scavenger hybrid scaffolds and novel AChEi-metal-A modulator hybrid 
scaffolds. Chapter 2 describes two series of tacrine- and 6-chlorotacrine-mefenamic acid 
hybrids. Several compounds that showed remarkable inhibition of AChE were identified 
from these series. Chapter 3 investigates the role of linker moieties in bifunctional tacrine 
hybrids through the synthesis of 6-chlorotacrine analogs and comparison to 6-chlortacrine-
mefenamic acid hybrids in AChE inhibition assays. Chapter 4 describes the synthesis of a 
novel 6-chlorotacrine-metal-A modulator hybrid. In addition to strong inhibition of AChE 
and BChE under various conditions, this compound showed the ability to interact with 
metal ions involved in AD, control metal-free and metal-induced A aggregate assembly, 
and disaggregate preformed metal-free and metal-associated A aggregates. Chapter 5 
suggests various future directions for these projects.  
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Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase 
 
2.1. Abstract 
Alzheimer’s disease (AD) is a complex syndrome characterized by the degeneration of the 
brain and central nervous system that may be caused by an assortment of genetic and 
environmental factors. Consequently, a conjunctive approach targeting multiple affecters 
of AD could lead to improved drug candidates for the treatment of AD. A convergent 
chemical synthetic approach yielded a series of tacrine-mefenamic acid hybrids that were 
evaluated for their ability to inhibit acetylcholinesterase (AChE). A majority of the 
compounds tested showed low nanomolar IC50 values, an improvement over the parent 
compound, tacrine, suggesting that they could be effective in increasing cholinergic 
function. Additionally, an assay to evaluate the compounds upon exposure to reactive 
oxygen species (ROS) was performed, the results of which may suggest a role for the 
mefenamic acid moiety in the inhibition of AChE. Molecular modeling studies were 
performed to rationalize the experimental results. 
 
2.2. Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the 
atrophy of cholinergic neurons in areas of the brain vital for cognitive function, leading to 
symptoms that range from memory loss to the loss of motor abilities and eventually death. 
Pathologies associated with AD include the degeneration of brain cells due to the 
development of plaques and tangles associated with the aggregation of the protein fragment 
amyloid- (A) and the irregular phosphorylation of the Tau protein, respectively. 
Additionally, concurrent deficits in excitatory amino acid (EAA) transmission via 
acetylcholine (ACh) are observed due to substantial deficits in choline acetyltransferase 
(ChAT),1-3 the enzyme responsible for the formation of ACh in the brain. 
14 
 
One of the primary pharmacological strategies 
employed in the treatment of AD has been inhibition of 
cholinesterases (ChEs). These therapies aim to decrease 
the rate of decomposition of ACh at synapses in the 
brain thereby raising the potential for increased levels of 
EAA transmission and improved cognitive function. This strategy has proved  moderately 
successful, yielding potent reversible acetylcholinesterase inhibitors (AChEis) such as 
tacrine (1) (Fig. 2.1), donepezil, and galantamine, as well as substrate mimics such as 
neostigmine and pyridostigmine, all of which have shown benefit in the management of 
AD symptoms to varying degrees. However, despite the moderate clinical successes that 
have been observed, it has been suggested that these treatments, highlighted by clinical 
studies of donepezil, are not cost-effective and that an alternative approach may provide 
better outcomes.4,5 Nonetheless, interest in developing improved ChE inhibitors for 
treatment of AD has increased recently, likely due to the body of empirical evidence 
showing the benefits of ChE inhibitors in AD patients as well as the lack of successful 
alternative approaches. 
 
Other factors responsible for the onset and progression of AD have been identified, 
including inflammatory responses and the resultant increased oxidative stress in the form 
of free-radicals. The increase in oxidative stress related to the natural decline in an aging 
body’s defense mechanisms often precedes the onset of the previously mentioned 
indications associated with AD. There is substantial epidemiological evidence linking the 
development of AD to inflammatory processes in the brain6 as well as evidence that 
treatment with non-steroidal anti-inflammatory drugs (NSAIDs) may improve cognition 
and delay the progression of AD.7-10 Given this information, it is evident that treatment of 
only a single determinant of the pathology of AD is not an effective approach. Furthermore, 
the evidence implies that treatment of multiple determinants of the disease, especially those 
related to oxidative stress, may provide synergistic effects. 
 
One solution to this type of problem that has recently emerged is a conjunctive approach 
in which two biologically active molecules with similar or dissimilar mechanisms of action 
 
Fig. 2.1. Structures of tacrine (1) 
and mefenamic acid (2). 
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are combined into a single molecule to improve potency and/or exhibit multiple modes of 
action, resulting in a synergistic effect. Tacrine-based dimers and hybrids with improved 
pharmacological properties have been the target of a number of discovery efforts in the 
past decade, leading in several cases to compounds with desirable synergy and improved 
potency.11-15 
 
Based on the potential of reported tacrine-based molecules, we decided to take a similar 
approach in identifying compounds with the potential to serve as multi-functioning 
therapeutics. The ability of NSAIDS such as mefenamic acid (2) (Fig. 2.1) to inactivate 
enzymes, including AChE, in the presence of peroxidases and their potential for AD 
treatment has been well-characterized in the literature.9,16-18 Studies have shown that 
mefenamic acid is capable of decreasing the occurrence of free-radicals and attenuating A 
peptide-induced neurotoxicity while improving cognitive impairments.10 Additionally, it 
has been suggested that AChE may accelerate the formation of stable amyloid fibrils and 
stable A complexes.19 This role is attributed to the peripheral anionic site (PAS) as 
propidium iodide, a PAS binding molecule, has proved effective in reducing A 
aggregation while there are no similar reports implicating catalytic active site (CAS) 
inhibitors.20 The numerous desirable properties of mefenamic acid led us to believe that it 
would be an ideal scaffold to incorporate into a series of tacrine-based hybrid molecules 
aimed at both the CAS and PAS, taking advantage of tacrine’s affinity for the CAS and 
using it to guide the mefenamic acid portion of the molecules to the PAS. This type of 
strategy has been widely discussed in the literature and was recently reviewed.21 
 
Herein, we report the synthesis and evaluation of a series of tacrine- and 6-chlorotacrine-
mefenamic acid hybrid molecules aimed at combining the AChE inhibitor properties of 
tacrine with the antioxidant and AChE modulating properties of mefenamic acid into a 
single, dual-action molecule for the treatment of AD. This conjunctive medicinal chemistry 
approach led to the identification of nanomolar and sub-nanomolar inhibitors of AChE. 
 





Fig. 2.2. Synthetic schemes for the preparation of A. tacrine-containing portion of bifunctional 
molecules, B. mefenamic acid-containing portion of Series B of bifunctional compounds, C. Series 
A of tacrine- and 6-chlorotacrine-mefenamic acid bifunctional molecules, and D. Series B of tacrine- 
and 6-chlorotacrine-mefenamic acid bifunctional molecules. Reagents and conditions: (i) POCl3, Δ. 
(ii) H2N(CH2)nNH2 (3 eq), 1-pentanol, Δ. (iii) DCC (3 eq), HOBt (3 eq), DIPEA (7 eq), DMF. (iv) 1 
M NaOH (H2O), THF. (v) 2, EDAC·HCl (1.1 eq), HOBt (1.1 eq), Et3N (1.8 eq), DMF. (vi) 9a-d, 
EDAC·HCl (1.1 eq), HOBt (1.1 eq), Et3N (1.8 eq), DMF. 
 
Figure 2.2 illustrates the convergent synthetic approach to the synthesis of tacrine-based 
bifunctional inhibitors of AChE comprised of mefenamic acid (2) connected to tacrine (1) 
or 6-chlorotacrine via a hydrophobic linker moiety which in some cases (Series B) contains 
an amide functionality. This approach allows for the fine tuning of the linker region in 
order to assess the optimal spacing between the two active molecules. The starting 
compounds 9-chlorotacrine (3) and 6,9-dichlorotacrine (4) were synthesized as previously 
reported (Fig. 2.2A).22 The tacrine-containing portion of the bifunctional molecules (Series 
A and B) was prepared by an established method.23 Nucleophilic aromatic substitution of 
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various diamines at the 9-Cl position of tacrine derivatives 3 and 4 gave 5a, b, d-i and 6a, 
b, d-i in yields from 18-83% (Fig. 2.2A). The mefenamic acid-containing portion of the 
bifunctional molecules of Series B was prepared by coupling methyl esters 7a-d to 2 to 
yield 8a-d in low to moderate yield. The subsequent hydrolysis of esters 8a-d yielded 
compounds 9a-d quantitatively (Fig. 2.2B). Compound 7a was commercially available 
whereas 7b-d were prepared using stoichiometric hydrochloric acid in methanol followed 
by evaporation of the solvents to yield the HCl salts in quantitative yield. The coupling of 
5a, b, d-i and 6a, b, d-i with mefenamic acid or with 9a-d gave compounds 10a-f and 11a-
f (Series A) as well as compounds 12a-t and 13a-t (Series B), respectively (Fig. 2.2C,D). 
After purification by chromatographic techniques, the final bifunctional inhibitors were 
obtained in varying yields, 10-94%. 
 
2.3.2. Biochemical evaluation 
2.3.2.1. AChE inhibition 
In order to evaluate the potential of the bifunctional compounds as therapeutic agents for 
the symptoms of AD, their IC50 values were determined via two biochemical assays (Table 
2.1 and Fig. 2.3). The first assay, which employed the method of Ellman,24 was used to 
determine the inhibitory potential of each molecule towards AChE from Electrophorus 
electricus (EeAChE). All compounds of interest were incubated in the presence of the 
enzyme for 10 min before initiation of the enzymatic reaction with acetylcholine, allowing 
for binding of the potential inhibitors. Additionally, a ROS inhibition assay was performed 
according to the method of Muraoka and Miura to assess the potential of ROS-induced 
inactivation of AChE.16 The compounds of interest were incubated in the presence of 
horseradish peroxidase and hydrogen peroxide prior to incubation with AChE in order to 
generate radical species. It is thought that mefenamic acid radical species generated by 
peroxidases that are triggered during inflammatory responses are capable of effectively 
inactivating AChE.16 We hypothesized that by inhibiting the enzyme with tacrine while 
simultaneously using the tacrine moiety to direct the mefenamic acid radical to the vicinity 
of the AChE active site, we may see a synergistic effect evidenced by a decrease in the IC50 
value relative to that obtained without ROS. In fact, this trend was observed for most of 
the tested compounds. All ROS IC50 values were within one order of magnitude or showed 
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improvement relative to their performance using the Ellman method. Interestingly, this 
trend is opposite of that seen with the parent compound, tacrine, suggesting the mefenamic 
acid moiety is contributing to the increased potency of the molecules. 
 
An additional set of experiments were completed in which the assays were performed with 
a 1:1 equimolar ratio of mefenamic acid and tacrine in order to confirm that linking these 
two molecules was indeed beneficial. The results reported in Table 2.1 show that the best 
inhibitors did in fact outperform a 1:1 mixture, with compound 13m being over 150-fold 
and 9300-fold more potent in the EeAChE and ROS assays, respectively. These results 
confirm that linking the two molecules yields more potent inhibitors than concurrent 
exposure to the two parent compounds. 
 
Series A showed an overall better performance in the assays, consistently yielding potent 
compounds, particularly in the ROS assay. All compounds tested were in the low 
nanomolar range with several molecules that were active at picomolar concentrations, 
showing drastic improvement over tacrine (AChE IC50 = 52.4 ± 7.3 nM, ROS AChE IC50 
= 183 ± 21 nM). The data for Series A indicate that compounds with a 6-chlorotacrine 
moiety are more potent than their non-chlorinated tacrine counterparts, a trend observed in 
similar studies with tacrine hybrids.12,15,25 A linker region comprised of 8 to 10 aliphatic 
carbons between the amine and amide nitrogen atoms of the respective parent molecules 
was found to be ideal for this series as several of these compounds showed sub-nanomolar 
IC50 values, the best being compounds 11c and 11e (Table 2.1). 
 
Close examination of the data for Series B revealed several trends. The 6-chlorotacrine 
derivatives consistently outperformed their non-halogenated counterparts, similarly to 
Series A, a trend observed in a number of other studies.12,15,25 Previous studies have also 
shown that the 6-Cl moiety may cause an increase in selectivity for AChE over 
butyrylcholinesterase (BChE), thus decreasing the occurrence of unwanted side 
effects.11,12,15 An optimal length for the amide containing methylene linker between 1 and 
2 was determined to be about 10 atoms, which was determined by direct comparison after 
adding the total number of methylene units to the amide atoms (n + n’ + 2 = number of 
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atoms in linker). An optimal length for the methylene linker between tacrine and the amide 
nitrogen was determined to be n = 7 by a direct comparison of all molecules with a value 
of n = 3, 4, 5, 6, 7, and 8. Without exception, all compounds with n = 7 showed IC50 values 
below 50 nM. Following these two trends led to the most potent compound 13m (AChE 
IC50 = 0.418 ± 0.025 nM, ROS AChE IC50 = 0.009 ± 0.003 nM). This compound exhibits 
>100-fold increase in potency in the AChE assay and >20,000-fold increase in the AChE 
ROS assay compared to the parent compound, tacrine (1). 
 
In order to investigate the mode of inhibition of the tacrine-mefenamic acid hybrids, 
representative compounds from each series were selected and evaluated at constant 
inhibitor concentration and varying substrate concentrations. Surprisingly, Lineweaver-
Burk analysis of the most potent compounds suggested that those inhibitors are non-
competitive (Fig. 2.4). This is an interesting result considering what is known about 
tacrine’s competitive mode of inhibition with regards to the natural acetylcholine substrate. 
A more likely scenario than the observed non-competitive inhibition, given what is known 
of tacrine, is that mixed inhibition is observed to some degree, but the non-competitive 
aspect dominates under the given reaction conditions. The inhibition assay indicated that 
tacrine acted as a competitive inhibitor. It may not be ruled out as a possibility that tacrine 
is interacting with the CAS, disrupting the enzyme function, and in fact, analysis of a 
selection of weaker inhibitors (data not shown) indicated mixed inhibition patterns in a 
Lineweaver-Burk analysis. Studies of similar compounds, in which a class of hydrocarbon-
linked tacrine dimers were co-crystallized with AChE from Torpedo californica 
(TcAChE), suggested that the tacrine moieties may also interact via - stacking with the 
heterocyclic residues of the PAS.26 Given this crystallographic evidence, another plausible 
scenario in which the reported compounds interact with the PAS, but do not form additional 
contacts with the CAS, could explain this non-competitive pattern of inhibition. 
Interestingly, a recent study of tacrine-ferulic acid hybrids showed a similar non-
competitive inhibition profile,27 while many other hybrids’ mode of inhibition was not 
reported, but rather assigned based on docking studies. However, the exact mode of 
interaction may not be strictly defined based on the current study, and will be the target of 
future research efforts with this interesting set of compounds. 
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Table 2.1. Inhibition of EeAChE activity by tacrine-mefenamic acid hybrids. 
Compounda Series R n n’ IC50 (nM) ROS IC50 (nM) 
1     52.4 ± 7.3 183 ± 21 
2     > 1.25 mM 6120 ± 680 
1 and 2 (1:1 mix)     68.7 ± 3.8 83.9 ± 0.4 
3     > 25 M  
4     > 50M  
Neostigmine     4.6 ± 1.0  
Pyridostigmine     82.0 ± 1.5  
10a A H 6  2.24 ± 0.11 0.129 ± 0.030 
10b A H 7  1.39 ± 0.21 25.2 ± 4.5 
10c A H 8  75.5 ± 19.2 0.045 ± 0.015 
10d A H 9  1.54 ± 0.17 15.1 ± 0.2 
10e A H 10  385 ± 48 0.908 ± 0.267 
10f A H 12  50.9 ± 1.4 6.94 ± 1.42 
11a A Cl 6  7230 ± 187 1.02 ± 0.36 
11b A Cl 7  1380 ± 340 29.8 ± 4.0 
11c A Cl 8  0.495 ± 0.064 1.49 ± 0.30 
11d A Cl 9  6.94 ± 0.66 6.72 ± 0.78 
11e A Cl 10  0.776 ± 0.108 1.85 ± 0.11 
11f A Cl 12  2360 ± 830 16.2 ± 1.8 
12a B H 3 1 87.3 ± 33.6 47.5 ± 11.5 
12b B H 3 2 3800 ± 280 7.92 ± 1.96 
12c B H 3 3 3730 ± 253 23.0 ± 9.0 
12d B H 3 5 811 ± 70 20.2 ± 6.5 
12e B H 4 1 262 ± 68 53.6 ± 3.8 
12f B H 4 2 426 ± 86 2.43 ± 0.36 
12g B H 4 3 89.7 ± 11.3 14.6 ± 2.4 
12h B H 4 5 1860 ± 290 34.0 ± 9.0 
12i B H 6 1 18.3 ± 4.0 54.8 ± 4.7 
12j B H 6 2 985 ± 95 40.2 ± 8.4 
12k B H 6 3 195 ± 27 29.9 ± 11.1 
12l B H 6 5 1440 ± 197 34.0 ± 2.4 
12m B H 7 1 5.55 ± 1.21 15.3 ± 6.6 
12n B H 7 2 13.9 ± 1.4 1.02 ± 0.36 
12o B H 7 3 8.09 ± 0.91 44.6 ± 1.2 
12p B H 7 5 3.60 ± 0.16 3.66 ± 0.24 
12q B H 8 1 3.30 ± 0.75 17.2 ± 4.3 
12r B H 8 2 8.58 ± 1.42 4.07 ± 0.56 
12s B H 8 3 17.4 ± 6.2 14.6 ± 5.2 
12t B H 8 5 18.7 ± 5.0 6.26 ± 1.79 
13a B Cl 3 1 28.1 ± 5.2 3.10 ± 0.94 
13b B Cl 3 2 20.3 ± 1.4 21.3 ± 3.3 
13c B Cl 3 3 7.13 ± 0.41 1.03 ± 0.22 
13d B Cl 3 5 1.65 ± 0.33 7.85 ± 2.45 
13e B Cl 4 1 156 ± 34 89.4 ± 6.2 
13f B Cl 4 2 2470 ± 98 33.0 ± 9.3 
13g B Cl 4 3 13.6 ± 1.8 12.4 ± 1.8 
13h B Cl 4 5 37.4 ± 9.4 0.299 ± 0.067 
13i B Cl 6 1 7.65 ± 0.24 3.46 ± 0.49 
13j B Cl 6 2 1.14 ± 0.31 2.96 ± 0.41 
13k B Cl 6 3 41.7 ± 11.5 15.6 ± 1.5 
13l B Cl 6 5 2.94 ± 0.45 7.39 ± 1.51 
13m B Cl 7 1 0.418 ± 0.025 0.009 ± 0.003 
13n B Cl 7 2 6.67 ± 1.82 10.0 ± 1.6 
13o B Cl 7 3 7.91 ± 0.69 6.55 ± 1.66 
13p B Cl 7 5 11.1 ± 1.1 13.4 ± 3.9 
13q B Cl 8 1 39.8 ± 3.3 18.1 ± 3.7 
13r B Cl 8 2 18.3 ± 5.5 4.97 ± 0.26 
13s B Cl 8 3 17.0 ± 3.0 6.59 ± 0.83 
13t B Cl 8 5 80.1 ± 16.6 8.67 ± 0.73 




Fig. 2.3. Representative examples of IC50 curves (A-C) and ROS IC50 curves (D-E) for selected 
compounds from Series A (10b and 10c) and Series B (13l). 
 
2.3.2.2. Molecular modeling 
In order to elucidate the trends 
observed in the inhibition data, 
molecular modeling experiments were 
performed with a selection of the most 
potent molecules. A structure of 
TcAChE complexed with tacrine 
(PDB: 1ACJ)28 was used for the 
modeling studies. Although the 
following results remain speculative in 
the absence of crystallographic data, they do provide a basis for rationalizing the observed 
trends. Our goal was to visualize the interactions of the three sections of our inhibitors with 
their suspected regions of interaction in the TcAChE active site: the tacrine moiety, the 
linker region, and the mefenamic acid moiety with the CAS, the mid-gorge region, and the 
PAS, respectively. Modeling was performed using AutoDock. The best scoring 
conformations in terms of energetics were selected after 100 docking iterations focused 
around the active site (see experimental section for further details). Models of several 
tacrine-mefenamic acid hybrids were constructed, all of which suggested strong 
interactions between the energy minimized hybrids and the enzyme complex. A selection 
 
Fig. 2.4. Representative plot showing the non-
competitive inhibition with respect to acetylthiocholine 




of these results are depicted in Fig. 2.5. 
 
The energy-minimized complexes of all 
molecules modeled predicted that the 
tacrine portion would be situated in the 
CAS. In accordance with similar 
docking studies of tacrine containing 
molecules, the quinoline ring system is 
stacked between Trp84 and Phe330 
while the nitrogen atom of the ring is 
positioned such that it indicates the 
formation of a hydrogen bond with the 
backbone carbonyl of His440 (Fig. 
2.5A). This is consistent with previous 
docking studies that used tacrine-based 
molecules with TcAChE25,29 and 
suggests that these tacrine-mefenamic 
acid hybrids could be capable of acting 
as substrate competitive inhibitors like 
tacrine (Fig. 2.5A-C). We suspect that 
the non-competitive or mixed-mode of 
inhibition may arise from additional 
beneficial interactions that are not 
predicted by these modeling 
experiments. 
 
The methylene linker portion of both 
series spans the active-site gorge, 
allowing the tacrine and mefenamic acid 
moieties to interact with the CAS and 
PAS, respectively. There are 
 
Fig. 2.5. A selection of hybrid molecules docked in 
TcAChE showing A. the interaction of the 6-
chlorotacrine moiety of compounds 11c (yellow) and 
13m (orange) with Trp84, Phe330, and His440 in the 
CAS, B. the proximity of the mefenamic acid moiety in 
compounds 10c (yellow), 11e (blue), and 13j (magenta) 
to Tyr70 and Trp279 of the PAS, and C. the proximity 
of the mefenamic acid moiety of compounds 11c 
(yellow) and 13m (orange) to Trp279 and Tyr residues 
(70, 121, and 334) near the PAS. Oxygen, nitrogen, and 




approximately 16 Å between the two binding sites from the quinolone ring nitrogen atom,30 
and a similar distance is observed in the TcAChE structure used in this study. As 
mentioned, a linker length of approximately 10 atoms showed the strongest inhibition in 
the biochemical assays. This trend is not perfectly defined across the two series of 
inhibitors with regards to inhibition data, and the same is true of the modeling studies, 
which fail to further elucidate specific beneficial interactions. Yet, it is quite clear that a 
linker length of approximately 8-10 atoms, with or without an amide bond, would allow 
for the mefenamic acid portion to interact with the PAS if the tacrine moiety bound in the 
CAS. 
 
A great deal of variability in the orientation of the mefenamic acid moiety was observed 
in the molecules docked. Variations in the interactions of the linker section may explain 
the inconsistencies observed with the mefenamic acid moiety. One trend that is 
immediately apparent is the ability of the tacrine moiety, if bound in the CAS, to direct 
the mefenamic acid to the vicinity of the PAS (Fig. 2.5B). Mefenamic acid is thought to 
deactivate AChE through a free-radical mechanism, not through specific interaction or 
modification of the CAS.16 Our modeling studies showed that the mefenamic acid moiety 
would be in close proximity to Trp279 as well as tyrosines (Tyr70, 121, and 334) near the 
PAS (Fig. 2.5C), which may have two implications. 
 
Since IC50 values were dependent on the enzyme concentration, it was hypothesized that 
the low IC50 values observed in the ROS assay may be due to the inactivation of some 
amount of the enzyme by radicals through interaction with tyrosine or tryptophan residues 
proximal to the PAS, which provides another possible explanation for the non-competitive 
or mixed-mode of inhibition (Fig. 2.5B,C). It is known that AChE has an adhesion function, 
located at the PAS, that governs AChE’s interactions with A and is believed to induce A 
fibril formation.19,31,32 Perturbation of the PAS by a number of small molecules and 
antibodies has been shown to inhibit A fibril formation, presumably by blocking the 
interaction at the PAS.19,33 Consequently, we believe that the tacrine-mefenamic acid 
hybrids reported herein may be capable of disrupting A fibril formation and further 




Tacrine-mefenamic acid hybrid molecules were synthesized via an easily accessible, 
convergent synthetic route and evaluated as inhibitors of AChE in two biochemical assays. 
The compounds appeared to act as non-competitive or mixed-mode inhibitors with respect 
to acetylthiocholine in the instances tested, and most were capable of inducing a half-
maximal enzymatic response at low nanomolar concentrations with instances of picomolar 
IC50 values observed. One plausible explanation is that mixed inhibition is observed with 
a predominantly non-competitive mode of inhibition being observed for the most potent 
inhibitors tested. Several sub-nanomolar inhibitors were identified and selected for 
molecular modeling experiments. Taken together, the results suggest that the tacrine 
portion of the inhibitors may be capable of binding in the AChE CAS, spanning the active-
site gorge via a methylene-based linker, and positioning the mefenamic acid moiety to 
interact with the PAS. While there is some discrepancy between the modeling studies and 
analysis of the mode of inhibition, these compounds provide the framework for the 
development of novel AChE inhibitors that may be capable of alleviating the symptoms of 
AD associated with a decrease in cholinergic function and may also be capable of 
diminishing A aggregation to the extent that AChE is involved. Along with a more 
thorough investigation aimed at determining the mechanism by which AChE function is 
reduced by these inhibitors, further optimization studies aimed at improving potency and 
determining the possible secondary effects of the hybrid molecules are currently underway. 
 
2.5. Materials and instrumentation 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without 
further purification. Reactions were monitored by TLC (Merck, Silica gel 60 F254). 
Visualization was achieved using one or more of the following methods: UV absorption 
by fluorescence quenching, a cerium-molybdate stain ((NH4)2Ce(NO3)6 (5 g), 
(NH4)6Mo7O24•4H2O (120 g), H2SO4 (80 mL), H2O (720 mL)), a ninhydrin stain 
(ninhydrin (1.5 g), n-butanol (100 mL), AcOH (3 mL)), a KMnO4 stain (KMnO4 (1.5 g), 
K2CO3 (10 g), NaOH (1.25 mL 10%), H2O (200 mL)), a bromocresol green stain 
(bromocresol green (0.04 g), EtOH (100 mL, absolute), slowly drip NaOH (0.1 M) until 
the solution just turns pale blue), or Dragendorff’s reagent (solution A: BiNO3 (0.17 g) in 
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AcOH (2 mL), H2O (8 mL); solution B: KI (4 g) in AcOH (10 mL) and H2O (20 mL). 
Solutions A and B were mixed and diluted to 100 mL with H2O). Compounds were purified 
by SiO2 flash chromatography (Dynamic Adsorbents Inc., Flash Silica Gel 32-63u). 
1H 
NMR and 13C NMR spectra were recorded on Bruker AvanceTM DPX 300 or 500 or Varian 
400 MHz spectrometers. Liquid chromatography mass spectrometry (LCMS) was 
performed on a Shimadzu LCMS- 2019EV equipped with a SPD-20AV UV-Vis detector 
and a LC-20AD liquid chromatograph. IR measurements were taken by using a Perkin-
Elmer SpectrumBX FT-IR system. Analyses by UV-Vis assays were done on a multimode 
SpectraMax M5 plate reader using 96-well plates (Fisher Scientific). Molecular modeling 
was performed using AutoDock 4.2 and Cygwin 1.7. 
 
2.6. Methods 
2.6.1. Chemical methods 
2.6.1.1. General procedure for the synthesis of 9-chlorotacrine derivatives 
9-Chloro-1,2,3,4-tetrahydroacridine (3). The known compound 322 was 
prepared using the following procedure. To a mixture of anthranilic acid 
(5.00 g, 36.5 mmol, 1 eq) and cyclohexanone (4.0 mL, 38.6 mmol, 1.1 eq) at 0 °C was 
carefully added POCl3 (20 mL, 214.5 mmol, 5.9 eq). After being refluxed for 2 h, the 
reaction was cooled down to rt and concentrated under reduced pressure. The crude product 
was diluted with EtOAc (100 mL) and neutralized with a 10% aq. K2CO3 solution. The 
organic layer was washed with brine (2x100 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure. Further purification by flash column chromatography 
(SiO2; 5:1/hexane:EtOAc, Rf 0.59 (2:1/hexane:EtOAc)) gave 3 (7.30 g, 92%) as a light 
yellow powder: 1H NMR (CDCl3, 400 MHz)  8.10 (dd, 1H, J1 = 8.0 Hz, J2 = 1.6 Hz), 7.94 
(d, 1H, J = 8.8 Hz), 7.62 (ddd, 1H, J1 = 8.8 Hz, J2 = 7.2 Hz, J3 = 1.6 Hz), 7.48 (ddd, 1H, J1 
= 8.0 Hz, J2 = 7.2 Hz, J3 = 1.2 Hz), 3.08 (t, 2H, J = 6.8 Hz), 2.95 (t, 2H, J = 6.8 Hz), 1.91 
(m, 4H); 13C NMR (CDCl3, 100 MHz)  159.4, 146.5, 141.5, 129.2, 128.8,  128.5,  126.5,  





6,9-Dichloro-1,2,3,4-tetrahydroacridine (4). The known compound 422 
was prepared as described for the synthesis of 3. Reaction of 2-amino-4-
chlorobenzoic acid (5.00 g, 29.2 mmol, 1 eq), cyclohexanone (3.02 mL, 29.2 mmol, 1 eq), 
and POCl3 (20 mL, 215 mmol, 5.9 eq) yielded, after purification by flash column 
chromatography (SiO2; 5:1/hexane:EtOAc, Rf 0.76 (2:1/hexane:EtOAc)), 4 (6.62 g, 90%) 
as a light yellow powder: 1H NMR (CDCl3, 300 MHz)  8.08 (d, 1H, J = 9.0 Hz), 7.97 (d, 
1H, J = 2.0 Hz), 7.47 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz), 3.11 (t, 2H, J = 6.4 Hz), 3.00 (t, 
2H, J = 6.4 Hz), 1.96 (m, 4H); 13C NMR (CDCl3, 75 MHz)  160.9, 147.0, 141.4, 135.2, 
129.2, 127.6, 127.4, 125.2, 123.9, 34.2, 27.5, 22.5; m/z calcd for C13H11Cl2N: 252.14; found 
253.95 [M+H]+. 
 
2.6.1.2. General procedure for attachment of amine linkers to tacrine and 6-
chlorotacrine 
N1-(1,2,3,4-Tetrahydroacridin-9-yl)propane-1,3-diamine (5a). 9-
Chloro-1,2,3,4-tetrahydroacridine (3) (0.4 g, 1.84 mmol, 1 eq), 1,3-
diaminopropane (0.7 mL, 8.38 mmol, 3.65 eq) and 1-pentanol (3 mL) 
were combined and heated to reflux for 48 h. The reaction was cooled to rt, diluted with 
CH2Cl2 (50 mL), and washed with 10% aq. KOH (2x50 mL), H2O (2x50 mL), and brine 
(50 mL). The organic layer was dried (MgSO4), filtered, and concentrated in vacuo to 
afford the crude product, which was purified by flash column chromatography (SiO2; 
7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.05) to afford 5a (310 mg, 66%) 
as a yellow oil: 1H NMR (CDCl3, 300 MHz)  8.04 (dd, 1H, J1 = 8.6 Hz, J2 = 0.8 Hz), 7.98 
(d, 1H, J = 8.4 Hz), 7.56 (m, 1H), 7.33 (m, 1H), 3.68 (t, 2H, J = 6.5 Hz), 3.07 (m, 2H), 2.93 
(t, 2H, J = 6.3 Hz), 2.70 (m, 2H), 2.34 (br s, 2H), 1.90 (m, 4H), 1.82 (p, 2H, J = 6.4 Hz), 
1.45 (br s, 1H); 13C NMR (CDCl3, 125 MHz)  158.4, 151.0, 147.4, 128.6, 128.3, 123.5, 
122.9, 120.2, 115.9, 48.1, 40.5, 34.4, 34.0, 25.1, 23.1, 22.8; m/z calcd for C16H21N3: 255.17; 
found 256.00 [M+H]+. 
 
N1-(1,2,3,4-Tetrahydroacridin-9-yl)butane-1,4-diamine (5b). 
Compound 5b was prepared as described for the synthesis of 5a. The 
reaction of 9-chloro-1,2,3,4-tetrahydroacridine (3) (0.5 g, 2.30 mmol, 
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1 eq), 1,4-diaminobutane (0.803 mL, 8.00 mmol, 3.48 eq), and 1-pentanol (3.5 mL) 
yielded, after purification by flash column chromatography (SiO2; 7:3/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.05), 5b (345 mg, 56%) as a yellow solid: 
1H NMR 
(CDCl3, 300 MHz)  7.75 (t, 2H, J = 8.4 Hz), 7.35 (t, 1H, J = 7.6 Hz), 7.13 (t, 1H, J = 7.6 
Hz), 3.89 (br s, 1H), 3.25 (t, 2H, J = 7.1 Hz), 2.87 (t, 2H, J = 6.0 Hz), 2.49 (m, 4H), 1.70 
(m, 4H), 1.45 (p, 2H, J = 7.4 Hz), 1.28 (p, 2H, J = 7.4 Hz), 1.08 (br s, 2H); 13C NMR 
(CDCl3, 75 MHz)  158.3, 150.5, 147.4, 128.7, 128.0, 123.3, 122.8, 120.1, 115.8, 49.1, 




Compound 5d was prepared as described for the synthesis of 5a. 
The reaction of 9-chloro-1,2,3,4-tetrahydroacridine (3) (0.84 g, 
2.30 mmol, 1 eq), 1,6-diaminohexane (2.31 mL, 15.9 mmol, 4.2 eq), and 1-pentanol (5 mL) 
yielded, after purification by flash column chromatography (SiO2; 7:3/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.10), 5d (452 mg, 56%) as a yellow solid: 
1H NMR 
(CDCl3, 300 MHz)  7.90 (d, 1H, J = 8.5 Hz), 7.85 (d, 1H, J = 8.6 Hz), 7.49 (t, 1H, J = 7.6 
Hz), 7.28 (t, 1H, J = 7.6 Hz), 3.89 (br s, 1H), 3.41 (t, 2H, J = 7.1 Hz), 3.01 (m, 2H), 2.61 
(m, 4H), 1.85 (m, 4H), 1.59 (m, 4H), 1.35 (m, 6H); 13C NMR (CDCl3, 75 MHz)  158.4, 
150.7, 147.5, 128.8, 128.2, 123.5, 122.8, 120.2, 115.9, 49.4, 42.0, 34.1, 33.5, 31.7, 26.8, 




Compound 5e was prepared as described for the synthesis of 5a. 
The reaction of 9-chloro-1,2,3,4-tetrahydroacridine (3) (250 mg, 
1.15 mmol, 1 eq), 1,7-diaminoheptane (449 mg, 3.45 mmol, 3 eq), and 1-pentanol (3 mL) 
yielded, after purification by flash column chromatography (SiO2; 7:3/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.13), 5e (144 mg, 40%) as a yellow oil: 
1H NMR (CDCl3, 
500 MHz)  7.91 (d, 1H, J = 8.5 Hz), 7.86 (d, 1H, J = 8.5 Hz), 7.50 (t, 1H, J = 7.4 Hz), 
7.29 (t, 1H, J = 7.7 Hz), 3.93 (br s, 1H), 3.41 (t, 2H, J = 7.2 Hz), 3.01 (m, 2H), 2.65 (br s, 
4H), 2.48 (br s, 2H), 1.86 (m, 4H), 1.59 (p, 2H, J = 7.0 Hz), 1.40 (br p, 2H), 1.32 (br p, 
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2H), 1.27 (m, 4H); 13C NMR (CDCl3, 125 MHz) , 150.7, 147.5, 128.7, 128.2, 123.5, 
122.9, 120.2, 115.8, 49.4, 41.9, 34.0, 33.1, 31.7, 29.2, 26.9, 26.7, 24.8, 23.0, 22.8; m/z calcd 




Compound 5f was prepared as described for the synthesis of 5a. 
The reaction of 9-chloro-1,2,3,4-tetrahydroacridine (3) (250 
mg, 1.15 mmol, 1 eq), 1,8-diaminooctane (498 mg, 3.45 mmol, 3 eq), and 1-pentanol (3 
mL) yielded, after purification by flash column chromatography (SiO2; 7:3/CH2Cl2:MeOH 
with NH4OH (7 mL/L of solvent), Rf 0.10), 5f (208 mg, 56%) as a yellow oil: 
1H NMR 
(CDCl3, 500 MHz)  7.92 (d, 1H, J = 8.5 Hz), 7.87 (d, 1H, J = 8.4 Hz), 7.51 (t, 1H, J = 7.1 
Hz), 7.30 (t, 1H, J = 7.3 Hz), 3.91 (br s, 1H), 3.41 (t, 2H, J = 6.9 Hz), 3.02 (m, 2H), 2.67 
(m, 4H), 1.87 (m, 4H), 1.58 (p, 2H, J = 7.1 Hz), 1.44 (br p, 2H), 1.31 (br p, 2H), 1.25 (br 
s, 6H); 13C NMR (CDCl3, 125 MHz) , 150.7, 147.5, 128.8, 128.2, 123.5, 122.8, 
120.2, 115.8, 49.4, 41.6, 34.1, 31.7, 29.3, 26.9, 26.8, 24.8, 23.1, 22.8; m/z calcd for 




(5g). Compound 5g was prepared as described for the 
synthesis of 5a. The reaction of 9-chloro-1,2,3,4-
tetrahydroacridine (3) (250 mg, 1.15 mmol, 1 eq), 1,9-diaminononane (546 mg, 3.45 mmol, 
3 eq), and 1-pentanol (3 mL) yielded, after purification by flash column chromatography 
(SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.08), 5g (276 mg, 71%) 
as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.85 (d, 1H, J = 8.5 Hz), 7.80 (d, 1H, J = 
8.4 Hz), 7.42 (t, 1H, J = 7.3 Hz), 7.21 (t, 1H, J = 7.4 Hz), 3.91 (br s, 1H), 3.76 (br s, 1H) 
3.34 (m, 2H) 2.94 (m, 2H), 2.61 (t, 2H, J = 7.0 Hz), 2.56 (m, 2H), 1.77 (br s, 4H), 1.50 (p, 
2H, J = 7.1 Hz), 1.38 (br p, 2H), 1.23 (br p, 2H), 1.15 (br s, 8H); 13C NMR (CDCl3, 125 
MHz) , 150.8, 147.3, 128.4, 128.2, 123.4, 122.9, 120.1, 115.6, 49.3, 41.5, 33.9, 
32.2, 31.6, 29.4, 29.22, 29.19, 26.79, 26.75, 24.7, 23.0, 22.7; m/z calcd for C22H33N3: 





diamine (5h). Compound 5h was prepared as described for 
the synthesis of 5a. The reaction of 9-chloro-1,2,3,4-
tetrahydroacridine (3) (250 mg, 1.15 mmol, 1 eq), 1,10-diaminodecane (595 mg, 3.45 
mmol, 3 eq), and 1-pentanol (3 mL) yielded, after purification by flash column 
chromatography (SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.09), 5h 
(143 mg, 35%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.92 (d, 1H, J = 8.5 Hz), 
7.87 (d, 1H, J = 8.5 Hz), 7.51 (t, 1H, J = 7.4 Hz), 7.30 (t, 1H, J = 7.6 Hz), 3.92 (br s, 1H), 
3.43 (t, 2H, J = 7.1 Hz) 3.02 (m, 2H), 2.64 (m, 4H), 1.87 (m, 4H), 1.80 (very br s, 2H), 
1.60 (p, 2H, J = 7.4 Hz), 1.39 (br p, 2H), 1.33 (m, 2H), 1.24 (br s, 10H); 13C NMR (CDCl3, 
125 MHz) , 150.7, 147.5, 128.8, 128.2, 123.5, 122.9, 120.2, 115.8, 49.5 , 42.1, 34.1, 
33.5, 31.8, 29.49, 29.46, 29.43, 29.3, 26.91, 26.85, 24.8, 23.1, 22.8; m/z calcd for C23H35N3: 
353.28; found 354.15 [M+H]+. 
 
N1-(1,2,3,4-Tetrahydroacridin-9-yl)dodecane-1,12-
diamine (5i). Compound 5i was prepared as described 
for the synthesis of 5a. The reaction of 9-chloro-1,2,3,4-
tetrahydroacridine (3) (250 mg, 1.15 mmol, 1 eq), 1,12-diaminododecane (691 mg, 3.45 
mmol, 3 eq), and 1-pentanol (3 mL) yielded, after purification by flash column 
chromatography (SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.11), 5i 
(313 mg, 71%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.96 (d, 1H, J = 8.5 Hz), 
7.90 (d, 1H, J = 8.5 Hz), 7.54 (t, 1H, J = 7.6 Hz), 7.34 (t, 1H, J = 7.6 Hz), 3.96 (br s, 1H), 
3.47 (t, 2H, J = 6.8 Hz) 3.06 (m, 2H), 2.71 (m, 2H), 2.67 (t, 2H, J = 7.1 Hz), 1.92 (m, 4H), 
1.65 (p, 2H, J = 7.0 Hz), 1.39 (m, 4H), 1.26 (m, 16H); 13C NMR (CDCl3, 125 MHz) 
, 150.8, 147.5, 128.8, 128.2, 123.5, 122.9, 120.2, 115.8, 49.6, 42.3, 34.1, 33.8, 31.8, 
29.6, 29.56 , 29.53, 29.50, 29.41, 29.37, 26.94, 26.90, 24.8, 23.1, 22.8; m/z calcd for 




diamine (6a). Compound 6a was prepared as described for the 
synthesis of 5a. The reaction of 6,9-dichloro-1,2,3,4-
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tetrahydroacridine (4) (756 mg, 3 mmol, 1 eq), 1,3-diaminopropane (1.00 mL, 12 mmol, 4 
eq), and 1-pentanol (6 mL) yielded, after purification by flash column chromatography 
(SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.13), 6a (703 mg, 81%) 
as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.96 (d, 1H, J = 9.1 Hz), 7.90 (d, 1H, J = 
1.9 Hz), 7.27 (dd, 1H, J1 = 9.1 Hz, J2 = 1.9 Hz), 5.03 (br s, 1H), 3.65 (t, 2H, J = 6.4 Hz), 
3.04 (br s, 2H), 2.94 (t, 2H, J = 6.4 Hz), 2.70 (br s, 2H), 1.92 (br s, 4H), 1.82 (p, 2H, J = 
6.4 Hz), 1.58 (br s, 2H); 13C NMR (CDCl3, 125 MHz)  159.5, 151.1, 148.2, 133.9, 127.5, 
124.7, 124.1, 118.3, 115.7, 48.5, 40.6, 34.0, 25.0, 23.0, 22.7; m/z calcd for C16H20ClN3: 
289.13; found 289.95 [M+H]+. 
 
N1-(6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)butane-1,4-
diamine (6b). Compound 6b was prepared as described for the 
synthesis of 5a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (756 mg, 3 mmol, 1 eq), 1,4-diaminobutane (1.21 mL, 12 mmol, 4 
eq), and 1-pentanol (6 mL) yielded, after purification by flash column chromatography 
(SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.13), 6b (758 mg, 83%) 
as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.89 (d, 1H, J = 9.1 Hz), 7.87 (d, 1H, J = 
1.5 Hz), 7.26 (dd, 1H, J1 = 9.1 Hz, J2 = 1.5 Hz), 4.07 (br s, 1H), 3.49 (t, 2H, J = 7.1 Hz), 
3.02 (br s, 2H), 2.75 (t, 2H, J = 6.9 Hz), 2.67 (br s, 2H), 1.91 (bt t, 4H), 1.71 (p, 2H, J = 
7.5 Hz), 1.55 (p, 2H, J = 7.3 Hz), 1.49 (br s, 2H); 13C NMR (CDCl3, 125 MHz)  159.6, 
150.7, 148.2, 133.9, 127.6, 124.6, 124.2, 118.5, 115.9, 49.5, 41.8, 34.1, 30.9, 29.2, 24.7, 




diamine (6d). Compound 6d was prepared as described for the 
synthesis of 5a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (756 mg, 3 mmol, 1 eq), 1,6-diaminohexane (1.74 mL, 12 mmol, 4 
eq), and 1-pentanol (6 mL) yielded, after purification by flash column chromatography 
(SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.13), 6d (830 mg, 83%) 
as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.89 (d, 1H, J = 9.1 Hz), 7.87 (d, 1H, J = 
1.5 Hz), 7.26 (dd, 1H, J1 = 9.1 Hz, J2 = 1.5 Hz), 3.98 (br s, 1H), 3.47 (t, 2H, J = 7.0 Hz), 
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3.02 (br s, 2H), 2.69 (t, 2H, J = 7.0 Hz), 2.65 (br s, 2H), 2.23 (br s, 2H), 1.91 (br t, 4H), 
1.65 (p, 2H, J = 7.0 Hz), 1.46 (p, 2H, J = 7.3 Hz), 1.37 (m, 4H); 13C NMR (CDCl3, 125 
MHz)  159.5, 150.8, 148.1, 133.9, 127.5, 124.6, 124.2, 118.4, 115.7, 49.5, 41.9, 34.0, 




diamine (6e). Compound 6e was prepared as described for the 
synthesis of 5a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (250 mg, 0.99 mmol, 1 eq), 1,7-diaminoheptane (388 mg, 2.98 
mmol, 3 eq), and 1-pentanol (3 mL) yielded, after purification by flash column 
chromatography (SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.11), 6e 
(61 mg, 18%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.86 (d, 1H, J = 9.3 Hz), 7.85 
(s, 1H), 7.22 (dd, 1H, J1 = 9.0 Hz, J2 = 1.4 Hz), 3.93 (br s, 1H), 3.43 (m, 2H), 2.99 (br s, 
2H), 2.64 (m, 4H), 1.88 (m, 4H), 1.62 (p, 2H, J = 7.0 Hz), 1.50 (br s, 2H), 1.38 (m, 4H), 
1.29 (m, 4H); 13C NMR (CDCl3, 125 MHz)  159.5, 150.7, 148.2, 133.8, 127.6, 124.6, 
124.1, 118.4, 115.7, 49.6, 42.1, 34.1, 33.6, 31.7, 29.2, 26.87, 26.77, 24.6, 22.9, 22.7; m/z 




diamine (6f). Compound 6f was prepared as described for 
the synthesis of 5a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (250 mg, 0.99 mmol, 1 eq), 1,8-diaminooctane (429 mg, 2.98 mmol, 
3 eq), and 1-pentanol (3 mL) yielded, after purification by flash column chromatography 
(SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.13), 6f (232 mg, 65%) 
as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.86 (d, 1H, J = 9.4 Hz), 7.85 (s, 1H), 7.23 
(dd, 1H, J1 = 9.0 Hz, J2 = 1.9 Hz), 3.93 (br s, 1H), 3.44 (m, 2H), 2.99 (br t, 2H), 2.64 (m, 
4H), 1.88 (m, 4H), 1.71 (br s, 2H), 1.61 (p, 2H, J = 7.1 Hz), 1.40 (br p, 2H), 1.33 (br p, 
2H), 1.27 (br s, 6H); 13C NMR (CDCl3, 125 MHz)  159.5, 150.8, 148.2, 133.8, 127.6, 
124.6, 124.1, 118.4, 115.7, 49.6, 42.1, 34.1, 33.5, 31.8, 29.33, 29.28, 26.82, 26.75, 24.5, 






1,9-diamine (6g). Compound 6g was prepared as 
described for the synthesis of 5a. The reaction of 6,9-
dichloro-1,2,3,4-tetrahydroacridine (4) (250 mg, 0.99 mmol, 1 eq), 1,9-diaminononane 
(471 mg, 2.98 mmol, 3 eq), and 1-pentanol (3 mL) yielded, after purification by flash 
column chromatography (SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.15), 6g (237 mg, 64%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.84 (d, 1H, J = 
9.1 Hz), 7.83 (s, 1H), 7.20 (dd, 1H, J1 = 9.5 Hz, J2 = 2.0 Hz), 3.91 (br s, 1H), 3.41 (br t, 
2H), 2.97 (br s, 2H), 2.64 (t, 2H, J = 7.1 Hz), 2.60 (br s, 2H), 1.86 (m, 4H), 1.78 (very br 
s, 2H), 1.59 (p, 2H, J = 7.0 Hz), 1.39 (br p, 2H), 1.31 (br p, 2H), 1.24 (br s, 8H); 13C NMR 
(CDCl3, 125 MHz)  159.5, 150.7, 148.2, 133.8, 127.6, 124.6, 124.0, 118.4, 115.6, 49.6, 
42.1, 34.1, 33.4, 31.7, 29.4, 29.3, 29.2, 26.85, 26.81, 24.5, 22.9, 22.7; m/z calcd for 




1,10-diamine (6h). Compound 6h was prepared as 
described for the synthesis of 5a. The reaction of 6,9-
dichloro-1,2,3,4-tetrahydroacridine (4) (250 mg, 0.99 mmol, 1 eq), 1,10-diaminodecane 
(513 mg, 2.98 mmol, 3 eq), and 1-pentanol (3 mL) yielded, after purification by flash 
column chromatography (SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.15), 6h (190 mg, 49%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  7.81 (d, 1H, J = 
7.0 Hz), 7.80 (s, 1H), 7.17 (dd, 1H, J = 9.0 Hz, J2 = 2.1 Hz), 3.89 (br t, 1H), 3.39 (q, 2H, J 
= 6.7 Hz), 2.95 (br s, 2H), 2.60 (m, 4H), 1.83 (m, 4H), 1.56 (p, 2H, J = 7.1 Hz), 1.36 (br p, 
4H), 1.30 (br p, 2H), 1.21 (m, 10H); 13C NMR (CDCl3, 125 MHz)  159.5, 150.7, 148.2, 
133.7, 127.6, 124.6, 124.0, 118.3, 115.6, 49.5, 42.2, 34.1, 33.7, 31.7, 29.45, 29.41, 29.3, 




yl)dodecane-1,12-diamine (6i). Compound 6i was 
prepared as described for the synthesis of 5a. The 
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reaction of 6,9-dichloro-1,2,3,4-tetrahydroacridine (4) (250 mg, 0.99 mmol, 1 eq), 1,12-
diaminododecane (596 mg, 2.98 mmol, 3 eq), and 1-pentanol (3 mL) yielded, after 
purification by flash column chromatography (SiO2; 7:3/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent), Rf 0.15), 6i (207 mg, 50%) as a yellow oil: 
1H NMR (CDCl3, 500 MHz) 
 7.80 (d, 1H, J = 6.9 Hz), 7.79 (d, 1H, J = 1.8 Hz), 7.16 (dd, 1H, J1 = 9.1 Hz, J2 = 1.8 Hz), 
3.88 (br t, 1H), 3.37 (br q, 2H), 2.94 (br s, 2H), 2.62 (t, 2H, J = 7.1 Hz), 2.56 (br s, 2H), 
1.82 (m, 4H), 1.55 (p, 2H, J = 7.1 Hz), 1.36 (br p, 2H), 1.28 (br p, 2H), 1.18 (m, 16H); 13C 
NMR (CDCl3, 125 MHz)  159.4, 150.7, 148.2, 133.7, 127.6, 124.6, 123.9, 118.3, 115.6, 
49.5, 42.0, 34.1, 33.4, 31.7, 29.57, 29.52, 29.48, 29.46, 29.45, 29.3, 26.8, 24.5, 22.9, 22.6; 
m/z calcd for C25H38ClN3: 415.28; found 416.10 [M+H]
+. 
 
2.6.1.3. General procedure for esterification for the preparation of mefenamic acid 
linkers 
3-Methoxy-3-oxopropan-1-aminium chloride (7b). -Alanine (3.00 g, 
33.7 mmol, 1 eq) was dissolved in MeOH (60 mL). HCl (3.05 mL of 12.1 
M, 37.1 mmol, 1.1 eq) was added dropwise. The reaction mixture was stirred for 18 h at rt 
before being concentrated under reduced pressure. The residue was redissolved in MeOH 
(50 mL) and concentrated under reduced pressure to yield 7b (4.66 g, 99%) as a white 
powder: 1H NMR (DMSO-d6, 300 MHz)  8.29 (s, 3H), 3.62 (s, 3H), 2.98 (t, 2H, J = 4.3 
Hz), 2.73 (t, 2H, J = 4.3 Hz); 13C NMR (DMSO-d6, 75 MHz)  171.2, 52.2, 35.0, 31.7; IR 
(CD3OD cast):  3033 (NH3
+), 1740 (C=O), 1597, 1570, 1526, 1424, 1349, 1228 (C-O), 
1007, 797 cm-1. 
 
4-Methoxy-4-oxobutan-1-aminium chloride (7c). Compound 7c was 
prepared as described for the synthesis of 7b. Reaction of -aminobutyric 
acid (3.48 g, 33.7 mmol, 1 eq) and HCl (3.05 mL of 12 M, 37.1 mmol, 1.1 eq) yielded 7c 
(5.12 g, 99%) as a white powder: 1H NMR (DMSO-d6, 500 MHz)  8.26 (s, 3H), 3.59 (s, 
3H), 2.77 (m, 2H), 2.43 (t, 2H, J = 7.5 Hz), 1.82 (p, 2H, J = 7.5 Hz); 13C NMR (DMSO-
d6, 75 MHz)  173.1, 51.9, 38.4, 30.6, 22.8; IR (CD3OD cast):  2956 (NH3
+), 1733 (C=O), 




6-Methoxy-6-oxohexan-1-aminium chloride (7d). Compound 7d 
was prepared as described for the synthesis of 7b. Reaction of 6-
aminocaproic acid (3.50 g, 26.7 mmol, 1 eq) and HCl (2.3 mL of 12.1 M, 27.8 mmol, 1.04 
eq) yielded 7d (4.80 g, 99%) as a white powder: 1H NMR (DMSO-d6, 300 MHz)  8.07 
(s, 3H), 3.59 (s, 3H), 2.72 (m, 2H), 2.30 (t, 2H, J = 7.3 Hz), 1.54 (m, 4H), 1.30 (m, 2H); 
13C NMR (CDCl3, 75 MHz)  173.9, 51.6, 39.7, 33.6, 27.2, 25.9, 24.2; IR (CD3OD cast): 
 2950 (NH3
+), 1732 (C=O), 1623, 1582, 1516, 1426, 1315, 1253, 1196 (C-O), 1155, 978 
cm-1. 
 
2.6.1.4. General procedure for attachment of linkers to mefenamic acid 
Methyl 2-(2-((2,3-dimethylphenyl)amino)benzamido)acetate 
(8a). Under anhydrous conditions, mefenamic acid (1.09 g, 4.5 
mmol, 1 eq) and DCC (2.79 g, 13.5 mmol, 3 eq) were dissolved in 
DMF (45 mL). HOBt hydrate (1.82 g, 13.5 mmol, 3 eq) and DIPEA (5.49 mL, 31.5 mmol, 
7 eq) were added, followed by glycine methyl ester hydrochloride (7a) (1.70 g, 13.5 mmol, 
3 eq). The reaction progress was monitored by TLC for product formation 
(1:1/hexane:EtOAc, Rf 0.57). After stirring for 72 h at rt, the reaction mixture was diluted 
in EtOAc (150 mL). The organic mixture was successively washed with H2O (90 mL) and 
brine (100 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. Further 
purification by flash column chromatography (SiO2; 3:1/hexane:EtOAc, Rf 0.24) gave 8a 
(793 mg, 56%) as an orange oil: 1H NMR (CDCl3, 500 MHz)  9.18 (s, 1H), 7.53 (d, 1H, 
J = 7.9 Hz), 7.25 (t, 1H, J = 7.8 Hz), 7.18 (d, 1H, J = 7.9 Hz), 7.10 (t, 1H, J = 7.7 Hz), 6.99 
(d, 1H, J = 7.4 Hz), 6.91 (d, 1H, J = 8.5 Hz), 6.73 (t, 1H, J = 7.5 Hz), 6.71 (br s, 1H), 4.26 
(d, 2H, J = 5.0 Hz), 3.84 (s, 3H), 2.35 (s, 3H), 2.21 (s, 3H); 13C NMR (CDCl3, 75 MHz)  
170.6, 169.6, 147.5, 139.3, 138.1, 132.7, 131.2, 127.7, 125.9, 125.8, 121.4, 116.7, 115.6, 





Compound 8b was prepared as described for the synthesis of 8a. 
The reaction of mefenamic acid (967 mg, 4.0 mmol, 1 eq), DCC (2.48 g, 12.0 mmol, 3 eq), 
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DMF (40 mL), HOBt hydrate (1.62 g, 12.0 mmol, 3 eq), DIPEA (4.88 mL, 28.0 mmol, 7 
eq) and 7b (1.67 g, 12.0 mmol, 3 eq) was monitored by TLC for product formation 
(1:1/hexane:EtOAc, Rf 0.73). Purification by flash column chromatography (SiO2; 
3:1/hexane:EtOAc, Rf 0.35) gave 8b (338 mg, 26%) as a yellow oil: 
1H NMR (CDCl3, 300 
MHz)  9.32 (s, 1H), 7.46 (d, 1H, J = 7.9 Hz), 7.24 (m, 2H), 7.11 (t, 1H, J = 7.7 Hz), 7.01 
(s, 1H), 6.99 (d, 1H, J = 7.6 Hz), 6.96 (d, 1H, J = 8.5 Hz),  6.70 (t, 1H, J = 7.5 Hz), 3.75 
(m, 5H), 2.69 (t, 2H, J = 6.0 Hz), 2.38 (s, 3H), 2.25 (s, 3H); 13C NMR (CDCl3, 125 MHz) 
 173.3, 169.6, 147.2, 139.5, 138.1, 132.4, 130.9, 127.5, 125.8, 125.6, 120.9, 116.8, 116.5, 





Compound 8c was prepared as described for the synthesis of 8a. 
The reaction of mefenamic acid (725 mg, 3 mmol, 1 eq), DCC (1.86 g, 9 mmol, 3 eq), 
DMF (30 mL), HOBt hydrate (1.22 g, 9 mmol, 3 eq), DIPEA (3.66 mL, 21 mmol, 7 eq) 
and 7c (1.37 g, 9 mmol, 3 eq) was monitored by TLC for product formation 
(1:1/hexane:EtOAc, Rf 0.69). Purification by flash column chromatography (SiO2; 
3:1/hexane:EtOAc, Rf 0.30) gave 8c (362 mg, 36%) as a yellow oil: 
1H NMR (DMSO-d6, 
300 MHz)  9.62 (s, 1H), 8.58 (t, 1H, J = 4.9 Hz), 7.66 (d, 1H, J = 7.9 Hz), 7.22 (t, 1H, J 
= 7.9 Hz), 7.09 (d, 1H, J = 7.9 Hz), 7.04 (m, 1H), 6.89 (d, 1H, J = 7.4 Hz), 6.86 (d, 1H, J 
= 8.7 Hz), 6.72 (t, 1H, J = 7.4 Hz), 3.58 (s, 3H), 3.30 (q, 2H, J = 5.9 Hz), 2.38 (t, 2H, J = 
7.3 Hz), 2.25 (s, 3H), 2.10 (s, 3H), 1.81 (p, 2H, J = 7.0 Hz); 13C NMR (DMSO-d6, 75 
MHz)  173.6, 169.6, 146.6, 139.7, 138.1, 132.3, 129.7, 129.1, 126.2, 125.4, 120.0, 117.5, 





Compound 8d was prepared as described for the synthesis 
of 8a. The reaction of mefenamic acid (725 mg, 3 mmol, 1 eq), DCC (1.86 g, 9 mmol, 3 
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eq), DMF (30 mL), HOBt hydrate (1.22 g, 9 mmol, 3 eq), DIPEA (3.66 mL, 21 mmol, 7 
eq), and 7d (1.63 g, 9 mmol, 3 eq) was monitored by TLC for product formation 
(1:1/hexane:EtOAc, Rf 0.73). Purification by flash column chromatography (SiO2; 
3:1/hexane:EtOAc, Rf 0.35) gave 8d (389 mg, 35%) as an orange oil: 
1H NMR (DMSO-
d6, 300 MHz)  9.61 (s, 1H), 8.54 (t, 1H, J = 5.4 Hz), 7.64 (d, 1H, J = 7.9 Hz), 7.22 (t, 1H, 
J = 7.8 Hz), 7.09 (d, 1H, J = 7.9 Hz), 7.04 (t, 1H, J = 7.7 Hz), 6.89 (d, 1H, J = 7.2 Hz), 6.86 
(d, 1H, J = 8.4 Hz), 6.72 (t, 1H, J = 7.5 Hz), 3.57 (s, 3H), 3.25 (q, 2H, J = 6.5 Hz), 2.29 (t, 
2H, J = 7.5 Hz), 2.26 (s, 3H), 2.10 (s, 3H), 1.54 (m, 4H), 1.31 (m, 2H); 13C NMR (DMSO-
d6, 75 MHz)  173.8, 169.4, 146.5, 139.8, 138.1, 132.2, 129.6, 129.0, 126.2, 125.4, 119.9, 
117.8, 117.2, 114.4, 51.6, 39.2, 33.7, 29.2, 26.4, 24.7, 20.7, 13.9; m/z calcd for C22H28N2O3: 
368.21; found 369.05 [M+H]+. 
 
2.6.1.5. General procedure for ester hydrolysis of mefenamic acid linkers 
2-(2-((2,3-Dimethylphenyl)amino)benzamido)acetic acid (9a). 1 
M NaOH (70 mL) was added to 8a (793 mg, 2.4 mmol) dissolved 
in THF (30 mL). After stirring for 48 h at 40 °C, the reaction mixture 
was cooled to 0 °C and acidified to pH 1-2 using 1 M HCl. The product was extracted from 
the reaction mixture using EtOAc (2x200 mL), dried (MgSO4), and concentrated under 
reduced pressure to yield 9a (759 mg, 99%) as a pale yellow powder: 1H NMR (CDCl3, 
300 MHz)  9.12 (br s, 1H), 7.51 (d, 1H, J = 7.8 Hz), 7.25 (t, 1H, J = 7.8 Hz), 7.17 (d, 1H, 
J = 7.8 Hz), 7.10 (t, 1H, J = 7.6 Hz), 6.99 (d, 1H, J = 7.4 Hz), 6.90 (d, 1H, J = 8.5 Hz), 
6.73 (m, 2H), 4.29 (d, 2H, J = 3.0 Hz), 2.34 (s, 3H), 2.20 (s, 3H); 13C NMR (CDCl3, 75 
MHz)  174.0, 170.0, 147.6, 139.2, 138.1, 132.9, 131.3, 127.7, 126.0, 125.8, 121.5, 116.8, 




(9b). Compound 9b was prepared as described for the synthesis 
of 9a. The reaction of 8b (338 mg, 1.04 mmol, 1 eq) in THF (30 
mL) with 1 M NaOH (70 mL) yielded 9b (323 mg, 99%) as a pink powder: 1H NMR 
(CDCl3, 300 MHz)  9.16 (s, 1H), 7.42 (dd, 1H, J1 = 7.8 Hz, J2 = 1.2 Hz), 7.23 (m, 2H), 
7.10 (t, 1H, J = 7.6 Hz), 6.98 (d, 1H, J = 7.4 Hz), 6.94 (d, 1H, J = 8.4 Hz), 6.90 (m, 1H), 
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6.70 (t, 1H, J = 7.3 Hz), 3.73 (q, 2H, J = 5.9 Hz), 2.74 (t, 2H, J = 5.8 Hz), 2.35 (s, 3H), 
2.22 (s, 3H); 13C NMR (CDCl3, 75 MHz)  177.0, 169.8, 147.3, 139.4, 138.1, 132.5, 130.9, 
127.4, 125.8, 125.7, 121.0, 116.8, 116.3, 114.9, 34.9, 33.7, 20.7, 13.9; m/z calcd for 




(9c). Compound 9c was prepared as described for the synthesis 
of 9a. The reaction of 8c (360 mg, 1.06 mmol, 1 eq) in THF (30 
mL) with 1 M NaOH (70 mL) yielded 9c (346 mg, 99%) as a pink powder: 1H NMR 
(CDCl3, 300 MHz)  9.19 (s, 1H), 7.41 (d, 1H, J = 6.8 Hz), 7.23 (td, 1H, J1 = 7.2 Hz, J2 = 
1.2 Hz), 7.17 (d, 1H, J = 7.7 Hz), 7.08 (t, 1H, J = 7.7 Hz), 6.97 (d, 1H, J = 7.5 Hz), 6.93 
(d, 1H, J = 8.5 Hz), 6.70 (t, 1H, J = 7.5 Hz), 6.49 (br t, 1H), 3.54 (q, 2H, J = 6.5 Hz), 2.52 
(t, 2H, J = 6.9 Hz), 2.34 (s, 3H), 2.20 (s, 3H), 2.00 (p, 2H, J = 6.8 Hz); 13C NMR (CDCl3, 
75 MHz)  177.5, 170.1, 147.2, 139.4, 138.1, 132.4, 130.9, 127.3, 125.8, 125.7, 121.0, 




acid (9d). Compound 9d was prepared as described for the 
synthesis of 9a. The reaction of 8d (382 mg, 1.04 mmol, 1 
eq) in THF (30 mL) with 1 M NaOH (70 mL) yielded 9d (368 mg, 99%) as a pink powder: 
1H NMR (CDCl3, 300 MHz)  9.16 (s, 1H), 7.41 (d, 1H, J = 7.8 Hz), 7.23 (d, 1H, J = 7.3 
Hz), 7.19 (t, 1H, J = 8.4 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.95 (d, 1H, J = 7.1 Hz), 6.94 (d, 1H, 
J = 8.5 Hz), 6.70 (t, 1H, J = 7.5 Hz), 6.28 (br t, 1H), 3.45 (q, 2H, J = 6.6 Hz), 2.38 (t, 2H, 
J = 7.4 Hz), 2.34 (s, 3H), 2.21 (s, 3H), 1.68 (m, 4H), 1.46 (m, 2H); 13C NMR (CDCl3, 75 
MHz)  179.3, 169.8, 147.0, 139.5, 138.1, 132.2, 130.8, 127.3, 125.7, 125.5, 120.7, 117.1, 
116.8, 114.9, 39.6, 33.9, 29.3, 26.4, 24.3, 20.7, 13.9; m/z calcd for C21H26N2O3: 354.19; 
found 354.95 [M+H]+. 
 






(10a). Under anhydrous conditions, EDAC 
hydrochloride (40 mg, 0.209 mmol, 1.1 eq) and HOBt hydrate (32 mg, 0.209 mmol, 1.1 
eq) were added to mefenamic acid (2) (46 mg, 0.190 mmol, 1 eq) in DMF (3 mL). After 3 
min, 5d (57 mg, 0.190 mmol, 1 eq) dissolved in DMF (1 mL) was added to the reaction 
mixture. After 5 min, Et3N (47 L, 0.342 mmol, 1.8 eq) was added and the reaction mixture 
was stirred for 72 h at rt before dilution with CH2Cl2 (100 mL). The organic mixture was 
successively washed with 1 M HCl (80 mL), 1 M NaOH (90 mL), H2O (100 mL), and brine 
(100 mL), dried (MgSO4), filtered, and concentrated under reduced pressure. Further 
purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent), Rf 0.29) gave 10a (97 mg, 74%) as a pale yellow powder: 
1H NMR 
(CDCl3, 500 MHz) 9.20 (s, 1H), 7.97 (d, 1H, J = 8.5 Hz), 7.93 (d, 1H, J = 8.5 Hz), 7.57 
(t, 1H, J = 7.4 Hz), 7.40 (d, 1H, J = 7.6 Hz), 7.36 (t, 1H, J = 7.6 Hz), 7.22 (t, 1H, J = 7.8 
Hz), 7.18 (d, 1H, J = 7.9 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.96 (m, 2H), 6.70 (t, 1H, J = 7.4 
Hz), 6.22 (br t, 1H), 3.99 (very br s, 1H), 3.51 (t, 2H, J = 7.2 Hz), 3.44 (q, 2H, J = 6.7 Hz), 
3.08 (br t, 2H), 2.73 (br t, 2H), 2.34 (s, 3H), 2.22 (s, 3H), 1.94 (m, 4H), 1.70 (p, 2H, J = 
7.0 Hz), 1.65 (p, 2H, J = 6.9 Hz), 1.46 (m, 4H); 13C NMR (CDCl3, 125 MHz)  169.7, 
158.5, 150.7, 147.5, 147.0, 139.6, 138.1, 132.2, 130.8, 128.8, 128.3, 127.2, 125.7, 125.6, 
123.7, 122.8, 120.8, 120.3, 117.1, 116.8, 116.0, 114.9, 49.4, 39.6, 34.1, 31.7, 29.6, 26.7, 





(10b). Compound 10b was prepared as described for the 
synthesis of 10a. The reaction of mefenamic acid (2) (57 
mg, 0.235 mmol, 1 eq), EDAC hydrochloride (50 mg, 
0.259 mmol, 1.1 eq), HOBt hydrate (40 mg, 0.259 mmol, 1.1 eq), 5e (88 mg, 0.282 mmol, 
1.2 eq), and Et3N (59 L, 0.423 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification 
by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of 
solvent), Rf 0.32), 10b (44 mg, 40%) as a pale yellow solid: 
1H NMR (CDCl3, 500 MHz) 
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9.22 (s, 1H), 7.97 (d, 1H, J = 8.5 Hz), 7.92 (d, 1H, J = 8.4 Hz), 7.56 (t, 1H, J = 7.0 Hz), 
7.42 (d, 1H, J = 7.9 Hz), 7.35 (t, 1H, J = 7.2 Hz), 7.21 (t, 1H, J = 7.2 Hz), 7.18 (d, 1H, J = 
7.9 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.95 (d, 2H, J = 7.8 Hz), 6.69 (t, 1H, J = 7.2 Hz), 6.35 (br 
t, 1H), 3.98 (very br s, 1H), 3.49 (t, 2H, J = 7.2 Hz), 3.42 (q, 2H, J = 7.0 Hz), 3.07 (br t, 
2H), 2.72 (br t, 2H), 2.33 (s, 3H), 2.22 (s, 3H), 1.93 (m, 4H), 1.67 (p, 2H, J = 6.3 Hz), 1.60 
(p, 2H, J = 6.3 Hz), 1.39 (br s, 6H); 13C NMR (CDCl3, 125 MHz)  169.7, 158.5, 150.8, 
147.5, 147.0, 139.6, 138.0, 132.1, 130.7, 128.7, 128.3, 127.3, 125.7, 125.5, 123.6, 122.9, 
120.7, 120.3, 117.2, 116.7, 115.9, 114.9, 49.4, 39.7, 34.1, 31.7, 29.6, 29.0, 26.9, 26.8, 24.8, 





(10c). Compound 10c was prepared as described for 
the synthesis of 10a. The reaction of mefenamic acid (2) (43 mg, 0.177 mmol, 1 eq), EDAC 
hydrochloride (37 mg, 0.194 mmol, 1.1 eq), HOBt hydrate (30 mg, 0.194 mmol, 1.1 eq), 
5f (69 mg, 0.212 mmol, 1.2 eq), and Et3N (44 L, 0.318 mmol, 1.8 eq) in DMF (3 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.42), 10c (17 mg, 17%) as a pale yellow oil: 
1H NMR 
(CDCl3, 500 MHz) 9.21 (s, 1H), 8.00 (d, 2H, J = 8.6 Hz), 7.59 (t, 1H, J = 7.7 Hz), 7.43 
(d, 1H, J = 7.3 Hz), 7.38 (t, 1H, J = 7.7 Hz), 7.22 (t, 1H, J = 7.8 Hz), 7.18 (d, 1H, J = 7.9 
Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.96 (d, 2H, J = 8.1 Hz), 6.70 (t, 1H, J = 7.4 Hz), 6.26 (br t, 
1H), 4.21 (very br s, 1H), 3.56 (t, 2H, J = 7.1 Hz), 3.43 (q, 2H, J = 6.8 Hz), 3.12 (br t, 2H), 
2.71 (br t, 2H), 2.34 (s, 3H), 2.22 (s, 3H), 1.94 (m, 4H, J = 3.1 Hz), 1.70 (p, 2H, J = 7.1 
Hz), 1.62 (p, 2H, J = 6.7 Hz), 1.37 (m, 8H); 13C NMR (CDCl3, 125 MHz)  169.7, 157.5, 
151.5, 147.0, 146.3, 139.6, 138.1, 132.1, 130.7, 128.9, 127.6, 127.3, 125.7, 125.5, 123.8, 
123.1, 120.7, 119.6, 117.2, 116.8, 115.1, 114.9, 49.4, 39.8, 33.2, 31.7, 29.6, 29.2, 29.1, 







(10d). Compound 10d was prepared as described for 
the synthesis of 10a. The reaction of mefenamic acid 
(2) (45 mg, 0.185 mmol, 1 eq), EDAC hydrochloride 
(39 mg, 0.204 mmol, 1.1 eq), HOBt hydrate (31 mg, 0.204 mmol, 1.1 eq), 5g (76 mg, 0.222 
mmol, 1.2 eq), and Et3N (46 L, 0.333 mmol, 1.8 eq) in DMF (4 mL) yielded, after 
purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent), Rf 0.37), 10d (39 mg, 37%) as an orange solid: 
1H NMR (CDCl3, 500 
MHz) 9.22 (s, 1H), 7.98 (d, 1H, J = 8.5 Hz), 7.93 (d, 1H, J = 8.4 Hz), 7.57 (t, 1H, J = 7.1 
Hz), 7.43 (d, 1H, J = 7.8 Hz), 7.36 (t, 1H, J = 7.3 Hz), 7.22 (t, 1H, J = 7.3 Hz), 7.18 (d, 1H, 
J = 7.9 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.95 (d, 2H, J = 8.0 Hz), 6.70 (t, 1H, J = 7.4 Hz), 6.30 
(br t, 1H), 4.00 (very br s, 1H), 3.51 (t, 2H, J = 7.2 Hz), 3.43 (q, 2H, J = 7.0 Hz), 3.09 (br 
s, 2H), 2.73 (br s, 2H), 2.34 (s, 3H), 2.22 (s, 3H), 1.94 (br s, 4H), 1.67 (p, 2H, J = 7.2 Hz), 
1.62 (p, 2H, J = 7.4 Hz), 1.39 (m, 4H), 1.32 (br s, 6H); 13C NMR (CDCl3, 125 MHz)  
169.7, 158.3, 150.9, 147.4, 147.0, 139.6, 138.0, 132.1, 130.7, 128.6, 128.4, 127.3, 125.7, 
125.5, 123.6, 122.9, 120.7, 120.2, 117.3, 116.7, 115.7, 114.9, 49.5, 39.8, 34.0, 31.8, 29.6, 
29.4, 29.24, 29.16, 26.94, 26.86, 24.8, 23.1, 22.8, 20.7, 13.9; m/z calcd for C37H46N4O: 




yl)amino)decyl)benzamide (10e). Compound 
10e was prepared as described for the synthesis of 10a. The reaction of mefenamic acid (2) 
(35 mg, 0.146 mmol, 1 eq), EDAC hydrochloride (31 mg, 0.160 mmol, 1.1 eq), HOBt 
hydrate (24 mg, 0.160 mmol, 1.1 eq), 5h (62 mg, 0.175 mmol, 1.2 eq), and Et3N (37 L, 
0..263 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.42), 10e 
(10 mg, 12%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz) 9.21 (s, 1H), 8.00 (d, 1H, 
J = 8.7 Hz), 7.98 (d, 1H, J = 11.5 Hz), 7.59 (t, 1H, J = 7.3 Hz), 7.42 (d, 1H, J = 7.8 Hz), 
7.38 (t, 1H, J = 7.5 Hz), 7.22 (t, 1H, J = 7.6 Hz), 7.19 (d, 1H, J = 8.0 Hz), 7.08 (t, 1H, J = 
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7.6 Hz), 6.96 (d, 2H, J = 8.2 Hz), 6.70 (t, 1H, J = 7.4 Hz), 6.23 (br t, 1H), 4.11 (br s, 1H), 
3.55 (t, 2H, J = 7.0 Hz), 3.44 (q, 2H, J = 6.8 Hz), 3.11 (br s, 2H), 2.72 (br s, 2H), 2.34 (s, 
3H), 2.22 (s, 3H), 1.95 (m, 4H), 1.69 (p, 2H, J = 7.1 Hz), 1.63 (p, 2H, J = 7.3 Hz), 1.40 (m, 
4H), 1.31 (m, 8H); 13C NMR (CDCl3, 125 MHz)  169.7, 157.9, 151.3, 147.0, 146.7, 139.6, 
138.1, 132.1, 130.7, 128.7, 128.1, 127.3, 125.7, 125.5, 123.7, 123.0, 120.7, 119.8, 117.3, 
116.7, 115.3, 114.9, 49.5, 39.8, 33.5, 31.8, 29.6, 29.41, 29.38, 29.28, 29.24, 27.0, 26.9, 






Compound 10f was prepared as described for the synthesis of 10a. The reaction of 
mefenamic acid (2) (57 mg, 0.236 mmol, 1 eq), EDAC hydrochloride (50 mg, 0.259 mmol, 
1.1 eq), HOBt hydrate (40 mg, 0.259 mmol, 1.1 eq), 5i (108 mg, 0.283 mmol, 1.2 eq), and 
Et3N (59 L, 0.425 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash 
column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.38), 10f (27 mg, 19%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz) 9.21 (s, 
1H), 7.99 (d, 1H, J = 8.5 Hz), 7.93 (d, 1H, J = 8.5 Hz), 7.57 (t, 1H, J = 7.3 Hz), 7.41 (d, 
1H, J = 7.8 Hz), 7.36 (t, 1H, J = 7.5 Hz), 7.22 (t, 1H, J = 7.7 Hz), 7.19 (d, 1H, J = 8.0 Hz), 
7.08 (t, 1H, J = 7.7 Hz), 6.95 (d, 2H, J = 8.8 Hz), 6.70 (t, 1H, J = 7.6 Hz), 6.27 (br t, 1H), 
4.00 (very br s, 1H), 3.51 (t, 2H, J = 7.2 Hz), 3.44 (q, 2H, J = 6.8 Hz), 3.09 (br s, 2H), 2.73 
(br s, 2H), 2.34 (s, 3H), 2.23 (s, 3H), 1.94 (m, 4H), 1.68 (p, 2H, J = 7.4 Hz), 1.63 (p, 2H, J 
= 7.3 Hz), 1.40 (m, 4H), 1.29 (m, 12H); 13C NMR (CDCl3, 125 MHz)  169.7, 158.4, 150.9, 
147.4, 147.0, 139.6, 138.0, 132.1, 130.8, 128.6, 128.3, 127.3, 125.7, 125.5, 123.6, 122.9, 
120.7, 120.2, 117.3, 116.7, 115.7, 114.9, 49.6, 39.9, 34.0, 31.8, 29.72, 29.67, 29.52, 29.51, 
29.49, 29.4, 29.3, 27.0, 26.9, 24.8, 23.1, 22.8, 20.7, 13.9; m/z calcd for C40H52N4O: 604.41; 







Compound 11a was prepared as described for the synthesis of 10a. The reaction of 
mefenamic acid (2) (57 mg, 0.238 mmol, 1 eq), EDAC hydrochloride (41 mg, 0.262 mmol, 
1.1 eq), HOBt hydrate (35 mg, 0.262 mmol, 1.1 eq), 6d (95 mg, 0.285 mmol, 1.2 eq), and 
Et3N (60 L, 0.428 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash 
column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.48), 11a (97 mg, 74%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.21 (br 
s, 1H), 7.90 (d, 1H, J = 8.6 Hz), 7.89 (s, 1H), 7.40 (d, 1H, J = 7.9 Hz), 7.26 (d, 1H, J = 9.6 
Hz), 7.21 (t, 1H, J = 7.4 Hz), 7.17 (d, 1H, J = 8.0 Hz), 7.07 (t, 1H, J = 7.7 Hz), 6.95 (d, 2H, 
J = 8.2 Hz), 6.67 (t, 1H, J = 7.5 Hz), 6.40 (br t, 1H), 3.99 (br s, 1H), 3.48 (br t, 2H), 3.43 
(q, 2H, J = 6.7 Hz), 3.03 (br s, 2H), 2.66 (br s, 2H), 2.33 (s, 3H), 2.21 (s, 3H), 1.91 (br s, 
4H), 1.65 (m, 4H), 1.44 (m, 4H); 13C NMR (CDCl3, 125 MHz)  169.8, 159.6, 150.8, 148.2, 
147.0, 139.6, 138.1, 133.9, 132.2, 130.7, 127.6, 127.3, 125.7, 125.5, 124.6, 124.2, 120.6, 
118.4, 117.2, 116.8, 115.8, 114.9, 49.5, 39.6, 34.1, 31.7, 29.6, 26.7, 26.6, 24.6, 22.9, 22.7, 






Compound 11b was prepared as described for the 
synthesis of 10a. The reaction of mefenamic acid (2) 
(30 mg, 0.123 mmol, 1 eq), EDAC hydrochloride (26 mg, 0.136 mmol, 1.1 eq), HOBt 
hydrate (21 mg, 0.136 mmol, 1.1 eq), 6e (57 mg, 0.148 mmol, 1.2 eq), and Et3N (31 L, 
0.222 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.50), 11b 
(29 mg, 41%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz) 9.20 (s, 1H), 7.91 (d, 1H, 
J = 7.1 Hz), 7.90 (d, 1H, J = 1.9 Hz), 7.41 (d, 1H, J = 7.8 Hz), 7.28 (dd, 1H, J1 = 8.9 Hz, 
J2 = 1.9 Hz), 7.22 (t, 1H, J = 7.6 Hz), 7.18 (d, 1H, J = 7.6 Hz), 7.08 (t, 1H, J = 7.6 Hz), 
6.95 (d, 2H, J = 8.2 Hz), 6.70 (t, 1H, J = 7.5 Hz), 6.27 (br t, 1H), 3.98 (br s, 1H), 3.49 (t, 
2H, J = 7.4 Hz), 3.43 (q, 2H, J = 6.8 Hz), 3.04 (br s, 2H), 2.68 (br s, 2H), 2.33 (s, 3H), 2.22 
(s, 3H), 1.92 (m, 4H), 1.67 (p, 2H, J = 7.1 Hz), 1.62 (p, 2H, J = 6.9 Hz), 1.40 (br s, 6H); 
13C NMR (CDCl3, 125 MHz)  169.7, 159.5, 150.9, 148.1, 147.0, 139.6, 138.1, 134.0, 
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132.2, 130.7, 127.5, 127.2, 125.7, 125.5, 124.6, 124.2, 120.7, 118.4, 117.2, 116.8, 115.8, 
114.9, 49.6, 39.7, 34.0, 31.7, 29.6, 29.0, 26.9, 26.8, 24.6, 22.9, 22.7, 20.7, 13.9; m/z calcd 






Compound 11c was prepared as described for the synthesis of 10a. The reaction of 
mefenamic acid (2) (38 mg, 0.158 mmol, 1 eq), EDAC hydrochloride (33 mg, 0.173 mmol, 
1.1 eq), HOBt hydrate (26 mg, 0.173 mmol, 1.1 eq), 6f (68 mg, 0.189 mmol, 1.2 eq), and 
Et3N (40 L, 0.284 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash 
column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.79), 11c (24 mg, 26%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz) 9.20 (s, 1H), 
7.92 (d, 1H, J = 9.6 Hz), 7.90 (s, 1H), 7.42 (d, 1H, J = 7.8 Hz), 7.28 (dd, 1H, J1 = 9.0 Hz, 
J2 = 1.9 Hz), 7.22 (t, 1H, J = 8.2 Hz), 7.18 (d, 1H, J = 7.9 Hz), 7.08 (t, 1H, J = 7.6 Hz), 
6.96 (d, 2H, J = 8.2 Hz), 6.70 (t, 1H, J = 7.5 Hz), 6.26 (br t, 1H), 3.98 (br s, 1H), 3.49 (t, 
2H, J = 7.1 Hz), 3.43 (q, 2H, J = 6.6 Hz), 3.04 (br s, 2H), 2.68 (br s, 2H), 2.34 (s, 3H), 2.22 
(s, 3H), 1.93 (m, 4H), 1.67 (p, 2H, J = 7.3 Hz), 1.62 (p, 2H, J = 7.1 Hz), 1.38 (m, 8H); 13C 
NMR (CDCl3, 125 MHz)  169.7, 159.5, 150.9, 148.2, 147.0, 139.6, 138.1, 134.0, 132.1, 
130.7, 127.6, 127.2, 125.7, 125.5, 124.7, 124.2, 120.7, 118.4, 117.2, 116.7, 115.7, 114.9, 
49.6, 39.8, 34.0, 31.8, 29.6, 29.20, 29.16, 26.9, 26.8, 24.6, 22.9, 22.7, 20.7, 13.9; m/z calcd 






Compound 11d was prepared as described for the 
synthesis of 10a. The reaction of mefenamic acid 
(2) (38 mg, 0.159 mmol, 1 eq), EDAC hydrochloride (34 mg, 0.175 mmol, 1.1 eq), HOBt 
hydrate (27 mg, 0.175 mmol, 1.1 eq), 6g (71 mg, 0.191 mmol, 1.2 eq), and Et3N (40 L, 
0.287 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash column 
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chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.53), 11d 
(42 mg, 44%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz) 9.23 (s, 1H), 7.91 (d, 1H, 
J = 10.6 Hz), 7.90 (s, 1H), 7.42 (d, 1H J = 7.8 Hz), 7.27 (d, 1H, J = 10.7 Hz), 7.21 (t, 1H, 
J = 7.5 Hz), 7.18 (d, 1H, J = 8.5 Hz), 7.07 (t, 1H, J = 7.6 Hz), 6.95 (d, 2H, J = 8.1 Hz), 
6.68 (t, 1H, J = 7.5 Hz), 6.36 (br t, 1H), 4.01 (br s, 1H), 3.49 (t, 2H, J = 6.9 Hz), 3.43 (q, 
2H, J = 6.8 Hz), 3.03 (br s, 2H), 2.67 (br s, 2H), 2.33 (s, 3H), 2.22 (s, 3H), 1.92 (m, 4H), 
1.68-1.58 (m, 4H), 1.35 (m, 12H); 13C NMR (CDCl3, 125 MHz)  169.7, 159.4, 150.9, 
148.1, 147.0, 139.6, 138.0, 134.0, 132.1, 130.7, 127.5, 127.3, 125.7, 125.5, 124.7, 124.2, 
120.7, 118.4, 117.3, 116.7, 115.6, 114.9, 49.6, 39.8, 34.0, 31.8, 29.6, 29.4, 29.22, 29.16, 






Compound 11e was prepared as described for the synthesis of 10a. The reaction of 
mefenamic acid (2) 35 mg, 0.146 mmol, 1 eq), EDAC hydrochloride (31 mg, 0.160 mmol, 
1.1 eq), HOBt hydrate (24 mg, 0.160 mmol, 1.1 eq), 6h (68 mg, 0.175 mmol, 1.2 eq), and 
Et3N (37 L, 0.263 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash 
column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.69), 11e (35 mg, 39%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz) 9.21 (s, 1H), 
7.93 (d, 1H, J = 9.5 Hz), 7.92 (d, 1H, J = 2.1 Hz), 7.42 (d, 1H, J = 7.8 Hz), 7.28 (dd, 1H, 
J1 = 9.0 Hz, J2 = 2.1 Hz), 7.22 (t, 1H, J = 7.6 Hz), 7.18 (d, 1H, J = 8.0 Hz), 7.08 (t, 1H, J 
= 7.6 Hz), 6.95 (d, 2H, J = 8.2 Hz), 6.69 (t, 1H, J = 7.4 Hz), 6.30 (br t, 1H), 4.09 (very br 
s, 1H), 3.52 (t, 2H, J = 7.2 Hz), 3.44 (q, 2H, J = 6.8 Hz), 3.04 (br s, 2H), 2.67 (br s, 2H), 
2.34 (s, 3H), 2.22 (s, 3H), 1.93 (m, 4H), 1.67 (p, 2H, J = 7.4 Hz), 1.62 (p, 2H, J = 7.3 Hz), 
1.38 (m, 4H), 1.30 (m, 8H); 13C NMR (CDCl3, 125 MHz)  169.7, 159.1, 151.1, 147.7, 
147.0, 139.6, 138.0, 134.2, 132.1, 130.7, 127.3, 127.1, 125.7, 125.5, 124.7, 124.3, 120.7, 
118.2, 117.3, 116.7, 115.4, 114.9, 49.6, 39.8, 33.7, 31.8, 29.6, 29.40, 29.38, 29.26, 29.24, 








dimethylphenyl)amino)benzamide (11f). Compound 11f was prepared as described for 
the synthesis of 10a. The reaction of mefenamic acid (2) (32 mg, 0.131 mmol, 1 eq), EDAC 
hydrochloride (28 mg, 0.144 mmol, 1.1 eq), HOBt hydrate (22 mg, 0.144 mmol, 1.1 eq), 
6i (66 mg, 0.157 mmol, 1.2 eq), and Et3N (33 L, 0..234 mmol, 1.8 eq) in DMF (3 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.51), 11f (43 mg, 55%) as a pale yellow oil: 
1H NMR 
(CDCl3, 500 MHz) 9.22 (s, 1H), 7.91 (d, 1H, J = 9.3 Hz), 7.90 (s, 1H), 7.41 (d, 1H, J = 
7.8 Hz), 7.28 (d, 1H, J = 9.0 Hz), 7.21 (t, 1H, J = 7.5 Hz), 7.18 (d, 1H, J = 8.6 Hz), 7.08 (t, 
1H, J = 7.6 Hz), 6.95 (d, 2H, J = 8.2 Hz), 6.69 (t, 1H, J = 7.4 Hz), 6.31 (br t, 1H), 3.99 (br 
s, 1H), 3.50 (t, 2H, J = 6.9 Hz), 3.44 (q, 2H, J = 6.6 Hz), 3.04 (br s, 2H), 2.68 (br s, 2H), 
2.34 (s, 3H), 2.22 (s, 3H), 1.93 (m, 4H), 1.69-1.60 (m, 4H), 1.33 (m, 18H); 13C NMR 
(CDCl3, 125 MHz)  169.7, 159.5, 150.9, 148.2, 147.0, 139.6, 138.0, 134.0, 132.1, 130.7, 
127.6, 127.3, 125.7, 125.5, 124.7, 124.2, 120.7, 118.4, 117.3, 116.7, 115.6, 114.9, 49.6, 
39.9, 34.1, 31.8, 29.7, 29.53, 29.49, 29.3, 27.0, 26.9, 24.6, 23.0, 22.7, 20.7, 13.9; m/z calcd 






Compound 12a was prepared as described for the synthesis of 10a. The reaction of 9a (78 
mg, 0.261 mmol, 1 eq), EDAC hydrochloride (55 mg, 0.287 mmol, 1.1 eq), HOBt hydrate 
(44 mg, 0.287 mmol, 1.1 eq), 5a (80 mg, 0.313 mmol, 1.2 eq), and Et3N (65 L, 0.470 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.28), 12a (38 mg, 41%) 
as a white powder: 1H NMR (CDCl3, 500 MHz)  9.19 (s, 1H), 8.00 (d, 1H, J = 8.4 Hz), 
7.93 (d, 1H, J = 8.4 Hz), 7.55 (t, 1H, J = 7.5 Hz), 7.51 (d, 1H, J = 7.5 Hz), 7.35 (t, 1H, J = 
7.5 Hz), 7.22 (t, 2H, J = 7.2 Hz), 7.12 (d, 1H, J = 7.8 Hz), 7.07 (t, 1H, J = 7.6 Hz), 6.97 (d, 
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1H, J = 7.3 Hz), 6.88 (d, 1H, J = 8.5 Hz), 6.84 (br t, 1H), 6.65 (t, 1H, J = 7.4 Hz), 4.91 (br 
s, 1H), 4.14 (d, 2H, J = 5.3 Hz), 3.52 (m, 2H), 3.48 (q, 2H, J = 6.2 Hz), 3.05 (m, 2H), 2.71 
(m, 2H), 2.32 (s, 3H), 2.19 (s, 3H), 1.88 (m, 4H), 1.83 (p, 2H, J = 6.3 Hz); 13C NMR 
(CDCl3, 125 MHz)  170.2, 170.0, 151.1, 147.6, 146.3, 139.2, 138.1, 136.4, 132.9, 131.1, 
129.9, 128.7, 127.8, 126.0, 125.9, 124.1, 122.6, 121.3, 120.0, 116.9, 116.3, 115.3, 115.0, 
45.4, 43.7, 37.0, 33.4, 31.2, 25.0, 22.9, 22.5, 20.7, 13.9; m/z calcd for C33H37N5O2: 535.29; 





Compound 12b was prepared as described for the 
synthesis of 10a. The reaction of 9b (83 mg, 0.264 
mmol, 1 eq), EDAC hydrochloride (56 mg, 0.291 mmol, 1.1 eq), HOBt hydrate (44 mg, 
0.291 mmol, 1.1 eq), 5a (80 mg, 0.317 mmol, 1.2 eq), and Et3N (66 L, 0.474 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.19), 12b (46 mg, 32%) as a 
white powder: 1H NMR (CDCl3, 500 MHz)  9.30 (s, 1H), 7.99 (d, 1H, J = 8.5 Hz), 7.90 
(d, 1H, J = 8.5 Hz), 7.54 (t, 1H, J = 7.6 Hz), 7.45 (d, 1H, J = 7.9 Hz), 7.33 (m, 2H), 7.20 
(t, 1H, J = 7.8 Hz), 7.16 (d, 1H, J = 7.9 Hz), 7.07 (t, 1H, J = 7.7 Hz), 6.96 (d, 1H, J = 7.4 
Hz), 6.93 (d, 1H, J = 8.5 Hz), 6.64 (m, 2H), 4.78 (br t, 1H,), 3.74 (q, 2H, J = 5.9 Hz), 3.48 
(q, 2H, J = 6.2 Hz), 3.42 (q, 2H, J = 6.3 Hz), 3.05 (t, 2H, J = 5.9 Hz), 2.73 (t, 2H, J = 5.7 
Hz), 2.56 (t, 2H, J = 5.9 Hz), 2.32 (s, 3H), 2.20 (s, 3H), 1.89 (m, 4H), 1.79 (p, 2H, J = 6.4 
Hz); 13C NMR (CDCl3, 125 MHz)  172.5, 169.9, 158.3, 150.7, 147.2, 147.0, 139.5, 138.1, 
132.4, 130.8, 128.5, 128.3, 127.6, 125.8, 125.6, 123.9, 122.6, 120.8, 120.3, 116.9, 116.44, 
116.42, 114.9, 45.4, 36.7, 35.8, 35.5, 33.8, 31.4, 25.1, 23.0, 22.7, 20.7, 13.9; m/z calcd for 








Compound 12c was prepared as described for the synthesis of 10a. The reaction of 9c (85 
mg, 0.261 mmol, 1 eq), EDAC hydrochloride (55 mg, 0.287 mmol, 1.1 eq), HOBt hydrate 
(44 mg, 0.287 mmol, 1.1 eq), 5a (80 mg, 0.313 mmol, 1.2 eq), and Et3N (65 L, 0.470 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.19), 12c (52 mg, 35%) 
as a white powder: 1H NMR (CDCl3, 500 MHz)  9.30 (s, 1H), 8.02 (d, 1H, J = 8.2 Hz), 
7.90 (d, 1H, J = 8.2 Hz), 7.54 (ddd, 1H, J1 = 7.6 Hz, J2 = 7.0 Hz, J3 = 1.0 Hz), 7.50 (dd, 
1H, J1 = 7.9 Hz, J2 = 1.3 Hz), 7.33 (ddd, 1H, J1 = 7.6 Hz, J2 = 7.1 Hz, J3 = 1.0 Hz), 7.18 
(m, 3H), 7.07 (t, 1H, J = 7.7 Hz), 6.95 (m, 2H), 6.85 (t, 1H, J = 5.9 Hz), 6.67 (m, 1H), 4.83 
(br t, 1H), 3.50 (m, 4H), 3.41 (q, 2H, J = 6.3 Hz), 3.04 (t, 2H, J = 6.1 Hz), 2.74 (t, 2H, J = 
5.9 Hz), 2.35 (t, 2H, J = 6.5 Hz), 2.32 (s, 3H), 2.20 (s, 3H), 1.97 (p, 2H, J = 6.3 Hz), 1.89 
(m, 4H), 1.79 (p, 2H, J = 6.4 Hz); 13C NMR (CDCl3, 125 MHz)  173.8, 170.3, 158.3, 
150.7, 147.1, 147.0, 139.5, 138.1, 132.3, 130.7, 128.5, 128.3, 127.6, 125.8, 125.6, 123.9, 
122.7, 120.7, 120.3, 116.9, 116.6, 116.4, 114.9, 45.4, 39.4, 36.7, 34.0, 33.8, 31.4, 25.4, 






(12d). Compound 12d was prepared as described for the synthesis of 10a. The reaction of 
9d (104 mg, 0.294 mmol, 1 eq), EDAC hydrochloride (62 mg, 0.323 mmol, 1.1 eq), HOBt 
hydrate (50 mg, 0.323 mmol, 1.1 eq), 5a (90 mg, 0.352 mmol, 1.2 eq), and Et3N (73 L, 
0.529 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.19), 12d 
(58 mg, 33%) as a pale yellow: 1H NMR (CDCl3, 300 MHz)  9.24 (s, 1H), 8.04 (d, 1H, J 
= 8.5 Hz), 7.89 (d, 1H, J = 8.4 Hz), 7.53 (d, 1H, J = 7.2 Hz), 7.49 (t, 1H, J = 9.0 Hz), 7.32 
(t, 1H, J = 7.6 Hz), 7.15 (m, 2H), 7.04 (t, 1H, J = 7.6 Hz), 6.91 (m, 2H), 6.82 (t, 1H, J = 
5.5 Hz), 6.76 (t, 1H, J = 5.8 Hz), 6.62 (t, 1H, J = 7.5 Hz), 5.30 (br s, 1H), 3.50 (m, 2H), 
3.38 (m, 4H), 3.02 (m, 2H), 2.71 (m, 2H), 2.30 (s, 3H), 2.23 (m, 2H), 2.21 (s, 3H), 1.86 
(m, 4H), 1.76-1.58 (m, 6H), 1.38 (m, 2H); 13C NMR (CDCl3, 75 MHz)  174.2, 169.9, 
157.4, 151.4, 146.9, 146.0, 139.6, 138.1, 132.1, 130.6, 128.9, 127.6, 127.1, 125.7, 125.5, 
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124.0, 123.0, 120.5, 119.7, 117.1, 116.8, 115.6, 114.8, 45.0, 39.4, 36.34, 36.28, 33.1, 31.4, 






Compound 12e was prepared as described for the 
synthesis of 10a. The reaction of 9a (83 mg, 0.278 mmol, 
1 eq), EDAC hydrochloride (59 mg, 0.306 mmol, 1.1 eq), HOBt hydrate (47 mg, 0.306 
mmol, 1.1 eq), 5b (90 mg, 0.334 mmol, 1.2 eq), and Et3N (70 L, 0.500 mmol, 1.8 eq) in 
DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.29), 12e (54 mg, 36%) as a 
white powder: 1H NMR (CDCl3, 500 MHz)  9.23 (s, 1H), 7.91 (t, 2H, J = 9.1 Hz), 7.57 
(d, 2H, J = 6.6 Hz), 7.53 (t, 1H, J = 7.2 Hz), 7.31 (t, 1H, J = 7.3 Hz), 7.19 (t, 1H, J = 7.4 
Hz), 7.12 (d, 1H, J = 7.9 Hz), 7.05 (t, 2H, J = 7.3 Hz), 6.95 (d, 1H, J = 7.4 Hz), 6.86 (d, 
1H, J = 8.4 Hz), 6.65 (t, 1H, J = 7.3 Hz), 4.10 (d, 3H, J = 5.2 Hz), 3.46 (br s, 2H), 3.31 (q, 
2H, J = 6.6 Hz), 3.03 (t, 2H, J = 5.4 Hz), 2.64 (t, 2H, J = 5.9 Hz), 2.29 (s, 3H), 2.15 (s, 
3H), 1.87 (m, 4H), 1.66 (m, 2H), 1.61 (m, 2H); 13C NMR (CDCl3, 125 MHz)  170.2, 
169.4, 158.1, 150.9, 147.6, 146.9, 139.3, 138.1, 132.8, 131.2, 128.6, 128.00, 127.98, 126.0, 
125.9, 123.8, 122.9, 121.4, 120.1, 116.8, 116.0, 115.4, 114.8, 48.8, 43.7, 39.2, 33.6, 28.8, 






Compound 12f was prepared as described for the synthesis of 10a. The reaction of 9b (75 
mg, 0.2404 mmol, 1 eq), EDAC hydrochloride (50.7 mg, 0.2644 mmol, 1.1 eq), HOBt 
hydrate (40.5 mg, 0.2644 mmol, 1.1 eq), 5b (127.2 mg, .4722 mmol, 1.96 eq), and Et3N 
(60 L, 0.4327 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.19), 12f 
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(65 mg, 48%) as a pink powder: 1H NMR (CDCl3, 300 MHz)  9.32 (s, 1H), 7.92 (d, 1H, 
J = 6.0 Hz), 7.90 (d, 1H, J = 7.1 Hz), 7.53 (t, 1H, J = 7.6 Hz), 7.46 (d, 1H, J = 7.9 Hz), 
7.40 (t, 1H, J = 5.6 Hz), 7.32 (t, 1H, J = 7.7 Hz), 7.18 (t, 1H, J = 7.0 Hz), 7.14 (d, 1H, J = 
5.0 Hz), 7.05 (t, 1H, J = 7.7 Hz), 6.93 (d, 1H, J = 4.9 Hz), 6.91 (d, 1H, J = 8.4 Hz), 6.65 (t, 
1H, J = 7.5 Hz), 6.60 (t, 1H, J = 5.9 Hz), 4.17 (br s, 1H), 3.69 (q, 2H, J = 5.8 Hz), 3.46 (m, 
2H), 2.28 (q, 2H, J = 6.3 Hz), 3.03 (br t, 2H), 2.64 (br t, 2H), 2.51 (t, 2H, J = 5.8 Hz), 2.30 
(s, 3H), 2.18 (s, 3H), 1.87 (m, 4H), 1.64 (m, 4H); 13C NMR (CDCl3, 75 MHz)  171.9, 
169.8, 157.8, 151.0, 147.2, 146.6, 139.5, 138.1, 132.3, 130.7, 128.7, 127.8, 127.7, 125.8, 
125.6, 123.9, 122.9, 120.7, 119.9, 116.8, 116.5, 115.8, 114.8, 48.7, 39.1, 35.8, 35.4, 33.5, 






Compound 12g was prepared as described for the 
synthesis of 10a. The reaction of 9c (114 mg, 0.348 
mmol, 1 eq), EDAC hydrochloride (73 mg, 0.383 mmol, 1.1 eq), HOBt hydrate (59 mg, 
0.383 mmol, 1.1 eq), 5b (122 mg, 0.453 mmol, 1.3 eq), and Et3N (87 L, 0.627 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.14), 12g (32 mg, 16%) as a pink 
solid: 1H NMR (CDCl3, 300 MHz)  9.33 (s, 1H), 7.94 (d, 1H, J = 8.5 Hz), 7.91 (d, 1H, J 
= 8.4 Hz), 7.53 (t, 2H, J = 8.0 Hz), 7.32 (t, 1H, J = 7.5 Hz), 7.26 (br t, 1H), 7.18 (t, 1H, J 
= 7.4 Hz), 7.14 (d, 1H, J = 7.9 Hz), 7.04 (t, 1H, J = 7.7 Hz), 6.92 (m, 2H), 6.74 (br t, 1H), 
6.69 (t, 1H, J = 7.3 Hz), 4.28 (br s, 1H), 3.48 (m, 4H), 3.31 (m, 2H), 3.04 (m, 2H), 2.65 
(m, 2H), 2.32 (m, 5H), 2.17 (s, 3H), 1.93 (m, 2H), 1.87 (m, 4H), 1.70 (m, 2H), 1.61 (m, 
2H); 13C NMR (CDCl3, 75 MHz)  173.2, 170.3, 157.6, 151.2, 147.1, 146.3, 139.6, 138.1, 
132.3, 130.6, 128.8, 127.8, 127.5, 125.8, 125.6, 123.9, 123.0, 120.7, 119.8, 116.9, 116.6, 
115.7, 114.8, 48.8, 39.4, 39.2, 34.1, 33.3, 28.9, 27.0, 25.2, 24.7, 22.9, 22.5, 20.7, 13.9; m/z 








Compound 12h was prepared as described for the 
synthesis of 10a. The reaction of 9d (80 mg, 
0.226 mmol, 1 eq), EDAC hydrochloride (47.6 mg, 0.248 mmol, 1.1 eq), HOBt hydrate 
(38 mg, 0.248 mmol, 1.1 eq), 5b (102 mg, 0.377 mmol, 1.7 eq), and Et3N (57 L, 0.406 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.17), 12h (43 mg, 31%) 
as a pink powder: 1H NMR (CDCl3, 300 MHz)  9.23 (s, 1H), 7.91 (t, 2H, J = 8.7 Hz), 7.53 
(td, 1H, J1 = 7.6 Hz, J2 = 1.2 Hz), 7.45 (dd, 1H, J1 = 7.9 Hz, J2 = 1.3 Hz), 7.32 (td, 1H, J1 
= 7.4 Hz, J2 = 1.1 Hz), 7.17 (td, 1H, J1 = 7.8 Hz, J2 = 1.4 Hz), 7.14 (d, 1H, J = 7.6 Hz), 
7.04 (t, 1H, J = 7.7 Hz), 6.93 (br s, 1H), 6.90 (br s, 1H), 6.65 (m, 2H), 5.99 (t, 1H, J = 5.7 
Hz), 4.10 (br s, 1H), 3.46 (m, 2H), 3.39 (q, 2H, J = 6.8 Hz), 3.24 (q, 2H, J = 6.5 Hz), 3.03 
(br t, 2H), 2.66 (br t, 2H), 2.30 (s, 3H), 2.18 (s, 3H), 2.14 (t, 2H, J = 7.3 Hz), 1.88 (m, 4H), 
1.62 (m, 8H), 1.36 (m, 2H); 13C NMR (CDCl3, 75 MHz)  173.1, 169.9, 158.0, 150.9, 
146.9, 146.7, 139.6, 138.1, 132.1, 130.6, 128.6, 127.9, 127.6, 125.7, 125.5, 123.8, 122.9, 
120.6, 120.0, 117.1, 116.8, 115.9, 114.8, 48.8, 39.3, 39.0, 36.3, 33.5, 29.1, 28.9, 27.1, 26.3, 






Compound 12i was prepared as described for the 
synthesis of 10a. The reaction of 9a (73 mg, 0.246 
mmol, 1 eq), EDAC hydrochloride (52 mg, 0.270 mmol, 1.1 eq), HOBt hydrate (41 mg, 
0.270 mmol, 1.1 eq), 5d (88 mg, 0.295 mmol, 1.2 eq), and Et3N (62 L, 0.442 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.30), 12i (123 mg, 87%) as a 
pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.21 (s, 1H), 7.95 (d, 1H, J = 8.5 Hz), 
7.93 (d, 1H, J = 8.4 Hz), 7.55 (m, 2H), 7.35 (t, 1H, J = 7.6 Hz), 7.21 (m, 2H), 7.15 (d, 1H, 
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J = 7.9 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.97 (d, 1H, J = 7.3 Hz), 6.88 (d, 1H, J = 8.4 Hz), 
6.69 (t, 1H, J = 7.5 Hz), 6.37 (br t, 1H), 4.09 (d, 2H, J = 4.9 Hz), 4.08 (br s, 1H), 3.46 (m, 
2H), 3.30 (q, 2H, J = 6.3 Hz), 3.08 (br t, 2H), 2.70 (br t, 2H), 2.32 (s, 3H), 2.19 (s, 3H), 
1.93 (m, 4H), 1.63 (p, 2H, J = 7.0 Hz), 1.53 (p, 2H, J = 7.0 Hz), 1.38 (m, 4H); 13C NMR 
(CDCl3, 125 MHz)  170.1, 169.0, 158.2, 150.9, 147.6, 147.2, 139.3, 138.1, 132.8, 131.2, 
128.5, 128.4, 127.8, 126.0, 125.9, 123.7, 122.9, 121.4, 120.1, 116.8, 115.8, 115.4, 114.9, 
49.3, 43.7, 39.4, 33.8, 31.6, 29.4, 26.53, 26.50, 24.8, 23.0, 22.7, 20.7, 13.9; m/z calcd for 






(12j). Compound 12j was prepared as described for the synthesis of 10a. The reaction of 
9b (85 mg, 0.272 mmol, 1 eq), EDAC hydrochloride (57 mg, 0.299 mmol, 1.1 eq), HOBt 
hydrate (46 mg, 0.299 mmol, 1.1 eq), 5d (110 mg, 0.369 mmol, 1.36 eq), and Et3N (68 L, 
0.490 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.50), 12j 
(113 mg, 70%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.34 (s, 1H), 7.95 
(d, 1H, J = 8.5 Hz), 7.91 (d, 1H, J = 8.5 Hz), 7.55 (t, 1H, J = 7.6 Hz), 7.46 (d, 1H, J = 7.8 
Hz), 7.40 (br t, 1H), 7.34 (t, 1H, J = 7.6 Hz), 7.18 (m, 2H), 7.06 (t, 1H, J = 7.7 Hz), 6.93 
(t, 2H, J = 8.6 Hz), 6.66 (t, 1H, J = 7.5 Hz), 6.33 (br t, 1H), 4.04 (br s, 1H), 3.70 (q, 2H, J 
= 5.7 Hz), 3.46 (br t, 2H), 3.24 (q, 2H, J = 6.6 Hz), 3.06 (br t, 2H), 2.69 (br t, 2H), 2.51 (t, 
2H, J = 5.8 Hz), 2.32 (s, 3H), 2.20 (s, 3H), 1.91 (br s, 4H), 1.61 (p, 2H, J = 7.1 Hz), 1.49 
(p, 2H, J = 7.1 Hz), 1.34 (m, 4H); 13C NMR (CDCl3, 75 MHz)  171.7, 169.8, 158.2, 150.9, 
147.2, 139.5, 138.1, 132.3, 130.8, 128.5, 128.4, 127.7, 125.8, 125.6, 123.7, 122.9, 120.8, 
120.1, 116.8, 116.5, 115.8, 114.8, 49.3, 39.4, 35.8, 35.5, 33.8, 31.6, 29.5, 26.6, 26.5, 24.8, 








Compound 12k was prepared as described for the 
synthesis of 10a. The reaction of 9c (70 mg, 
0.214 mmol, 1 eq), EDAC hydrochloride (45 mg, 0.236 mmol, 1.1 eq), HOBt hydrate (36 
mg, 0.236 mmol, 1.1 eq), 5d (77 mg, 0.257 mmol, 1.2 eq), and Et3N (54 L, 0.386 mmol, 
1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.19), 12k (46 mg, 35%) as a pink 
powder: 1H NMR (CDCl3, 300 MHz)  9.38 (s, 1H), 7.96 (d, 1H, J = 8.5 Hz), 7.92 (d, 1H, 
J = 8.5 Hz), 7.55 (t, 1H, J = 7.6 Hz), 7.51 (d, 1H, J = 7.9 Hz), 7.34 (t, 1H, J = 7.6 Hz), 7.30 
(t, 1H, J = 5.1 Hz), 7.18 (m, 2H), 7.06 (t, 1H, J = 7.7 Hz), 6.93 (d, 2H, J = 8.1 Hz), 6.68 (t, 
1H, J = 7.5 Hz), 6.53 (br t, 1H), 4.11 (br s, 1H), 3.47 (m, 4H), 3.23 (q, 2H, J = 6.5 Hz), 
3.06 (br t, 2H), 2.68 (br t, 2H), 2.30 (m, 5H), 2.20 (s, 3H), 1.94 (m, 2H, J = 6.4 Hz), 1.90 
(m, 4H), 1.63 (p, 2H, J = 7.0 Hz), 1.49 (p, 2H, J = 6.9 Hz), 1.34 (m, 4H); 13C NMR (CDCl3, 
75 MHz)  173.1, 170.2, 158.0, 151.1, 147.1, 146.9, 139.6, 138.1, 132.2, 130.6, 128.6, 
128.0, 127.8, 125.8, 125.5, 123.7, 123.0, 120.7, 119.9, 116.9, 116.6, 115.5, 114.8, 49.2, 
39.5, 39.4, 34.1, 33.6, 31.6, 29.5, 26.6, 26.5, 25.2, 24.7, 23.0, 22.6, 20.7, 13.9; m/z calcd 






(12l). Compound 12l was prepared as 
described for the synthesis of 10a. The 
reaction of 9d (88 mg, 0.247 mmol, 1 eq), EDAC hydrochloride (42 mg, 0.272 mmol, 1.1 
eq), HOBt hydrate (37 mg, 0.272 mmol, 1.1 eq), 5d (90 mg, 0.302 mmol, 1.2 eq), and Et3N 
(62 L, 0.445 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.56), 12l 
(97 mg, 62%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.27 (s, 1H), 7.95 
(d, 1H, J = 9.1 Hz), 7.89 (d, 1H, J = 8.5 Hz), 7.52 (t, 1H, J = 7.2 Hz), 7.47 (d, 1H, J = 7.8 
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Hz), 7.31 (t, 1H, J = 7.4 Hz), 7.14 (m, 2H), 7.02 (t, 1H, J = 7.6 Hz), 6.95 (t, 1H, J = 5.5 
Hz), 6.90 (m, 2H), 6.62 (t, 1H, J = 7.4 Hz), 6.27 (t, 1H, J = 5.5 Hz), 4.18 (br s, 1H), 3.45 
(t, 2H, J = 7.0 Hz), 3.38 (q, 2H, J = 6.7 Hz), 3.17 (q, 2H, J = 6.6 Hz), 3.02 (br t, 2H), 2.65 
(br t, 2H), 2.28 (s, 3H), 2.17 (s, 3H), 2.13 (t, 2H, J = 7.4 Hz), 1.87 (br s, 4H), 1.61 (m, 6H), 
1.44 (m, 2H), 1.35 (m, 4H), 1.25 (m, 2H); 13C NMR (CDCl3, 125 MHz)  173.1, 169.9, 
157.9, 151.1, 146.9, 146.8, 139.6, 138.0, 132.0, 130.5, 128.6, 128.0, 127.7, 125.7, 125.4, 
123.7, 123.1, 120.5, 119.9, 117.2, 116.8, 115.5, 114.7, 49.2, 39.4, 39.2, 36.3, 33.6, 31.6, 
29.5, 29.1, 26.6, 26.5, 26.4, 25.1, 24.7, 23.0, 22.6, 20.7, 13.9; m/z calcd for C40H51N5O2: 





(12m). Compound 12m was prepared as described for the synthesis of 10a. The reaction 
of 9a (56 mg, 0.186 mmol, 1 eq), EDAC hydrochloride (39 mg, 0.205 mmol, 1.1 eq), HOBt 
hydrate (31 mg, 0.205 mmol, 1.1 eq), 5e (70 mg, 0.223 mmol, 1.2 eq), and Et3N (47 L, 
0.335 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.29), 
12m (35 mg, 32%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.24 (s, 1H), 
7.97 (d, 1H, J = 8.3 Hz), 7.93 (d, 1H, J = 8.4 Hz), 7.56 (m, 2H), 7.36 (m, 2H), 7.21 (td, 1H, 
J1 = 7.2 Hz, J2 = 1.2 Hz), 7.15 (d, 1H, J = 7.8 Hz), 7.07 (t, 1H, J = 7.6 Hz), 6.96 (d, 1H, J 
= 7.4 Hz), 6.88 (d, 1H, J = 8.4 Hz), 6.67 (t, 1H, J = 7.2 Hz), 6.55 (t, 1H, J = 5.5 Hz), 4.11 
(d, 2H, J = 5.2 Hz), 3.48 (t, 2H, J = 7.2 Hz), 3.27 (q, 2H, J = 6.8 Hz), 3.07 (br s, 2H), 2.70 
(br s, 2H), 2.32 (s, 3H), 2.18 (s, 3H), 1.92 (m, 4H), 1.63 (p, 2H, J = 7.2 Hz), 1.48 (br p, 2H, 
J = 6.4 Hz), 1.33 (m, 7H); 13C NMR (CDCl3, 125 MHz)  170.1, 169.0, 157.9, 151.2, 147.6, 
146.8, 139.3, 138.1, 132.7, 131.2, 128.6, 128.0, 127.9, 125.9, 125.8, 123.7, 123.0, 121.4, 
119.9, 116.8, 115.53, 115.48, 114.8, 49.3, 43.6, 39.6, 33.6, 31.6, 29.3, 28.9, 26.70, 26.65, 








(12n). Compound 12n was prepared as described 
for the synthesis of 10a. The reaction of 9b (56 
mg, 0.178 mmol, 1 eq), EDAC hydrochloride (38 mg, 0.196 mmol, 1.1 eq), HOBt hydrate 
(30 mg, 0.196 mmol, 1.1 eq), 5e (67 mg, 0.214 mmol, 1.2 eq), and Et3N (45 L, 0.320 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.24), 12n (50 mg, 47%) 
as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.34 (s, 1H), 7.96 (d, 1H, J = 8.5 
Hz), 7.91 (d, 1H, J = 8.5 Hz), 7.56 (t, 1H, J = 7.2 Hz), 7.45 (d, 1H, J = 7.9 Hz), 7.34 (m, 
2H), 7.19 (t, 1H, J = 7.6 Hz), 7.17 (d, 1H, J = 7.4 Hz), 7.07 (t, 1H, J = 7.6 Hz), 6.95 (d, 
1H, J = 7.6 Hz), 6.92 (d, 1H, J = 8.4 Hz), 6.67 (t, 1H, J = 7.4 Hz), 6.10 (t, 1H, J = 5.3 Hz), 
4.02 (br s, 1H), 3.72 (q, 2H, J = 5.8 Hz), 3.48 (t, 2H, J = 7.2 Hz), 3.23 (q, 2H, J = 6.7 Hz), 
3.07 (br s, 2H), 2.71 (br s, 2H), 2.52 (t, 2H, J = 5.8 Hz), 2.33 (s, 3H), 2.21 (s, 3H), 1.92 (m, 
4H), 1.63 (p, 2H, J = 7.0 Hz), 1.46 (br p, 2H, J = 6.8 Hz), 1.32 (m, 6H); 13C NMR (CDCl3, 
125 MHz)  171.7, 169.8, 158.3, 150.9, 147.3, 147.2, 139.6, 138.0, 132.3, 130.8, 128.4, 
127.7, 125.8, 125.6, 123.7, 122.9, 120.8, 120.1, 116.8, 116.5, 115.8, 114.7, 49.4, 39.5, 35.8, 
35.5, 33.9, 31.7, 29.4, 28.9, 26.7, 24.8, 23.0, 22.8, 20.7, 13.9; m/z calcd for C38H47N5O2: 





(12o). Compound 12o was prepared as described for the synthesis of 10a. The reaction of 
9c (61 mg, 0.188 mmol, 1 eq), EDAC hydrochloride (40 mg, 0.207 mmol, 1.1 eq), HOBt 
hydrate (32 mg, 0.207 mmol, 1.1 eq), 5e (70 mg, 0.226 mmol, 1.2 eq), and Et3N (47 L, 
0.338 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.40), 12o 
(27 mg, 23%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.36 (s, 1H), 7.96 
(d, 1H, J = 8.3 Hz), 7.92 (d, 1H, J = 8.4 Hz), 7.56 (t, 1H, J = 7.2 Hz), 7.49 (dd, 1H, J1 = 
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7.9 Hz, J2 = 1.2 Hz), 7.35 (t, 1H, J = 8.0 Hz), 7.20 (td, 1H, J1 = 7.2 Hz, J2 = 1.2 Hz), 7.17 
(d, 1H, J = 8.0 Hz), 7.15 (br t, 1H, J = 5.4 Hz), 7.07 (t, 1H, J = 7.7 Hz), 6.94 (m, 2H), 6.70 
(t, 1H, J = 7.3 Hz), 6.25 (br t, 1H), 4.00 (very br s, 1H), 3.49 (p, 4H, J = 6.6 Hz), 3.23 (q, 
2H, J = 6.7 Hz), 3.07 (br t, 2H), 2.71 (br t, 2H), 2.32 (m, 5H), 2.21 (s, 3H), 1.97 (p, 2H, J 
= 6.3 Hz) 1.93 (m, 4H), 1.63 (p, 2H, J = 7.4 Hz), 1.46 (br p, 2H, J = 6.7 Hz), 1.31 (m, 6H); 
13C NMR (CDCl3, 125 MHz)  173.0, 170.2, 158.3, 150.9, 147.3, 147.2, 139.6, 138.1, 
132.2, 130.7, 128.5, 128.4, 127.6, 125.7, 125.5, 123.6, 122.9, 120.7, 120.1, 116.9, 116.6, 
115.8, 114.8, 49.4, 39.6, 39.5, 34.2, 33.9, 31.7, 29.4, 28.9, 26.8, 26.7, 25.1, 24.8, 23.0, 22.8, 






yl)amino)heptyl)amino)hexyl)benzamide (12p). Compound 12p was prepared as 
described for the synthesis of 10a. The reaction of 9d (53 mg, 0.148 mmol, 1 eq), EDAC 
hydrochloride (31 mg, 0.163 mmol, 1.1 eq), HOBt hydrate (25 mg, 0.163 mmol, 1.1 eq), 
5e (55 mg, 0.178 mmol, 1.2 eq), and Et3N (37 L, 0.266 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.23), 12p (35 mg, 37%) as a pale yellow powder: 
1H 
NMR (CDCl3, 500 MHz)  9.24 (s, 1H), 7.97 (d, 1H, J = 8.5 Hz), 7.92 (d, 1H, J = 8.4 Hz), 
7.57 (t, 1H, J = 7.5 Hz), 7.45 (d, 1H, J = 7.6 Hz), 7.36 (t, 1H, J = 7.6 Hz), 7.21 (t, 1H, J = 
7.6 Hz), 7.17 (d, 1H, J = 7.9 Hz), 7.07 (t, 1H, J = 7.6 Hz), 6.94 (d, 2H, J = 8.4 Hz), 6.68 (t, 
1H, J = 7.5 Hz), 6.48 (br t, 1H), 5.66 (br t, 1H), 4.02 (very br s, 1H), 3.49 (t, 2H, J = 7.2 
Hz), 3.44 (q, 2H, J = 6.7 Hz), 3.21 (q, 2H, J = 6.7 Hz), 3.07 (br s, 2H), 2.71 (br s, 2H), 2.33 
(s, 3H), 2.21 (s, 3H), 2.18 (t, 2H, J = 7.3 Hz), 1.93 (m, 4H), 1.68 (m, 6H), 1.37 (m, 10H); 
13C NMR (CDCl3, 125 MHz)  172.8, 169.8, 158.3, 150.9, 147.3, 147.0, 139.6 , 138.1, 
132.1, 130.7, 128.5, 128.4, 127.4, 125.7, 125.5, 123.6, 122.9, 120.6, 120.1, 117.2, 116.8, 
115.8, 114.9, 49.4, 39.4, 36.4, 33.9, 31.7, 29.6, 29.2, 28.9, 26.8, 26.7, 26.4, 25.0, 24.8, 23.0, 








Compound 12q was prepared as described for the 
synthesis of 10a. The reaction of 9a (44 mg, 
0.146 mmol, 1 eq), EDAC hydrochloride (31 mg, 0.161 mmol, 1.1 eq), HOBt hydrate (25 
mg, 0.161 mmol, 1.1 eq), 5f (57 mg, 0.175 mmol, 1.2 eq), and Et3N (37 L, 0.263 mmol, 
1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.30), 12q (36 mg, 41%) as a pale 
yellow powder: 1H NMR (CDCl3, 500 MHz)  9.24 (s, 1H), 7.97 (d, 1H, J = 8.2 Hz), 7.91 
(d, 1H, J = 8.3 Hz), 7.56 (m, 2H), 7.35 (m, 2H), 7.21 (t, 1H, J = 7.3 Hz), 7.16 (d, 1H, J = 
7.8 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.97 (d, 1H, J = 7.4 Hz), 6.88 (d, 1H, J = 8.4 Hz), 6.68 (t, 
1H, J = 7.2 Hz), 6.51 (br t, 1H, J = 5.4 Hz), 4.11 (d, 2H, J = 5.2 Hz), 3.99 (very br s, 1H), 
3.48 (t, 2H, J = 7.2 Hz), 3.27 (q, 2H, J = 6.8 Hz), 3.07 (br s, 2H), 2.71 (br s, 2H), 2.33 (s, 
3H), 2.19 (s, 3H), 1.93 (m, 4H), 1.64 (p, 2H, J = 7.1 Hz), 1.48 (br p, 2H), 1.35 (br p, 2H), 
1.28 (br s, 6H); 13C NMR (CDCl3, 125 MHz)  170.1, 168.9, 158.3, 150.9, 147.6, 147.3, 
139.3, 138.1, 132.7, 131.2, 128.5, 128.4, 127.9, 125.9, 125.8, 123.6, 123.0, 121.5, 120.1, 
116.8, 115.7, 115.5, 114.8, 49.4, 43.6, 39.6, 33.9, 31.8, 29.4, 29.14, 29.08, 26.8, 26.7, 24.8, 






(12r). Compound 12r was prepared as described for the synthesis of 10a. The reaction of 
9b (54 mg, 0.172 mmol, 1 eq), EDAC hydrochloride (36 mg, 0.189 mmol, 1.1 eq), HOBt 
hydrate (29 mg, 0.189 mmol, 1.1 eq), 5f (67 mg, 0.206 mmol, 1.2 eq), and Et3N (43 L, 
0.310 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.39), 12r 
(30 mg, 28%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.34 (s, 1H), 7.97 
(d, 1H, J = 8.5 Hz), 7.91 (d, 1H, J = 8.5 Hz), 7.56 (t, 1H, J = 7.1 Hz), 7.45 (d, 1H, J = 6.8 
Hz), 7.34 (m, 2H), 7.19 (m, 2H), 7.07 (t, 1H, J = 7.6 Hz), 6.94 (t, 2H, J = 9.2 Hz), 6.68 (t, 
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1H, J = 7.2 Hz), 6.10 (t, 1H, J = 5.3 Hz), 4.00 (very br s, 1H), 3.72 (q, 2H, J = 5.8 Hz), 
3.49 (t, 2H, J = 7.2 Hz), 3.24 (q, 2H, J = 6.8 Hz), 3.07 (br t, 2H), 2.71 (br t, 2H), 2.52 (t, 
2H, J = 5.9 Hz), 2.33 (s, 3H), 2.21 (s, 3H), 1.93 (m, 4H), 1.64 (p, 2H, J = 7.1 Hz), 1.46 (br 
p, 2H, J = 6.7 Hz), 1.35 (br p, 2H), 1.27 (br s, 6H); 13C NMR (CDCl3, 125 MHz)  171.7, 
169.8, 158.3, 150.9, 147.3, 147.2, 139.6, 138.0, 132.3, 130.8, 128.5, 128.4, 127.7, 125.7, 
125.5, 123.6, 122.9, 120.8, 120.1, 116.8, 116.5, 115.7, 114.7, 49.4, 39.6, 35.8, 35.5, 33.9, 
31.8, 29.5, 29.14, 29.10, 26.78, 26.75, 24.8, 23.1, 22.8, 20.7, 13.9; m/z calcd for 






(12s). Compound 12s was prepared as 
described for the synthesis of 10a. The 
reaction of 9c (61 mg, 0.187 mmol, 0.87 eq), EDAC hydrochloride (45 mg, 0.237 mmol, 
1.1 eq), HOBt hydrate (36 mg, 0.237 mmol, 1.1 eq), 5f (84 mg, 0.258 mmol, 1.2 eq), and 
Et3N (54 L, 0.387 mmol, 1.8 eq) in DMF (3 mL) yielded, after purification by flash 
column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.44), 12s (60 mg, 51%) as a yellow oil: 1H NMR (CDCl3, 500 MHz)  9.38 (s, 1H), 7.99 
(d, 1H, J = 8.5 Hz), 7.95 (d, 1H, J = 8.4 Hz), 7.56 (t, 1H, J = 8.0 Hz), 7.52 (d, 1H, J = 7.9 
Hz), 7.34 (m, 2H), 7.18 (t, 1H, J = 8.4 Hz), 7.16 (d, 1H, J = 7.2 Hz), 7.06 (t, 1H, J = 7.6 
Hz), 6.93 (m, 2H), 6.67 (t, 1H, J = 7.8 Hz), 6.53 (t, 1H, J = 5.2 Hz), 4.23 (br s, 1H), 3.52 
(t, 2H, J = 7.1 Hz), 3.48 (q, 2H, J = 8.4 Hz), 3.22 (q, 2H, J = 6.7 Hz), 3.07 (br s, 2H), 2.69 
(br s, 2H), 2.32 (m, 5H), 2.20 (s, 3H), 1.96 (p, 2H, J = 6.5 Hz), 1.91 (m, 4H), 1.65 (p, 2H, 
J = 7.1 Hz), 1.46 (br p, 2H), 1.36 (br p, 2H), 1.27 (br s, 6H); 13C NMR (CDCl3, 125 MHz) 
 173.1, 170.2, 157.6, 151.5, 147.1, 146.5, 139.7, 138.0, 132.2, 130.6, 128.8, 127.8, 127.6, 
125.7, 125.5, 123.8, 123.1, 120.7, 119.7, 116.9, 116.7, 115.2, 114.8, 49.3, 39.6, 39.5, 34.2, 
33.3, 31.6, 29.5, 29.11, 29.07, 26.8, 26.7, 25.2, 24.6, 22.9, 22.5, 20.7, 13.9; m/z calcd for 








(12t). Compound 12t was prepared as 
described for the synthesis of 10a. The reaction of 9d (63 mg, 0.177 mmol, 0.80 eq), EDAC 
hydrochloride (47 mg, 0.244 mmol, 1.1 eq), HOBt hydrate (37 mg, 0.244 mmol, 1.1 eq), 
5f (87 mg, 0.266 mmol, 1.2 eq), and Et3N (57 L, 0.399 mmol, 1.8 eq) in DMF (3 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.31), 12t (70 mg, 60%) as a yellow oil: 
1H NMR (CDCl3, 
500 MHz)  9.25 (s, 1H), 7.99 (d, 1H, J = 8.5 Hz), 7.91 (d, 1H, J = 8.4 Hz), 7.55 (t, 1H, J 
= 7.6 Hz), 7.46 (d, 1H, J = 7.5 Hz), 7.34 (t, 1H, J = 7.7 Hz), 7.18 (t, 1H, J = 8.0 Hz), 7.16 
(d, 1H, J = 7.9 Hz), 7.06 (d, 1H, J = 7.7 Hz), 6.93 (d, 2H, J = 8.1 Hz), 6.70 (t, 1H, J = 5.4 
Hz), 6.66 (t, 1H, J = 7.4 Hz), 5.95 (t, 1H, J = 5.5 Hz), 4.08 (br s, 1H), 3.49 (t, 2H, J = 6.9 
Hz), 3.42 (q, 2H, J = 6.7 Hz), 3.19 (q, 2H, J = 6.6 Hz), 3.05 (m, 2H), 2.69 (m, 2H), 2.31 
(s, 3H), 2.20 (s, 3H), 2.16 (t, 2H, J = 7.4 Hz), 1.91 (m, 4H), 1.64 (m, 6H), 1.40 (m, 6H), 
1.27 (m, 6H); 13C NMR (CDCl3, 125 MHz)  173.0, 169.9, 158.1, 151.1, 147.1, 146.9, 
139.6, 138.0, 132.1, 130.6, 128.5, 128.3, 127.6, 125.7, 125.4, 123.6, 123.0, 120.6, 120.0, 
117.2, 116.8, 115.6, 114.8, 49.4, 39.5, 39.4, 36.4, 33.8, 31.7, 29.6, 29.2, 29.15, 29.10, 
26.79, 26.76, 26.4, 25.1, 24.7, 23.0, 22.7, 20.7, 13.9; m/z calcd for C42H55N5O2: 661.44; 





Compound 13a was prepared as described for the synthesis of 10a. The reaction of 9a (64 
mg, 0.213 mmol, 1 eq), EDAC hydrochloride (45 mg, 0.234 mmol, 1.1 eq), HOBt hydrate 
(36 mg, 0.234 mmol, 1.1 eq), 6a (74 mg, 0.255 mmol, 1.2 eq), and Et3N (53 L, 0.383 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.48), 13a (65 mg, 53%) 
as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.18 (s, 1H), 7.90 (d, 1H, J = 9.1 
Hz), 7.84 (s, 1H), 7.52 (d, 1H, J = 7.9 Hz), 7.45 (t, 1H, J = 5.2 Hz), 7.21 (m, 2H), 7.13 (t, 
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1H, J = 6.0 Hz), 7.09 (br s, 1H), 7.06 (t, 1H, J = 7.8 Hz), 6.97 (d, 1H, J = 7.2 Hz), 6.87 (d, 
1H, J = 8.5 Hz), 6.63 (t, 1H, J = 7.5 Hz), 4.76 (br t, 1H), 4.13 (d, 2H, J = 5.2 Hz), 3.45 (p, 
4H, J = 6.6 Hz), 2.99 (t, 2H, J = 6.0 Hz), 2.67 (t, 2H, J = 5.8 Hz), 2.30 (s, 3H), 2.14 (s, 
3H), 1.86 (m, 4H), 1.79 (p, 2H, J = 6.2 Hz); 13C NMR (CDCl3, 125 MHz)  170.3, 170.1, 
159.7, 150.6, 147.8, 147.6, 139.2, 138.2, 134.0, 132.9, 131.1, 127.8, 127.3, 126.1, 125.9, 
124.5, 124.2, 121.4, 118.6, 116.9, 116.6, 115.2, 115.0, 45.4, 43.8, 36.8, 33.9, 31.2, 24.9, 






Compound 13b was prepared as described for the 
synthesis of 10a. The reaction of 9b (73 mg, 0.234 
mmol, 1 eq), EDAC hydrochloride (49 mg, 0.257 mmol, 1.1 eq), HOBt hydrate (39 mg, 
0.257 mmol, 1.1 eq), 6a (81 mg, 0.280 mmol, 1.2 eq), and Et3N (59 L, 0.420 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.33), 13b (70 mg, 51%) as a 
white powder: 1H NMR (CDCl3, 500 MHz)  9.28 (s, 1H), 7.90 (d, 1H, J = 9.0 Hz), 7.81 
(s, 1H), 7.55 (br t, 1H), 7.46 (d, 1H, J = 7.7 Hz), 7.26 (br t, 1H), 7.19 (d, 1H, J = 9.1 Hz), 
7.17 (d, 1H, J = 8.0 Hz), 7.12 (d, 1H, J = 7.9 Hz), 7.04 (t, 1H, J = 7.7 Hz), 6.92 (d, 1H, J = 
7.4 Hz), 6.89 (d, 1H, J = 8.4 Hz), 6.61 (t, 1H, J = 7.4 Hz), 4.89 (br s, 1H), 3.71 (q, 2H, J = 
5.3 Hz), 3.43 (q, 2H, J = 5.8 Hz), 3.37 (q, 2H, J = 5.8 Hz), 2.97 (br s, 2H), 2.66 (br t, 2H), 
2.56 (br t, 2H), 2.29 (s, 3H), 2.16 (s, 3H), 1.84 (br s, 4H), 1.74 (br p, 2H, J = 5.8 Hz); 13C 
NMR (CDCl3, 125 MHz)  172.8, 169.9, 159.5, 150.7, 147.7, 147.2, 139.5, 138.1, 134.0, 
132.3, 130.7, 127.7, 127.0, 125.8, 125.6, 124.4, 124.3, 120.8, 118.5, 116.9, 116.5, 116.2, 
114.8, 45.2, 36.5, 36.0, 35.5, 33.9, 33.8, 31.3, 22.9, 22.6, 20.7, 13.9; m/z calcd for 








Compound 13c was prepared as described for the synthesis of 10a. The reaction of 9c (84 
mg, 0.257 mmol, 1 eq), EDAC hydrochloride (54 mg, 0.283 mmol, 1.1 eq), HOBt hydrate 
(43 mg, 0.283 mmol, 1.1 eq), 6a (95 mg, 0.327 mmol, 1.2 eq), and Et3N (64 L, 0.555 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.54), 13c (77 mg, 50%) 
as a white powder: 1H NMR (CDCl3, 300 MHz)  9.26 (s, 1H), 7.94 (d, 1H, J = 9.1 Hz), 
7.85 (d, 1H, J = 2.0 Hz), 7.48 (d, 1H, J = 7.1 Hz), 7.24 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz), 
7.17 (m, 2H), 7.08 (br s, 1H), 7.06 (t, 1H, J = 7.6 Hz), 6.81 (t, 1H, J = 5.8 Hz), 6.67 (t, 1H, 
J = 7.5 Hz), 4.87 (t, 1H, J = 6.5 Hz), 3.48 (m, 4H), 3.39 (q, 2H), 3.00 (m, 2H), 2.71 (br t, 
2H), 2.36 (m, 2H), 2.31 (s, 3H), 2.18 (s, 3H), 1.96 (m, 2H), 1.88 (m, 4H), 1.77 (m, 2H); 
13C NMR (CDCl3, 75 MHz)  173.9, 170.4, 159.7, 150.6, 148.0, 147.1, 139.5, 138.1, 133.9, 
132.4, 130.6, 127.5, 127.4, 125.8, 125.6, 124.4, 124.3, 120.7, 118.6, 116.9, 116.54, 116.49, 
114.9, 45.3, 39.4, 36.6, 34.0, 25.6, 25.5, 25.03, 24.95, 22.9, 22.7, 20.7, 13.9; m/z calcd for 






((2,3-dimethylphenyl)amino)benzamide (13d). Compound 13d was prepared as 
described for the synthesis of 10a. The reaction of 9d (83 mg, 0.235 mmol, 1 eq), EDAC 
hydrochloride (50 mg, 0.259 mmol, 1.1 eq), HOBt hydrate (40 mg, 0.259 mmol, 1.1 eq), 
6a (82 mg, 0.282 mmol, 1.2 eq), and Et3N (60 L, 0.423 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.28), 13d (111 mg, 75%) as a white powder: 
1H NMR 
(CDCl3, 500 MHz)  9.19 (s, 1H), 7.95 (d, 1H, J = 9.1 Hz), 7.86 (d, 1H, J = 1.5 Hz), 7.42 
(d, 1H, J = 7.8 Hz), 7.26 (dd, 1H, J1 = 9.0 Hz, J2 = 1.5 Hz), 7.19 (t, 1H, J = 7.8 Hz), 7.15 
(d, 1H, J = 7.9 Hz), 7.06 (t, 1H, J = 7.6 Hz), 6.94 (t, 2H, J = 7.9 Hz), 6.66 (t, 1H, J = 7.5 
Hz), 6.49 (br t, 1H), 6.13 (t, 1H, J = 5.8 Hz), 4.96 (br s, 1H), 3.43 (m, 4H), 3.37 (q, 2H, J 
= 6.2 Hz), 3.01 (m, 2H), 2.71 (br t, 2H), 2.32 (s, 3H), 2.22 (t, 2H, J = 7.3 Hz), 2.20 (s, 3H), 
1.89 (br s, 4H), 1.71 (m, 4H), 1.64 (p, 2H, J = 7.3 Hz), 1.42 (p, 2H, J = 7.2 Hz); 13C NMR 
(CDCl3, 125 MHz)  174.0, 169.9, 159.6, 150.7, 147.8, 147.0, 139.6, 138.1, 133.9, 132.2, 
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130.6, 127.4, 127.2, 125.8, 125.5, 124.4, 124.3, 120.6, 118.5, 117.1, 116.8, 116.4, 114.9, 
45.1, 39.4, 36.4, 36.3, 33.9, 31.5, 29.3, 26.4, 25.2, 25.0, 23.0, 22.6, 20.7, 13.9; m/z calcd 






Compound 13e was prepared as described for the 
synthesis of 10a. The reaction of 9a (59 mg, 0.198 
mmol, 1 eq), EDAC hydrochloride (42 mg, 0.218 mmol, 1.1 eq), HOBt hydrate (33 mg, 
0.218 mmol, 1.1 eq), 6b (72 mg, 0.238 mmol, 1.2 eq), and Et3N (50 L, 0.357 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.24), 13e (86 mg, 74%) as a pale 
yellow powder: 1H NMR (CDCl3, 500 MHz)  9.19 (s, 1H), 7.86 (d, 1H, J = 2.0 Hz), 7.83 
(d, 1H, J = 9.1 Hz), 7.53 (d, 1H, J = 7.8 Hz), 7.29 (m, 1H), 7.24 (m, 1H), 7.22 (t, 1H, J = 
8.5 Hz), 7.12 (d, 1H, J = 7.5 Hz), 7.05 (t, 1H, J = 7.6 Hz), 6.95 (d, 1H, J = 7.1 Hz), 6.87 
(d, 1H, J = 8.4 Hz), 6.70 (m, 1H), 6.66 (t, 1H, J = 7.4 Hz), 4.09 (d, 2H, J = 5.2 Hz), 3.96 
(br s, 1H), 3.44 (br t, 2H), 3.32 (q, 2H, J = 6.2 Hz), 3.01 (br t, 2H), 2.62 (br t, 2H), 2.29 (s, 
3H), 2.15 (s, 3H), 1.89 (m, 4H), 1.64 (m, 4H); 13C NMR (CDCl3, 125 MHz)  170.2, 169.2, 
159.6, 150.6, 148.0, 147.6, 139.2, 138.2, 134.0, 132.9, 131.2, 127.8, 127.4, 126.0, 125.9, 
124.5, 124.4, 121.4, 118.5, 116.9, 116.2, 115.3, 114.9, 48.9, 43.7, 39.2, 34.0, 28.9, 27.0, 






Compound 13f was prepared as described for the synthesis of 10a. The reaction of 9b (75 
mg, 0.240 mmol, 1 eq), EDAC hydrochloride (51 mg, 0.264 mmol, 1.1 eq), HOBt hydrate 
(40 mg, 0.264 mmol, 1.1 eq), 6b (151 mg, 0.496 mmol, 1.2 eq), and Et3N (60 L, 0.433 
mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column chromatography 
(SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.44), 13f (67 mg, 47%) 
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as a white powder: 1H NMR (CDCl3, 300 MHz)  9.30 (s, 1H), 7.85 (d, 1H, J = 2.0 Hz), 
7.83 (d, 1H, J = 9.1 Hz), 7.44 (d, 1H, J = 7.8 Hz), 7.33 (br s, 1H), 7.23 (dd, 1H, J1 = 9.1 
Hz, J2 = 2.0 Hz), 7.16 (t, 2H, J = 7.8 Hz), 7.04 (t, 1H, J = 7.7 Hz), 6.93 (d, 1H, J = 5.9 Hz), 
6.91 (d, 1H, J = 7.9 Hz), 6.64 (t, 1H, J = 7.5 Hz), 6.45 (br t, 1H), 4.00 (br s, 1H), 3.70 (q, 
2H, J = 5.8 Hz), 3.42 (br t, 2H), 3.28 (q, 2H, J = 6.1 Hz), 2.99 (br t, 2H), 2.61 (br t, 2H), 
2.50 (t, 2H, J = 5.8 Hz), 2.30 (s, 3H), 2.18 (s, 3H), 1.87 (br s, 4H), 1.63 (m, 4H); 13C NMR 
(CDCl3, 75 MHz)  171.8, 169.9, 159.4, 150.7, 147.8, 147.2, 139.4, 138.1, 134.1, 132.4, 
130.7, 127.6, 127.2, 125.8, 125.7, 124.5, 124.4, 120.8, 118.4, 116.9, 116.4, 116.0, 114.8, 
48.9, 39.1, 35.8, 35.5, 33.8, 28.9, 27.0, 24.6, 22.8, 22.5, 20.7, 13.9; m/z calcd for 






Compound 13g was prepared as described for the 
synthesis of 10a. The reaction of 9c (58 mg, 0.177 
mmol, 1 eq), EDAC hydrochloride (42 mg, 0.218 mmol, 1.1 eq), HOBt hydrate (33 mg, 
0.218 mmol, 1.1 eq), 6b (72 mg, 0.238 mmol, 1.2 eq), and Et3N (50 L, 0.357 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.30), 13g (102 mg, 94%) as a 
white powder: 1H NMR (CDCl3, 500 MHz)  9.29 (s, 1H), 7.89 (d, 1H, J = 2.1 Hz), 7.86 
(d, 1H, J = 9.1 Hz), 7.49 (dd, 1H, J1 = 7.9 Hz, J2 = 1.4 Hz), 7.25 (dd, 1H, J1 = 9.0 Hz, J2 = 
2.1 Hz), 7.21 (m, 1H), 7.14 (d, 1H, J = 7.9 Hz), 7.06 (t, 1H, J = 7.7 Hz), 6.98 (br t, 1H, J = 
5.5 Hz), 6.95 (d, 1H, J = 7.5 Hz), 6.92 (dd, 1H, J1 = 7.8 Hz, J2 = 0.7 Hz), 6.71 (m, 1H), 
6.39 (br t, 1H), 4.04 (br s, 1H), 3.48 (m, 4H), 3.31 (q, 2H, J = 6.5 Hz), 3.02 (br t, 2H), 2.65 
(br t, 2H), 2.31 (m, 5H), 2.18 (s, 3H), 1.96 (p, 2H, J = 6.3 Hz), 1.89 (m, 4H), 1.70 (m, 2H), 
1.62 (m, 2H); 13C NMR (CDCl3, 125 MHz)  173.1, 170.3, 159.5, 150.7, 147.9, 147.2, 
139.5, 138.1, 134.1, 132.4, 130.7, 127.6, 127.4, 125.8, 125.7, 124.5, 124.4, 120.8, 118.4, 
116.9, 116.5, 116.2, 114.89, 49.0, 39.4, 39.2, 34.1, 33.9, 29.0, 27.1, 25.3, 24.6, 22.9, 22.6, 









(13h). Compound 13h was prepared as 
described for the synthesis of 10a. The reaction of 9d (66 mg, 0.185 mmol, 1 eq), EDAC 
hydrochloride (39 mg, 0.204 mmol, 1.1 eq), HOBt hydrate (31 mg, 0.204 mmol, 1.1 eq), 
6b (68 mg, 0.223 mmol, 1.2 eq), and Et3N (51 L, 0.367 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.44), 13h (23 mg, 20%) as a pale yellow powder: 
1H 
NMR (CDCl3, 500 MHz)  9.21 (s, 1H), 7.89 (d, 1H, J = 2.3 Hz), 7.87 (d, 1H, J = 9.0 Hz), 
7.45 (dd, 1H, J1 = 7.4 Hz, J2 = 1.0 Hz), 7.27 (dd, 1H, J1 = 9.0 Hz, J2 = 2.1 Hz), 7.20 (td, 
1H, J1 = 7.2 Hz, J2 = 1.0 Hz), 7.16 (d, 1H, J = 7.9 Hz), 7.06 (t, 1H, J = 7.7 Hz), 6.94 (t, 2H, 
J = 7.1 Hz), 6.69 (t, 1H, J = 7.3 Hz), 6.49 (t, 1H, J = 5.5 Hz), 5.79 (t, 1H, J = 5.4 Hz), 4.06 
(br s, 1H), 3.47 (t, 2H), 3.44 (q, 2H, J = 6.8 Hz), 3.27 (q, 2H, J = 6.7 Hz), 3.03 (br t, 2H), 
2.66 (br t, 2H), 2.32 (s, 3H), 2.20 (s, 3H), 2.18 (t, 2H, J = 7.4 Hz), 1.91 (m, 4H), 1.65 (m, 
6H), 1.58 (p, 2H, J = 8.2 Hz), 1.41 (p, 2H, J = 8.0 Hz); 13C NMR (CDCl3, 125 MHz)  
173.0, 169.8, 159.5, 150.7, 147.9, 147.0, 139.6, 138.1, 134.1, 132.2, 130.7, 127.4, 125.7, 
125.5, 124.5, 124.4, 120.7, 118.4, 117.1, 116.8, 116.1, 114.9, 49.0, 39.3, 39.0, 36.4, 33.9, 
29.2, 28.9, 27.2, 26.3, 25.0, 24.7, 22.9, 22.6, 20.7, 13.9; m/z calcd for C38H46ClN5O2: 





Compound 13i was prepared as described for the 
synthesis of 10a. The reaction of 9a (55 mg, 0.185 
mmol, 1 eq), EDAC hydrochloride (39 mg, 0.204 mmol, 1.1 eq), HOBt hydrate (31 mg, 
0.204 mmol, 1.1 eq), 6d (74 mg, 0.223 mmol, 1.2 eq), and Et3N (51 L, 0.367 mmol, 1.8 
eq) in DMF (4 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.49), 13i (44 mg, 38%) as a pale 
64 
 
yellow powder: 1H NMR (CDCl3, 500 MHz)  9.21 (s, 1H), 7.90 (d, 1H, J = 1.6 Hz), 7.89 
(d, 1H, J = 5.0 Hz), 7.52 (d, 1H, J = 7.9 Hz), 7.29 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz), 7.24 
(t, 1H, J = 7.3 Hz), 7.16 (d, 1H, J = 7.8 Hz), 7.09 (t, 1H, J = 7.6 Hz), 6.99 (m, 2H), 6.90 
(d, 1H, J = 8.5 Hz), 6.72 (t, 1H, J = 7.3 Hz), 6.14 (br t, 1H), 4.10 (d, 2H, J = 5.2 Hz), 3.96 
(br s, 1H), 3.46 (t, 2H, J = 7.0 Hz), 3.31 (q, 2H, J = 6.6 Hz), 3.05 (br s, 2H), 2.67 (br s, 
2H), 2.33 (s, 3H), 2.20 (s, 3H), 1.93 (m, 4H), 1.64 (p, 2H, J = 7.1 Hz), 1.54 (p, 2H, J = 7.4 
Hz), 1.39 (m, 4H); 13C NMR (CDCl3, 125 MHz)  170.1, 169.0, 159.5, 150.8, 148.1, 147.6, 
139.3, 138.1, 134.0, 132.8, 131.2, 127.8, 127.4, 126.0, 125.9, 124.6, 124.2, 121.4, 118.4, 
116.8, 115.8, 115.4, 114.9, 49.4, 43.7, 39.4, 34.0, 31.6, 29.4, 26.52, 26.49, 24.6, 22.9, 22.6, 






((2,3-dimethylphenyl)amino)benzamide (13j). Compound 13j was prepared as described 
for the synthesis of 10a. The reaction of 9b (94 mg, 0.301 mmol, 1 eq), EDAC 
hydrochloride (64 mg, 0.331 mmol, 1.1 eq), HOBt hydrate (51 mg, 0.331 mmol, 1.1 eq), 
6d (130 mg, 0.391 mmol, 1.2 eq), and Et3N (76 L, 0.542 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.29), 13j (28 mg, 15%) as a white powder: 
1H NMR 
(CDCl3, 500 MHz)  9.32 (s, 1H), 7.90 (d, 1H, J = 2.7 Hz), 7.89 (d, 1H, J = 8.2 Hz), 7.44 
(d, 1H, J = 7.8 Hz), 7.28 (dd, 1H, J1 = 9.0 Hz, J2 = 2.3 Hz), 7.20 (t, 1H, J = 7.5 Hz), 7.19 
(m, 1H), 7.17 (d, 1H, J = 8.2 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.96 (d, 1H, J = 7.5 Hz), 6.93 
(d, 1H, J = 8.5 Hz), 6.68 (t, 1H, J = 7.4 Hz), 5.86 (m, 1H), 4.01 (br s, 1H), 3.73 (q, 2H, J = 
5.8 Hz), 3.47 (t, 2H, J = 7.2 Hz), 3.27 (q, 2H, J = 6.7 Hz), 3.04 (m, 2H), 2.67 (m, 2H), 2.52 
(t, 2H, J = 5.8 Hz), 2.33 (s, 3H), 2.21 (s, 3H), 1.93 (m, 4H), 1.63 (p, 2H, J = 6.9 Hz), 1.52 
(p, 2H, J = 7.4 Hz), 1.37 (m, 4H); 13C NMR (CDCl3, 125 MHz)  171.6, 169.8, 159.5, 
150.9, 147.2, 139.5, 138.1, 134.1, 132.3, 130.8, 127.6, 127.4, 125.8, 125.6, 124.6, 124.3, 
120.8, 118.3, 116.8, 116.5, 115.7, 114.8, 49.4, 39.4, 35.8, 35.6, 33.9, 31.6, 29.5, 26.6, 26.5, 









(13k). Compound 13k was prepared as 
described for the synthesis of 10a. The reaction of 9c (78 mg, 0.238 mmol, 1 eq), EDAC 
hydrochloride (50 mg, 0.262 mmol, 1.1 eq), HOBt hydrate (40 mg, 0.262 mmol, 1.1 eq), 
6d (95 mg, 0.285 mmol, 1.2 eq), and Et3N (60 L, 0.428 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.38), 13k (21 mg, 13%) as a pale yellow powder: 
1H 
NMR (CDCl3, 500 MHz)  9.33 (s, 1H), 7.90 (s, 1H), 7.89 (d, 1H, J = 9.3 Hz), 7.49 (d, 1H, 
J = 7.1 Hz), 7.27 (dd, 1H, J1 = 9.1 Hz, J2 = 2.1 Hz), 7.21 (t, 1H, J = 7.4 Hz), 7.17 (d, 1H, 
J = 7.9 Hz), 7.07 (t, 1H, J = 7.7 Hz), 7.02 (br t, 1H), 6.94 (t, 2H), 6.71 (t, 1H, J = 7.3 Hz), 
6.19 (br t, 1H), 4.00 (br s, 1H), 3.50 (q, 2H, J = 6.2 Hz), 3.46 (t, 2H, J = 7.2 Hz), 3.26 (q, 
2H, J = 6.8 Hz), 3.04 (br t, 2H), 2.66 (br t, 2H), 2.31 (m, 5H), 2.21 (s, 3H), 1.97 (p, 2H, J 
= 6.2 Hz), 1.92 (m, 4H), 1.64 (p, 2H, J = 7.2 Hz), 1.51 (p, 2H, J = 7.0 Hz), 1.36 (m, 4H); 
13C NMR (CDCl3, 125 MHz)  173.0, 170.2, 159.5, 150.8, 148.0, 147.1, 139.6, 138.1, 
134.0, 132.3, 130.7, 127.7, 127.4, 125.8, 125.6, 124.7, 124.2, 120.7, 118.3, 116.9, 116.6, 
115.7, 114.8, 49.4, 43.7, 39.5, 39.4, 34.1, 34.0, 31.6, 29.5, 26.6, 26.5, 25.2, 24.6, 22.9, 22.6, 







(13l). Compound 13l was prepared as 
described for the synthesis of 10a. The reaction of 9d (96 mg, 0.271 mmol, 1 eq), EDAC 
hydrochloride (57 mg, 0.298 mmol, 1.1 eq), HOBt hydrate (46 mg, 0.298 mmol, 1.1 eq), 
6d (108 mg, 0.325 mmol, 1.2 eq), and Et3N (68 L, 0.488 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 




(CDCl3, 500 MHz)  9.24 (s, 1H), 7.88 (d, 1H, J = 9.1 Hz), 7.85 (d, 1H, J = 1.8 Hz), 7.45 
(d, 1H, J = 7.8 Hz), 7.23 (dd, 1H, J1 = 9.0 Hz, J2 = 1.8 Hz), 7.17 (t, 1H, J = 7.4 Hz), 7.14 
(d, 1H, J = 8.6 Hz), 7.04 (t, 1H, J = 7.7 Hz), 6.91 (d, 2H, J = 8.0 Hz), 6.75 (t, 1H, J = 5.3 
Hz), 6.64 (t, 1H, J = 7.4 Hz), 6.02 (t, 1H, J = 5.4 Hz), 4.03 (br s, 1H), 3.41 (m, 4H), 3.19 
(q, 2H, J = 6.8 Hz), 2.99 (br s, 2H), 2.63 (br s, 2H), 2.30 (s, 3H), 2.18 (s, 3H), 2.15 (t, 2H, 
J = 7.3 Hz), 1.88 (br s, 4H), 1.65 (p, 2H, J = 7.5 Hz), 1.60 (p, 4H, J = 7.3 Hz), 1.45 (p, 2H, 
J = 7.4 Hz), 1.37 (m, 4H), 1.31 (m, 2H); 13C NMR (CDCl3, 125 MHz)  173.0, 169.9, 
159.5, 150.8, 148.1, 146.9, 139.6, 138.0, 133.9, 132.1, 130.6, 127.6, 127.4, 125.7, 125.5, 
124.7, 124.1, 120.6, 118.4, 117.2, 116.8, 115.7, 114.8, 49.4, 39.4, 39.2, 36.4, 34.0, 31.6, 
29.6, 29.2, 26.6, 26.5, 26.4, 25.1, 24.6, 22.9, 22.6, 20.7, 13.9; m/z calcd for C40H50ClN5O2: 





((2,3-dimethylphenyl)amino)benzamide (13m). Compound 13m was prepared as 
described for the synthesis of 10a. The reaction of 9a (53.4 mg, 0.179 mmol, 1 eq), EDAC 
hydrochloride (38 mg, 0.197 mmol, 1.1 eq), HOBt hydrate (30 mg, 0.197 mmol, 1.1 eq), 
6e (74.2 mg, 0.2155 mmol, 1.2 eq), and Et3N (45 L, 0.323 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.50), 13m (11 mg, 10%) as a white powder: 
1H NMR 
(CDCl3, 500 MHz)  9.22 (s, 1H), 7.91 (d, 1H, J = 5.7 Hz), 7.89 (d, 1H, J = 2.8 Hz), 7.53 
(d, 1H, J = 7.9 Hz), 7.28 (dd, 1H, J1 = 9.0 Hz, J2 = 2.8 Hz), 7.23 (t, 1H, J = 7.5 Hz), 7.15 
(d, 1H, J = 7.9 Hz), 7.14 (m, 1H), 7.08 (t, 1H, J = 7.6 Hz), 6.97 (d, 1H, J = 7.4 Hz), 6.89 
(d, 1H, J = 8.5 Hz), 6.70 (t, 1H, J = 7.4 Hz), 6.27 (t, 1H, J = 5.5 Hz), 4.10 (d, 2H, J = 5.2 
Hz), 3.90 (very br s, 1H), 3.47 (t, 2H, J = 7.3 Hz), 3.29 (q, 2H, J = 6.8 Hz), 3.05 (br s, 2H), 
2.67 (br s, 2H), 2.33 (s, 3H), 2.19 (s, 3H), 1.93 (m, 4H), 1.64 (p, 2H, J = 7.1 Hz), 1.50 (p, 
2H, J = 6.7 Hz), 1.33 (m, 6H) 13C NMR (CDCl3, 125 MHz)  170.0, 168.9, 160.0, 151.0, 
149.8, 147.6, 139.3, 138.1, 132.8, 132.6, 131.2, 127.8, 127.3, 126.0, 125.8, 124.6, 124.3, 
121.4, 118.3, 116.8, 115.6, 115.4, 114.9, 49.5, 43.6, 39.6, 33.9, 31.7, 29.4, 28.9, 26.7, 26.6, 









(13n). Compound 13n was prepared as 
described for the synthesis of 10a. The reaction of 9b (51 mg, 0.164 mmol, 0.86 eq), EDAC 
hydrochloride (40 mg, 0.209 mmol, 1.1 eq), HOBt hydrate (32 mg, 0.209 mmol, 1.1 eq), 
6e (79 mg, 0.228 mmol, 1.2 eq), and Et3N (48 L, 0.342 mmol, 1.8 eq) in DMF (3 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.46), 13n (61 mg, 58%) as a yellow oil: 
1H NMR (CDCl3, 
500 MHz)  9.33 (s, 1H), 7.87 (d, 1H, J = 9.0 Hz), 7.86 (d, 1H, J = 2.0 Hz), 7.45 (d, 1H, J 
= 7.7 Hz), 7.41 (t, 1H, J = 5.6 Hz), 7.25 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz), 7.17 (t, 1H, J = 
7.7 Hz), 7.15 (d, 1H, J = 7.6 Hz), 7.05 (t, 1H, J = 7.6 Hz), 6.93 (d, 1H, J = 7.5 Hz), 6.90 
(d, 1H, J = 8.5 Hz), 6.65 (t, 1H, J = 7.3 Hz), 6.36 (t, 1H, J = 5.5 Hz), 3.98 (br s, 1H), 3.70 
(q, 2H, J = 5.8 Hz), 3.44 (t, 2H, J = 6.7 Hz), 3.22 (q, 2H, J = 6.7 Hz), 3.01 (br t, 2H), 2.64 
(br t, 2H), 2.50 (t, 2H, J = 5.9 Hz), 2.30 (s, 3H), 2.19 (s, 3H), 1.89 (m, 4H), 1.60 (p, 2H, J 
= 7.2 Hz), 1.46 (p, 2H, J = 6.7 Hz), 1.30 (m, 6H); 13C NMR (CDCl3, 125 MHz)  171.7, 
169.8, 159.5, 150.8, 148.1, 147.2, 139.5, 138.0, 133.9, 132.2, 130.7, 127.7, 127.4, 125.7, 
125.5, 124.7, 124.2, 120.8, 118.4, 116.8, 116.5, 115.7, 114.7, 49.5, 39.5, 35.8, 35.4, 34.0, 
31.7, 29.4, 28.9, 26.8, 26.7, 24.6, 22.9, 22.6, 20.7, 13.9; m/z calcd for C38H46ClN5O2: 





((2,3-dimethylphenyl)amino)benzamide (13o). Compound 13o was prepared as 
described for the synthesis of 10a. The reaction of 9c (52 mg, 0.158 mmol, 0.87 eq), EDAC 
hydrochloride (38 mg, 0.200 mmol, 1.1 eq), HOBt hydrate (31 mg, 0.200 mmol, 1.1 eq), 
6e (84 mg, 0.258 mmol, 1.2 eq), and Et3N (46 L, 0.387 mmol, 1.8 eq) in DMF (3 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
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NH4OH (7 mL/L of solvent), Rf 0.50), 13o (59 mg, 57%) as a yellow oil: 
1H NMR (CDCl3, 
500 MHz)  9.35 (s, 1H), 7.87 (d, 1H, J = 9.2 Hz), 7.86 (d, 1H, J = 2.1 Hz), 7.50 (d, 1H, J 
= 7.8 Hz), 7.39 (t, 1H, J = 7.0 Hz), 7.23 (dd, 1H, J1 = 9.2 Hz, J2 = 2.1 Hz), 7.17 (t, 1H, J = 
7.5 Hz), 7.14 (d, 1H, J = 8.4 Hz), 7.04 (t, 1H, J = 7.6 Hz), 6.91 (d, 2H, J = 8.1 Hz), 6.66 (t, 
1H, J = 7.4 Hz), 6.62 (t, 1H, J = 5.5 Hz), 4.01 (br s, 1H), 3.47 (t, 2H, J = 5.9 Hz), 3.44 (q, 
2H, J = 5.4 Hz), 3.21 (q, 2H, J = 6.7 Hz), 3.00 (br t, 2H), 2.63 (br t, 2H), 2.29 (t, 2H, J = 
7.2 Hz), 2.29 (s, 3H), 2.18 (s, 3H), 1.94 (p, 2H, J = 6.5 Hz), 1.88 (m, 4H), 1.60 (p, 2H, J = 
7.0 Hz), 1.45 (p, 2H, J = 6.5 Hz), 1.29 (m, 6H); 13C NMR (CDCl3, 125 MHz)  173.1, 
170.2, 159.4, 150.9, 148.0, 147.1, 139.6, 138.0, 134.0, 132.1, 130.6, 127.8, 127.3, 125.7, 
125.5, 124.7, 124.1, 120.7, 118.3, 116.8, 116.7, 115.6, 114.7, 49.5, 39.6, 39.5, 34.1, 33.9, 
31.7, 29.4, 28.9, 26.8, 26.7, 25.2, 24.6, 22.9, 22.6, 20.7, 13.9; m/z calcd for C39H48ClN5O2: 





oxohexyl)-2-((2,3-dimethylphenyl)amino)benzamide (13p). Compound 13p was 
prepared as described for the synthesis of 10a. The reaction of 9d (55 mg, 0.155 mmol, 
0.80 eq), EDAC hydrochloride (41 mg, 0.214 mmol, 1.1 eq), HOBt hydrate (33 mg, 0.214 
mmol, 1.1 eq), 6e (81 mg, 0.233 mmol, 1.2 eq), and Et3N (49 L, 0.350 mmol, 1.8 eq) in 
DMF (3 mL) yielded, after purification by flash column chromatography (SiO2; 
9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.42), 13p (51 mg, 48%) as a 
yellow oil: 1H NMR (CDCl3, 500 MHz)  9.23 (s, 1H), 7.89 (d, 1H, J = 9.0 Hz), 7.87 (d, 
1H, J = 2.1 Hz), 7.44 (d, 1H, J = 7.1 Hz), 7.25 (dd, 1H, J1 = 9.0 Hz, J2 = 2.1 Hz), 7.18 (t, 
1H, J = 7.5 Hz), 7.15 (d, 1H, J = 7.7 Hz), 7.05 (t, 1H, J = 7.7 Hz), 6.92 (d, 2H, J = 8.4 Hz), 
6.66 (t, 1H, J = 7.4 Hz), 6.61 (t, 1H, J = 5.5 Hz), 5.85 (t, 1H, J = 5.5 Hz), 4.01 (br s, 1H), 
3.46 (t, 2H, J = 7.0 Hz), 3.42 (q, 2H, J = 6.8 Hz), 3.19 (q, 2H, J = 6.7 Hz), 3.01 (m, 2H), 
2.65 (m, 2H), 2.31 (s, 3H), 2.19 (s, 3H), 2.17 (t, 2H, J = 7.4 Hz), 1.90 (m, 4H), 1.68 (p, 2H, 
J = 7.4 Hz), 1.63 (p, 4H, J = 7.1 Hz), 1.42 (m, 4H), 1.29 (m, 6H); 13C NMR (CDCl3, 125 
MHz)  172.9, 169.8, 159.5, 150.9, 148.1, 147.0, 139.6, 138.0, 133.9, 132.1, 130.6, 127.5, 
127.4, 125.7, 125.5, 124.7, 124.2, 120.6, 118.4, 117.2, 116.8, 115.7, 114.8, 49.5, 39.40, 
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39.38, 36.4, 34.0, 31.7, 29.6, 29.2, 28.9, 26.8, 26.7, 26.4, 25.1, 24.6, 22.9, 22.6, 20.7, 13.9; 







Compound 13q was prepared as described for 
the synthesis of 10a. The reaction of 9a (47 mg, 0.158 mmol, 1 eq), EDAC hydrochloride 
(33 mg, 0.173 mmol, 1.1 eq), HOBt hydrate (27 mg, 0.173 mmol, 1.1 eq), 6f (68 mg, 0.205 
mmol, 1.2 eq), and Et3N (40 L, 0.284 mmol, 1.8 eq) in DMF (4 mL) yielded, after 
purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent), Rf 0.37), 13q (46 mg, 54%) as a pale yellow powder: 
1H NMR (CDCl3, 
500 MHz)  9.23 (s, 1H), 7.90 (d, 1H, J = 10.5 Hz), 7.88 (s, 1H), 7.56 (d, 1H, J = 7.9 Hz), 
7.41 (t, 1H, J = 4.8 Hz), 7.27 (d, 1H, J = 9.0 Hz), 7.20 (t, 1H, J = 7.6 Hz), 7.15 (d, 1H, J = 
7.8 Hz), 7.08 (t, 1H, J = 7.6 Hz), 6.97 (d, 1H, J = 7.3 Hz), 6.87 (d, 1H, J = 8.5 Hz), 6.66 (t, 
1H, J = 7.6 Hz), 6.64 (t, 1H, J = 5.4 Hz), 4.10 (d, 2H, J = 5.1 Hz), 3.99 (br s, 1H), 3.46 (t, 
2H, J = 6.7 Hz), 3.27 (q, 2H, J = 6.7 Hz), 3.03 (br s, 2H), 2.66 (br s, 2H), 2.32 (s, 3H), 2.18 
(s, 3H), 1.92 (m, 4H), 1.62 (p, 2H, J = 7.0 Hz), 1.48 (br p, 2H), 1.34 (m, 2H), 1.27 (m, 6H); 
13C NMR (CDCl3, 125 MHz)  170.1, 169.0, 159.5, 150.9, 148.1, 147.6, 139.3, 138.1, 
134.0, 132.7, 131.2, 127.9, 127.4, 126.0, 125.8, 124.7, 124.2, 121.5, 118.4, 116.8, 115.7, 
115.5, 114.8, 49.5, 43.7, 39.6, 34.0, 31.7, 29.4, 29.14, 29.07, 26.8, 26.7, 24.6, 22.9, 22.7, 






((2,3-dimethylphenyl)amino)benzamide (13r). Compound 13r was prepared as 
described for the synthesis of 10a. The reaction of 9b (50 mg, 0.159 mmol, 1 eq), EDAC 
hydrochloride (34 mg, 0.175 mmol, 1.1 eq), HOBt hydrate (27 mg, 0.175 mmol, 1.1 eq), 
6f (69 mg, 0.207 mmol, 1.2 eq), and Et3N (40 L, 0.286 mmol, 1.8 eq) in DMF (4 mL) 
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yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.45), 13r (20 mg, 20%) as a pale yellow powder: 
1H NMR 
(CDCl3, 500 MHz)  9.32 (s, 1H), 7.90 (d, 1H, J = 9.0 Hz), 7.89 (d, 1H, J = 2.0 Hz), 7.45 
(d, 1H, J = 7.8 Hz), 7.29 (m, 1H), 7.27 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz), 7.20 (t, 1H, J = 
8.0 Hz), 7.17 (d, 1H, J = 8.7 Hz), 7.07 (t, 1H, J = 7.6 Hz), 6.95 (d, 1H, J = 7.4 Hz), 6.92 
(d, 1H, J = 8.5 Hz), 6.68 (t, 1H, J = 7.4 Hz), 6.00 (t, 1H, J = 5.3 Hz), 3.99 (br s, 1H), 3.72 
(q, 2H, J = 5.8 Hz), 3.48 (t, 2H, J = 7.0 Hz), 3.25 (q, 2H, J = 6.6 Hz), 3.03 (m, 2H), 2.67 
(m, 2H), 2.52 (t, 2H, J = 5.8 Hz), 2.33 (s, 3H), 2.21 (s, 3H), 1.92 (m, 4H), 1.64 (p, 2H, J = 
7.4 Hz), 1.47 (br p, 2H), 1.36 (m, 4H), 1.28 (s, 4H); 13C NMR (CDCl3, 125 MHz)  171.7, 
169.8, 159.5, 150.9, 148.1, 147.2, 139.6, 138.0, 134.0, 132.3, 130.8, 127.6, 127.5, 125.7, 
125.6, 124.7, 124.2, 120.8, 118.4, 116.8, 116.5, 115.7, 114.8, 49.5, 39.6, 35.8, 35.5, 34.00, 
33.96, 31.7, 29.5, 29.13, 29.09, 26.8, 24.6, 22.9, 22.7, 20.7, 13.9; m/z calcd for 







(13s). Compound 13s was prepared as 
described for the synthesis of 10a. The reaction of 9c (45 mg, 0.137 mmol, 1 eq), EDAC 
hydrochloride (29 mg, 0.150 mmol, 1.1 eq), HOBt hydrate (23 mg, 0.150 mmol, 1.1 eq), 
6f (64 mg, 0.177 mmol, 1.2 eq), and Et3N (34 L, 0.247 mmol, 1.8 eq) in DMF (4 mL) 
yielded, after purification by flash column chromatography (SiO2; 9:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.35), 13s (28 mg, 31%) as a pale yellow powder: 
1H NMR 
(CDCl3, 500 MHz)  9.35 (s, 1H), 7.91 (d, 1H, J = 8.8 Hz), 7.92 (s, 1H), 7.49 (d, 1H, J = 
7.2 Hz), 7.29 (m, 1H), 7.22 (t, 1H, J = 7.3 Hz), 7.18 (d, 1H, J = 7.8 Hz), 7.08 (t, 1H, J = 
7.7 Hz), 6.99 (br t, 1H), 6.95 (m, 2H) 6.72 (t, 1H, J = 7.4 Hz), 6.07 (br t, 1H), 4.02 (very 
br s, 1H), 3.51 (p, 4H, J = 6.4 Hz), 3.25 (q, 2H, J = 6.7 Hz), 3.05 (br t, 2H), 2.68 (br t, 2H), 
2.33 (m, 5H), 2.22 (s, 3H), 1.99 (m, 2H), 1.94 (m, 4H), 1.66 (p, 2H, J = 7.3 Hz), 1.48 (m, 
2H), 1.35 (m, 2H), 1.29 (m, 6H); 13C NMR (CDCl3, 125 MHz)  172.9, 170.1, 147.2, 139.6, 
138.0, 135.3, 134.7, 134.2, 132.2, 130.7, 127.6, 126.8, 125.7, 125.5, 124.7, 124.3, 120.8, 
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116.9, 116.6, 114.8, 49.5, 39.6, 39.5, 34.2, 34.0, 31.7, 29.5, 29.11, 29.08, 26.8, 25.1, 25.0, 








(13t). Compound 13t was prepared as described for the synthesis of 10a. The reaction of 
9d (48 mg, 0.137 mmol, 1 eq), EDAC hydrochloride (29 mg, 0.152 mmol, 1.1 eq), HOBt 
hydrate (23 mg, 0.152 mmol, 1.1 eq), 6f (65 mg, 0.180 mmol, 1.2 eq), and Et3N (34 L, 
0.244 mmol, 1.8 eq) in DMF (4 mL) yielded, after purification by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.29), 13t 
(80 mg, 84%) as a pale yellow powder: 1H NMR (CDCl3, 500 MHz)  9.23 (s, 1H), 7.92 
(d, 1H, J = 7.7 Hz), 7.91 (d, 1H, J = 1.9 Hz), 7.45 (d, 1H, J = 7.3 Hz), 7.28 (dd, 1H, J1 = 
9.0 Hz, J2 = 1.9 Hz), 7.21 (t, 1H, J = 7.3 Hz), 7.17 (d, 1H, J = 7.9 Hz), 7.07 (t, 1H, J = 7.6 
Hz), 6.94 (m, 2H), 6.69 (t, 1H, J = 7.2 Hz), 6.44 (br t, 1H), 5.62 (br t, 1H), 4.10 (very br s, 
1H), 3.51 (t, 2H, J = 7.1 Hz), 3.45 (q, 2H, J = 6.3 Hz), 3.22 (q, 2H, J = 6.7 Hz), 3.05 (br t, 
2H), 2.67 (br t, 2H), 2.33 (s, 3H), 2.21 (s, 3H), 2.20 (t, 2H, J = 7.4 Hz), 1.93 (m, 4H), 1.69 
(m, 6H), 1.45 (p, 4H, J = 7.1 Hz), 1.38 (br p, 2H), 1.30 (m, 6H); 13C NMR (CDCl3, 125 
MHz)  172.8, 169.8, 162.5, 151.2, 147.0, 144.0, 139.6, 138.0, 132.1, 130.7, 127.4, 125.7, 
125.5, 124.7, 124.3, 120.7, 118.9, 118.1, 117.2, 116.8, 116.6, 115.5, 114.9, 49.5, 39.44, 
39.38, 36.5, 31.7, 30.9, 29.6, 29.2, 29.12, 29.06, 26.74, 26.71, 26.4, 25.0, 24.5, 22.9, 22.5, 
20.7, 13.9; m/z calcd for C42H54ClN5O2: 695.40; found 696.45 [M+H]
+. 
 
2.6.2. Biochemical and computational methods 
2.6.2.1. In vitro AChE assay 
Compounds were dissolved in sodium phosphate (dibasic) buffer ((125 L), 0.1 M, pH 8.0 
(adjusted at rt)), and a five-fold dilution was performed. To the solution of inhibitors was 
added AChE cocktail (50 L, containing 0.08 U/mL (~0.29 nM) AChE (final 
concentration) (Sigma-Aldrich cat #C2888 from eel) in sodium phosphate (dibasic) buffer 
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(0.1 M, pH 8.0 (adjusted at rt)). The mixture of inhibitor and enzyme was incubated for 10 
min before initiation with 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) (50 L, 0.25 mM 
final concentration) and acetylthiocholine (ATC) (0.5 mM final concentration) in 
phosphate buffer. The reaction was monitored at 412 nm taking measurements every 30 s 
for 30 min. Data was corrected with the negative control (no ATC) and normalized to the 
positive control (no inhibitor) using the initial rates (first 2-5 min). All assays were 
performed at least in triplicate. The resulting curve rate versus concentration of inhibitor 
was fitted to a sigmoidal curve, and IC50 values were calculated using KaleidaGraph 4.1.1. 
Three representative examples of IC50 curves are provided in Fig. 2.3. All IC50 values are 
provided in Table 2.1. 
 
2.6.2.2. Studies of the mode of inhibition 
Non-competitive inhibition was determined by incubating four concentrations of inhibitor 
(0, 0.2, 1, and 5 M) with AChE (as described above). The enzymatic reaction was then 
initiated by the addition of various concentrations of ATC (62.5, 250, 500, and 1000 M). 
The rates of the reactions were calculated using the first 2 min of the reaction and plotted 
on a Lineweaver-Burk plot. Separate lines were drawn for each concentration of inhibitor, 
and observation of intersection on the negative side of the x axis indicated non-competitive 
inhibition. A representative plot is provided in Fig. 2.4. 
 
2.6.2.3. In vitro AChE ROS inactivation assay 
In the wells of a 96-well plate, horseradish peroxidase (0.25 M), H2O2 (100 M), AChE 
(0.08 U/mL, ~0.29 nM), compound (25 M – 13 pM), and diethylenetriaminepentaacetic 
acid (DETAPAC) (100 M) were dissolved in acetate buffer (pH 6.0) (50 mM) and 
incubated at 37 °C for 30 min. Note: all concentrations are reported as final concentrations. 
To the above solution, a mixture of ATC (0.5 mM) and DTNB (0.25 mM) in sodium 
phosphate (dibasic) buffer (50 mM, pH 7.4 (adjusted at rt)) was added. Reaction rates were 
monitored at 25 °C for 20 min taking measurements every 30 s, and rates were calculated 
using the initial rate (first 2-5 min). Total reaction volume was 200 L. Rates were 
normalized to the reaction without compounds and plotted in KaleidaGraph 4.1.1 to 
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calculate the IC50. Three representative examples of IC50 curves are provided in Fig. 2.3. 
All IC50 values are provided in Table 2.1. 
 
2.6.2.4. Molecular modeling 
Molecular docking studies were run on an Intell Premium 4 CPU (3.19 GHz, 0.99 GB of 
RAM, Windows XP Professional (Version 2002)) using the modeling program AutoDock 
4.2 (2009. The Scripps Research Institute. 10550 North Torrey Pines Road, La Jolla, CA 
92037. http://autodock.scripps.edu). Additionally, the program Cygwin (version 1.7. 
http://www.cygwin.com) was used to properly run the Autogrid and AutoDock 
applications. The crystal structure of AChE from Torpedo californica in complex with 
tacrine (PDB ID: 1ACJ, 2.8 Å resolution) was first edited in PyMOL 
(http://www.pymol.org, (PyMOL Molecular Graphics System, version 1.1r1, Schrödinger, 
LLC)) by manually removing all H2O molecules. The tacrine molecule was also removed 
from the active site. The enzyme was then loaded into AutoDock where all polar hydrogens 
were added and Kollman charges were assigned. The various ligands were prepared in 
ChemBio3D Ultra 12.0 (http://www.cambridgesoft.com), and then loaded into AutoDock. 
The scoring grid for AutoDock was centered approximately in between the CAS and PAS 
(x-center: 4.795, y-center: 66.845, z-center: 72.226). The grid size was selected to be 
606060 points with a spacing between grid points of 0.375 Å. A Lamarckian genetic 
search algorithm was run 100 times using 150 population size and a maximum number of 
energy evaluations of 2,500,000, while the rest of the docking study parameters were kept 
at their default quantity. After the docking was finished, conformations that were shown to 
be the in the largest cluster or most thermodynamically stable were examined in PyMOL. 
All docking figures were made in PyMOL (Fig. 2.5). 
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Investigation of the role of linker moieties in bifunctional tacrine hybrids 
 
3.1. Abstract 
Alzheimer’s disease (AD) is a complex neurological disorder with multiple inter-connected 
factors playing roles in the onset and progression of the disease. One strategy currently 
being explored for the development of new therapeutics for AD involves linking tacrine, 
a known acetylcholinesterase (AChE) inhibitor, to another drug to create bifunctional 
hybrids. The role and influence on activity of the linker moiety in these hybrids remains 
ill-defined. In this study, three series of 6-chlorotacrine with linkers varying in terminal 
functional group and length were synthesized, evaluated for AChE inhibition, and 
compared to tacrine and 6-chlorotacrine-mefenamic acid hybrids. Out of the compounds 
with terminal amine, methyl, and hydroxyl moieties tested, several highly potent 
molecules (low nanomolar IC50 values) comprised of linkers with terminal amines were 
identified. These 6-chlorotacrine with linkers were significantly more potent than tacrine 
alone and were often more potent than similar 6-chlorotacrine-mefenamic acid hybrids. 
 
3.2. Introduction 
Alzheimer’s disease (AD), the 6th leading cause of death in the USA, is a progressive 
dementia whose symptoms include cognitive dysfunction, psychiatric and behavioral 
disturbances, and difficulties in performing tasks of daily living. In contrast to other major 
causes of death such as HIV, stroke, breast cancer, and heart disease, which have shown 
decreases in overall mortality over the past decade, the number of deaths due to AD has 
risen over 66%.1,2 Although the exact underlying cause of the disease is unknown, several 
factors are thought to play a role in the onset and progression of AD. These include plaque 




irregular phosphorylation of Tau protein, dyshomeostasis and miscompartmentalization of 
the metal ions copper, iron, and zinc, inflammation and oxidative stress from reactive 
oxygen species (ROS), and decreased cholinergic transmission and acetylcholine (ACh) 
levels. Current treatments for AD are largely centered on increasing ACh levels in the 
brain through the inhibition of acetylcholinesterase (AChE). In fact, four out of the five 
approved drugs for AD are acetylcholinesterase inhibitors (AChEis). These include tacrine 
(1) (Fig. 3.1A), donepezil, rivastigmine, and galantamine. There is evidence that AChEis 
are moderately successful in AD treatment.3,4 However, as highlighted by clinical studies 
of donepezil, it has been suggested that AChEis may not be cost-effective and new 
approaches should be sought.5,6 In addition, the current treatments for AD are only able 
to treat symptoms of the disease and do little to stop or reverse the progression. 
 
The development of new therapeutics to combat the multifactorial nature of AD is clearly 
an important research endeavor, and one approach to this end is the multitarget approach 
of hybrid drugs. In AD, this approach is based on the unique structural and biochemical 
properties of AChE. AChE is known to possess two binding sites: the catalytic active 
site (CAS) and the peripheral anionic site (PAS) connected by a gorge that is about 20 Å 
long.7-10 In addition, AChE is known to be found entangled in the A plaque, and the 
enzyme likely accelerates the formation of stable A aggregates through interactions with 
the PAS.11,12 Also found in the plaque are metal ions and ROS. Metal chelators and ROS 
scavengers have shown promise in the treatment of AD.13 A popular strategy over the past 
15 years has been to link a known AChEi with another compound capable of binding to 
the PAS and/or exerting other properties that are beneficial to the treatment of AD to 
create a bifunctional or multifunctional hybrid compound. The AChEi moiety of the 
resulting hybrid serves to direct the molecule to the CAS of AChE so the other moiety can 
interact with the PAS to increase potency, disrupt A aggregation, chelate metals, and/or 
scavenge ROS. Although the use of tacrine has been severely limited since its inception 
due to hepatotoxicity,14 it is often the AChEi of choice as a starting point for designing 
multifunctional hybrids due to its AChE inhibitory properties and the ease and low costs 
at which synthetic precursors, such as the 9-chloro derivative15 that is susceptible to 




By linking tacrine with another compound to create a multifunctional hybrid, it is 
possible to not only greatly increase potency towards AChE inhibition but also to attack 
the multifactorial nature of AD. For example, a heptylene-linked tacrine dimer was shown 
to be 150-fold more potent than tacrine16 by binding to the enzyme such that one 
tacrine moiety was positioned in the CAS and the other was positioned in the PAS.8 An 
inhibitor of this type has the potential to disrupt AChE-mediated A aggregation as 
mentioned above. As another example, tacrine-8-hydroxyquinoline hybrids were shown 
to be potent AChEis and antioxidants with low cell toxicity and the ability to complex 
copper ions, as well as the predicted ability to disrupt AChE-mediated A aggregation.17 
The best compound from this series showed a remarkable 700-fold greater potency towards 
human AChE than tacrine. To date, there have been roughly fifty tacrine hybrids that have 
been synthesized, tested, and reported in the literature. 
 
We recently synthesized and tested two series of 6-chlorotacrine-mefenamic acid hybrids 
(11a-f and 13f-h, 13j-l, 13n-p) (Fig. 3 . 1A).18 Mefenamic acid (2) is a NSAID with the 
ability to inactivate AChE in the presence of peroxidases,19 decrease the occurrence of 
free-radicals, attenuate A peptide-induced neurotoxicity, and improve cognitive 
impairments.20 The best compounds from these series contained an 8-10 atom linker 
between the 6-chlorotacrine and mefenamic acid moieties and displayed low nanomolar 
or subnanomolar IC50 values for AChE under normal and ROS conditions. Many of these 
hybrids showed improvement in potency in our assays over a 1:1 mixture of tacrine and 
mefenamic acid, which seems to indicate a benefit to linking the two molecules as was 
originally hypothesized. 
 
To further investigate the role of the linker itself, we report herein on the inhibition of 
AChE by 1:1 mixtures of 6-chlorotacrine with linkers 6b-i and mefenamic acid or 6-
chlorotacrine with linkers 6b-e and mefenamic acid with linkers 9b-d. These mixtures 
closely resemble hybrids 11a-f and 13f-h, 13j-l, 13n-p as they are essentially the hybrid 
lacking the final amide bond. In addition, we have synthesized new types of 6-
chlorotacrine derivatives, resembling previously published tacrine with linkers, which 




of tacrine hybrids in the literature, there remains little precedent for testing the inhibitory 
properties of 6-chlorotacrine with linkers by themselves. Our results should elucidate more 
clearly the role of the linker portion of the tacrine hybrid molecules and the benefit, if any, 
of linking together AChEis and other small molecules. 
 
3.3. Results and discussion 
3.3.1. Synthesis 
The synthetic approach to the 
generation of our new 6-
chlorotacrine derivatives is 
illustrated in Figure 3.1B. The 
6-Cl substitution on the tacrine 
core was chosen because we 
have previously discovered that 
it increases binding potency for 
AChE when compared to its 
non-chlorinated counterpart,18 a 
result that has also been 
observed in other studies.21-24 In 
addition, the 6-Cl moiety may 
decrease the occurrence of 
unwanted side effects by 
increasing selectivity for AChE 
over butyrylcholinesterase (BChE).25 Our new molecules contain various terminal 
functional groups connected to 6-chlorotacrine via a hydrophobic linker moiety of 
varying length and were synthesized from the starting compound 6,9-dichlorotacrine (4) 
using a nucleophilic aromatic substitution reaction in 1-pentanol. Compounds 6b and 6d-
i with terminal amine groups were prepared as we previously described.18 Compound 
6c, also with a terminal amine group, was prepared from 4 by substitution with cadaverine 
in 89% yield. Derivatives 14a-f with terminal methyl groups were prepared from 4 by 
substitution with various alkyl amines in yields ranging from 41% to 66%. Compounds  
 
Fig. 3.1. A. Structures of tacrine (1), mefenamic acid (2), 
mefenamic acid with linkers (9b-d), and 6-chlorotacrine-
mefenamic acid hybrids (11a-f and 13f-h, 13j-l, 13n-p). B. 
Synthetic scheme for the preparation of 6-chlorotacrine amine 
linkers (6b-i), methyl linkers (14a-f), and hydroxyl linkers (15a-
b). Reagents and conditions: (i) H2N(CH2)nNH2 (3-4 eq) or 




15a and 15b with terminal hydroxyl moieties were prepared from 4  by substitution with 
5-amino-1-pentanol and 6-amino-1-hexanol in 80% and 52% yield, respectively. 
 
 
3.3.2. Biochemical evaluation 
3.3.2.1. Molecular modeling 
We performed molecular modeling experiments using AutoDock and a tacrine-complexed 
AChE structure (PDB code: 1ACJ26). We constructed models of several 6-chlorotacrine 
linkers (Fig. 3 . 2A-D), and, although results remain speculative in the absence of 
crystallographic data, they can be used in an effort to rationalize the inhibition data 
described in the remainder of this manuscript. Our goal was to compare the predicted 
 
 
Fig. 3.2. A selection of linker molecules docked in TcAChE showing A. the interaction of 6-chlorotacrine 
amine linkers 6d (magenta), 6f (pink), 6g (green), 6h (yellow), and 6i (orange) with residues Trp84, 
Phe330, and His440 near the CAS and Gln69, Tyr70, Asp72, and Gln74 near the PAS, B. the interaction 
of 6-chlorotacrine hydroxyl linkers 15a (white) and 15b (turquoise) with residues Trp84, Phe330, and 
His440 and Tyr70 and Asp72, C. a comparison of the binding of 6-carbon amine linker 6d (magenta), 6-
carbon methyl linker 14c (yellow), and 6-carbon hydroxyl linker 15b (turquoise) showing the proximity 
of the terminal functional group to Gln69, Tyr70, and Asp72, and D. a comparison of the binding of 6-
chlorotacrine-mefenamic acid hybrid 11f (orange) and 12-carbon amine linker 6i (yellow) showing the 
proximity of the mefenamic acid moiety of 11f with Tyr70, Trp279, and Tyr334 near the PAS and the 
terminal amine group of 6i with Tyr70, Asp72, and Gln74. Oxygen, nitrogen, hydrogen, and chlorine 




interactions of 6-chlorotacrine linkers of different lengths with the same terminal 
functional group, 6-chlorotacrine linkers of the same length with different terminal 
functional groups, and 6-chlorotacrine linkers with their mefenamic acid counterpart. 
 
All models constructed predict that the 6-chlorotacrine portion of the molecules would be 
situated in the CAS of AChE with the quinoline ring system stacked between Trp84 and 
Phe330 (Fig. 3.2A-D). This is consistent with our previous modeling studies of tacrine-
mefenamic acid hybrids18 as well as other docking studies of tacrine-based molecules with 
TcAChE.24,27 
 
3.3.2.2. AChE inhibition 
To evaluate the potential 
cholinesterase inhibitory 
activity of our 6-
chlorotacrine derivatives 
6b-i, 14a-f, and 15a,b, 
their individual IC50 and 
ROS IC50 values were 
determined against AChE 
from Electrophorus 
electricus (EeAChE) (Fig. 
3.3A-D and Table 3.1). 
IC50 and ROS IC50 values were also established for 1:1 combinations of 6b-i with 
mefenamic acid (2) as well as 6b-e with mefenamic acid derivatives 9b-d (Table 3.2). 
Methods reported by Ellman28 and Muraoka and Miura19 were used to determine these 
various inhibitory constants. Our newly tested compounds were compared to a tacrine (1) 
standard, which had an IC50 = 52.4 ± 7.3 nM and a ROS IC50 = 183 ± 21 nM (Table 3 .1). 
The IC50 value for tacrine is in good agreement with literature values for EeAChE, 
which range from about 40 to 300 nM.29-31 Our newly tested compounds were also 
compared to a 1:1 equimolar mixture of tacrine (1) and mefenamic acid (2) standard, 
which had an IC50 = 68.7 ± 3.8 nM and a ROS IC50 = 83.9 ± 0.4 nM (Table 3 . 2). Finally, 
Table 3.1. Inhibition of EeAChE activity by 6-chlorotacrine with linkers 
generated in this study. 
Compounda R n IC50 (nM) ROS IC50 (nM) 
1   52.4  7.3b 183  21b 
6b NH2 4 38.0  3.7 65.8  8.9 
6c NH2 5 51.0  9.4 938  96 
6d NH2 6 11.1  0.7 7.85  2.91 
6e NH2 7 5.37  0.71 15.1  2.8 
6f NH2 8 1.14  0.27 293  91 
6g NH2 9 0.604  0.143 1.22  0.23 
6h NH2 10 0.932  0.220 2.18  0.27 
6i NH2 12 0.648  0.060 1.44  0.37 
14a CH3 4 26.3  9.5 43.2  7.8 
14b CH3 5 65.3  10.0 26.2  6.0 
14c CH3 6 16.0  3.0 2.03  0.11 
14d CH3 7 19.6  2.6 7.95  2.72 
14e CH3 8 2.27  0.20 16.9  2.2 
14f CH3 9 5.17  0.32 252  29 
15a OH 5 72.5  18.1 1520  137 
15b OH 6 42.4  10.8 2.47  0.47 
a See Fig. 3.1 for chemical structures. b These values were previously reported 




when applicable, our newly tested compounds were compared to similar literature 
compounds. However, a direct comparison was not possible because, while the Ellman 
method has been widely employed in the literature to determine AChE IC50 values of 
tacrine and tacrine hybrids, there is considerable variation in enzyme source. Indirect 
comparison based on inhibitory activity of the compound of interest relative to its tacrine 
standard was employed for this reason. 
 
Effect of terminal functional group and linker length on EeAChE inhibitory activity of 
derivatives 6b-i, 14a-f, and 15a,b. Without exception, 6-chlorotacrine derivatives 6b-i, 
14a-f, and 15a,b all showed lower or comparable IC50 values when compared to tacrine 
(Table 3.1). IC50 values ranged from 0.604 ± 0.143 nM to 51.0 ± 9.4 nM for derivatives 
6b-i with terminal amine functionalities and 2.27 ± 0.20 nM to 65.3 ± 10.0 for derivatives 
14a-f with terminal methyl groups, while compounds 15a and 15b with terminal hydroxyl 
moieties had IC50 values of 72.5 ± 18.1 nM and 42.4 ± 10.8 nM, respectively. Compounds 
6b,d,e,g-i with terminal amines, 14a-e with terminal methyl groups, and 15b with a 
terminal hydroxyl group all gave lower ROS IC50 values  than  tacrine (183 ± 21 nM) 
(Table 3.1) or a 1:1/tacrine:mefenamic acid mixture (83.9 ± 0.4 nM)   (Table   3.2). ROS 
IC50 values ranged from 1.22 ± 0.23 nM to 938 ± 96 nM for 6b-i and 2.03 ± 0.11 nM to 
252 ± 29 nM for 14a-f, while compounds 15a and 15b had ROS IC50 values of 1520 ± 
137 nM and 2.47 ± 0.47 nM, respectively. Overall, compounds 6g-i (n = 9, 10, 12) with 
terminal amines were the most potent of the derivatives tested. With IC50 values <1 nM 
and ROS IC50 values <2.5 nM, these compound were over 50-fold more potent than 
tacrine and 30-fold more potent than the 1:1/ tacrine:mefenamic acid mixture in terms of 
IC50 and ROS IC50 values, respectively. 
 
Molecular modeling shows the methylene portion of compounds 6d and 6f-i was 
predicted to extend up the AChE gorge allowing the terminal amine group to interact 
with residues near the PAS (Fig. 3.2A). The terminal amine of 6f-i is positioned such 
that it indicates the formation of hydrogen bonds with Tyr70, Asp72, and Gln74. The 
flexibility of the linker allows for a large amount of folding and little variation in the 




responsible for the similar IC50 values among these linkers. Interestingly, 6d shows an 
alternative positioning in AChE with hydrogen bonds to Gln69 and Trp84. This may be a 
function of the shorter length of the linker not allowing it to reach the same position as its 
longer counterparts, and the decreased number of hydrogen bonds may be responsible 
for the >10-fold increase in IC50 value when compared to 6f-i. The methylene portion 
of 15a and 15b was also predicted to extend up the AChE gorge allowing the terminal 
hydroxyl group to interact with residues near the PAS (Fig. 3 .2B). The terminal 
hydroxyl group of 15a and 15b is positioned such that it hydrogen bonds to Tyr70 and 
Asp72. 
 
In the literature, there have been structurally similar tacrine with linkers synthesized 
and tested. Recanatini et al. have previously synthesized and reported an IC50 value 
against human erythrocyte AChE for 14c.21 Our IC50 value is in good agreement with this 
previously reported value as in our hands 14c provided a 3-fold increase in potency over 
tacrine while the previously reported value represented a 19-fold increase. Other groups 
have synthesized and reported IC50 values against EeAChE for tacrine derivatives with 
terminal amine functionalities similar to 6b (n = 4),29,32 6c (n = 5),29 6d (n = 6),32,33 and 
6f (n = 8),29,32 but lacking the 6-chloro substituent. Overall the IC50 values reported were 
similar to those that we present here, with the exception of 6f (n = 8), which we observed 
to be 50-fold more potent than tacrine compared to a roughly 13-fold increase for Fang 
et. al.’s compound29 relative to tacrine. This result can be attributed to the 6-chloro 
substituent, which is known to increase inhibitory activity. Similarly, Carlier et al. have 
synthesized and reported IC50 values against rat brain AChE for tacrine derivatives with 
terminal amine groups similar to 6e-i (n = 7-10, 12) also lacking the 6-chloro substituent.34 
While all of their linkers showed minimal (<2.5-fold) increases in potency compared to 
tacrine, all of the similar compounds reported herein showed significant increase in 
potency compared to tacrine with most being over 80-fold more potent. Again, this 
difference could be attributed to the 6-chloro substituent. Also, Korabecny et al. have 
synthesized and reported IC50 values against human AChE for tacrine compounds with 
terminal methyl functionalities similar to compounds 14a-f with a 7-methoxy in place of 




potency compared to tacrine, and the same was true for most of the comparable 
compounds reported here with the exception of 14e and 14f, which showed 20- and 10-
fold increases in potency when compared to tacrine, respectively. Again, these differences 
can likely be attributed to the 6-chloro substituent present in our molecules. 
 
Among the n = 5 linkers, there was no major difference in functional group in terms of 
IC50 values, as there was <2-fold difference between compounds 6c, 14b, and 15a. 
However, in terms of ROS IC50 values, compound 14b with a terminal methyl was over 
30-fold more potent than compound 6c with a terminal amine, and over 50-fold more 
potent than derivative 15a with a terminal hydroxyl. Among the n = 6 linkers, 6d and 14c 
had similar potencies in terms of IC50 values, both of which were about 4-fold more potent 
than 15b. In terms of ROS IC50 values, 14c (CH3) and 15b (OH) had similar potencies, 
both of which were about 4-fold more potent than 6d (NH2). Compound 14c seems to be 
positioned such that its terminal methyl group is somewhere between the amine 
functionality of 6d and hydroxyl group of 15b (Fig. 3.2C). In comparing these n = 6 
linkers, all were within 4-fold of each other in terms of IC50 and ROS IC50, and their 
similar docking results would suggest little reason to expect a large difference in 
potency. Among the n = 4, 7, 8, and 9 linkers, there was <4-fold difference between 6b, 
e, and f and 14a, d, and e in terms of IC50 values. However, 6g was almost 10-fold 
more potent than 14f. In terms of ROS IC50, among the n = 4, 7, 8, and 9 linkers, there 
was <2-fold difference between 6b and 6e and 14a and 14d. However, 14e was 17-fold 
more potent than 6f, while 6g was over 200-fold more potent than 14f. Overall these 
results show little difference between terminal functional groups of 6-chlorotacrine 
derivatives in IC50 values except for compounds having 9 methylene groups between the 
6-chlorotacrine moiety and the terminal functionality. However, there is greater 
variability between functional groups in ROS IC50 values with significant differences in 
linkers with 5, 8, and 9 methylene groups. 
 
We have previously reported that a linker length of 8-10 atoms between the two parent 
molecules in tacrine-mefenamic acid hybrids is optimal for AChE inhibition.18 When 




terminal functional group of the linker, our current results are close to or consistent with 
this finding. Among the linkers with terminal amines, compounds 6g-i with n = 9, 10, and 
12 were the most potent in terms of IC50 and ROS IC50 values. Among the linkers with 
terminal methyls, compounds 14e and 14f with n = 8 and 9 were the most potent in terms 
of IC50 values, while compounds 14c and 14d with n = 6 and 7 were the most potent in 
terms of ROS IC50 values. 
 
To determine the mode of inhibition of our 6-chlorotacrine with linkers, we used a subset 
of our most potent compounds comprised of 6d, 6g, 14c, and 15b (Fig. 3.3A-D(inset)). We 
observed a non-competitive mode of inhibition for these compounds, which is consistent 
with what was previously observed with tacrine-mefenamic acid hybrids18 and tacrine-
ferulic acid hybrids.29 
 
 
Fig. 3.3. Representative examples of IC50 curves (A-D) for selected 6-chlorotacrine with linkers 
(compounds 6d, 6g, 14c, and 15b). Inset in panels A-D are representative plots showing the non-
competitive inhibition with respect to acetylthiocholine (ATC) for compounds 6d, 6g, 14c, and 15b using 
various concentrations of inhibitor and ATC. 
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Table 3.2. Comparison of inhibition of EeAChE activity by combination of 6-chlorotacrine with linkers with 
mefenamic acid (2) or 9b-d and by covalently linked 6-chlorotacrine-mefenamic acid hybrids. 
 
1:1 Mixture of 6-chlorotacrine derivative with 
linkers and mefenamic acid analogs 
 
Covalently linked 6-chlorotacrine-
mefenamic acid hybridsb 
Cmpdsa R n n’ IC50 (nM) 
ROS IC50 
(nM) 
Cmpdsa n n’ IC50 (nM) 
ROS IC50 
(nM) 
1 + 2    68.7  3.8b 83.9  0.4b      
6b + 2 NH2 4  59.2  4.7 61.3  11.1      
6b + 9b NH2 4 2 44.1  8.9 6.64  0.86 13f 4 2 2470  98 33.0  9.3 
6b + 9c NH2 4 3 11.4  3.5 40.9  8.1 13g 4 3 13.6  1.8 12.4  1.8 
6b + 9d NH2 4 5 51.8  16.7 210  88 13h 4 5 37.4  9.4 
0.299  
0.067 
6c + 2 NH2 5  51.1  11.5 915  93      
6c + 9b NH2 5 2 103  33 298  33      
6c + 9c NH2 5 3 109  22 328  18      
6c + 9d NH2 5 5 38.1  7.3 596  80      
6d + 2 NH2 6  24.7  5.9 70.4  12.3 11a 6  7230  187 1.02  0.36 
6d + 9b NH2 6 2 5.02  1.56 13.1  2.7 13j 6 2 1.14  0.31 2.96  0.41 
6d + 9c NH2 6 3 2.99  0.23 10.8  2.2 13k 6 3 41.7  11.5 15.6  1.5 
6d + 9d NH2 6 5 8.30  1.05 14.1  5.0 13l 6 5 2.94  0.45 7.39  1.51 
6e + 2 NH2 7  2.60  0.71 20.5  3.0 11b 7  1380  340 29.8  4.0 
6e + 9b NH2 7 2 8.38  1.29 4.20  0.53 13n 7 2 6.67  1.82 10.0  1.6 
6e + 9c NH2 7 3 7.17  1.42 22.7  3.1 13o 7 3 7.91  0.69 6.55  1.66 
6e + 9d NH2 7 5 4.55  0.94 7.85  1.83 13p 7 5 11.1  1.1 13.4  3.9 
6f + 2 NH2 8  23.8  8.5 81.8  7.4 11c 8  
0.495  
0.064 
1.49  0.30 
6g + 2 NH2 9  
0.544  
0.080 
2.22  0.45 11d 9  6.94  0.66 6.72  0.78 
6h + 2 NH2 10  1.23  0.20 2.22  0.47 11e 10  
0.776  
0.108 
1.85  0.11 
6i + 2 NH2 12  
0.493  
0.099 
2.74  0.71 11f 12  2360  830 16.2  1.8 
14a + 2 CH3 4  60.9  15.2 68.0  10.9      
14b + 2 CH3 5  53.8  11.9 10.9  3.9      
14c + 2 CH3 6  36.2  7.4 2.85  0.40      
14d + 2 CH3 7  19.3  3.4 3.31  0.48      
14e + 2 CH3 8  16.0  4.4 42.6  7.8      
14f + 2 CH3 9  4.17  0.33 284  32      
15a + 2 OH 5  64.3  15.3 513  69      
15b + 2 OH 6  35.1  7.9 1.96  0.34      
a See Fig. 3.1 for chemical structures. b These values were previously reported and are used here for comparison.18 
 
Effect of combining 6-chlorotacrine with linkers (series 6, 14, 15) with mefenamic acid 
(2) or mefenamic acid with linkers (series 9) on EeAChE inhibitory activity. After 
examining the effect of linker length and terminal functional group in our 6-chorotacrine 
derivatives with linkers on their activity, we wanted to determine if combining these 
compounds with mefenamic acid in a 1:1 equimolar mixture could increases their potency 
in either of the AChE inhibition assays. We first compared 6b-i to 1:1 equimolar mixtures 
of 6b-i and mefenamic acid (2) (6b-i + 2) (Table 3.2). The 1:1 mixtures of compounds 




values ranging from 2.22 ± 0.45 nM to 915 ± 93 nM. Overall, there was little difference in 
terms of IC50 and ROS IC50 values between compounds 6b-i and 6b-i + 2. There was <2.5-
fold difference in IC50 and ROS IC50 values between the corresponding compounds from 
these two series in most cases with the exceptions being 6d, which was 9-fold more potent 
in ROS IC50  than 6d + 2, and 6f, which was 21-fold more potent in IC50 but 3.5-fold 
less potent in ROS IC50 than 6f + 2. 
 
We next explored the effect of adding an equimolar equivalent of 2 to derivatives 14a-f 
and 15a,b. Mixtures of 14a-f + 2 displayed IC50 values ranging from 4.17 ± 0.33 nM to 
60.9 ± 15.2 nM  and ROS IC50 values ranging from 2.85 ± 0.40 nM to 284 ± 32 nM. 
Overall, there was little difference in terms of IC50 and ROS IC50 values between 
derivatives 14a-f and 14a-f + 2. There was <2.5-fold difference in IC50 and ROS IC50 
values between the corresponding compounds from these two series in most cases with 
the exception of 14e, which was 7-fold more potent in IC50 than 14e + 2. Similarly, 
equimolar mixtures of 15a + 2 and 15b + 2 displayed IC50 values of 64.3 ± 15.3 nM and 
35.1 ± 7.9 nM, respectively, and ROS IC50 values of 513 ± 69 nM and 1.96 ± 0.34 nM. 
Overall, there was little difference in terms of IC50 and ROS IC50 values between 15a or 
15b and 15a + 2 or 15b + 2. There was <3-fold difference in IC50 and ROS IC50 values 
between the corresponding compounds from these two series in all cases. 
 
We also investigated 1:1 equimolar mixtures of compounds 6b-e and 9b-d in combinations 
that provided total linker length in the ideal range identified. These 1:1 mixtures 
displayed IC50 values ranging from 2.99 ± 0.23 nM to 109 ± 22 nM and ROS IC50 values 
ranging from 4.20 ± 0.53 nM to 596 ± 80 nM. Here again,  there was overall little difference 
in terms of IC50 and ROS IC50 values between compounds 6b-e and 6b-e + 9b-d. There 
was <3-fold difference in IC50 and ROS IC50 values between the corresponding 
compounds from these two series in most cases with the exceptions of 6b, which was 
10-fold less potent in ROS IC50 than 6b + 9b, 6d, which was 4-fold less potent in IC50 
than 6d + 9c, and 6e, which was 3.6-fold less potent in ROS IC50 than 6e + 9b. Together, 




linkers (series 6, 14, 15) in trans has little to no effect on the activity of the latter 
compounds. 
 
Is a covalent linkage between tacrine and mefenamic acid required for optimal EeAChE 
inhibition? As mentioned previously, we have recently synthesized and tested in vitro 
two series of 6-chlorotacrine-mefenamic acid hybrids 11a-f and 13f-h, 13j-l, 13n-p (Fig. 
3.1).18 In order to elucidate the benefit, if any, of covalently linking 6-chlorotacrine and 
mefenamic acid, we decided to compare our previously published IC50 and ROS IC50 
values for 11a-f and 13f-h, 13j-l, 13n-p with the values obtained in the current study for 
6d-i (Table 3.1) and the corresponding combination 6d-i + 2 and 6b,d,e + 9b-d (Table 3.2). 
 
We first compared 6d-i to 11a-f, and observed that in all cases compounds 6d-i displayed 
more potent or comparable IC50 values than that for the linked counterparts 11a-f. For 
example, 6i was over 3600-fold more potent than 11f, while 6h and 11e were nearly 
identical in potency. However, the difference in ROS IC50 values between compounds 6d-
i and 11a-f is not as well defined. In two out of the six combinations tested, the 6-
chlorotacrine covalently linked to mefenamic acid (series 11) displayed more potent 
ROS IC50 values than the 6-chlorotacrine derivatives with a terminal amine linker. For 
example, 11c was almost 200-fold more potent than 6f. Of the remaining four 
combinations tested, 6-chlorotacrine derivatives with terminal amines displayed more 
potent ROS IC50 values in three instances. This is evidenced by 6i, which was 11-fold 
more potent than 11f. The remaining combination 6h and 11e displayed nearly equal 
potencies. 6-Chlorotacrine-mefenamic acid hybrid 11f was predicted to bind with the 
methylene linker extending up the AChE gorge and the mefenamic acid moiety in close 
proximity to Tyr70, Trp279, and Tyr334 (Fig. 3.2D). The methylene linker portion of 11f 
was predicted to be much more linear than the linker portion of 6i, which folds back on 
itself allowing the terminal amine to form potential hydrogen bonds with Tyr70, Asp72, 
and Gln74. This ability to fold may be a result of the decreased steric bulk at the linker 
terminus (amine vs mefenamic acid). The potential hydrogen bonds of 6i may be 
responsible for the over 3600-fold increase in potency in terms of IC50 when compared to 




ROS IC50. This is likely because of the suspected ability of mefenamic acid to deactivate 
AChE through a free-radical mechanism, which we have discussed previously.18 
 
Overall, these results indicate that derivatives 6d-i are equal to or more potent than the 
covalently linked counterparts 11a-f in terms of IC50, which is consistent with the results 
observed for tacrine-ferulic acid hybrids where the linkers with terminal amines used and 
the linked hybrids were equally more potent than tacrine in terms of EeAChE IC50.
29 
Altogether, this may indicate that the additional moiety in an amine-linked tacrine hybrid 
may not obviously affect the extent of AChE activity, and the linker alone may be 
responsible for the increase in inhibitory potency. However, there does not seem to be a 
clear trend between the linkers alone and the linked counterparts in terms of ROS IC50, 
which potentially indicates the importance of the covalent linkage for additional different 
activity of hybrid molecules. 
 
We next compared 6d-i + 2 to 11a-f. Again, in most cases, 6d-i + 2 displayed more 
potent IC50 values than the linked counterparts 11a-f. For example, 6i + 2 was over 
4700-fold more potent than the linked counterpart 11f. The lone exceptions were 11c 
and 11e, which were more potent or comparable to the combination of 6f + 2 and 6h + 
2, respectively. As observed above for 6d-i, the difference in ROS IC50 values between 
6d-i + 2 and 11a-f was not as well defined. Out of the six combinations tested, the 6-
chlorotacrine derivatives with a terminal amine linker plus mefenamic acid was more 
potent in two cases, the linked counterpart was more potent in two cases, and there was 
nearly equal potency in two cases. For example, 11c was 55-fold more potent than 6f + 
2. However, 6i + 2 was 6-fold more potent than 11f.  Also, 6h + 2 and 11e displayed 
nearly equal inhibitory activity. Overall, these results indicate that combinations of 6-
chlorotacrine with  linkers with terminal amines and mefenamic acid are usually more 
potent than the linked counterparts in terms of IC50, but there does not seem to be a clear 
trend between the linkers plus mefenamic acid and the linked counterparts in terms of 
ROS IC50. 
 




displayed equal or more potent IC50 values  than 13f-h, 13j-l, 13n-p. For example, 6b + 
9b was 56-fold more potent than 13f, while 6e + 9c and 13o were equally potent. 
However, the difference in ROS IC50 values between 6-chlorotacrine derivatives with 
terminal amine linkers plus mefenamic acid with linkers 6b,d,e + 9b-d and the linked 
counterparts 13f-h, 13j-l, 13n-p showed the opposite trend. In most cases, compounds 
13f-h, 13j-l, 13n-p displayed equal or more potent ROS IC50 values than mixtures of 
6b,d,e + 9b-d. For example, 13h and 13o were 6-fold and 3.5-fold more potent than 6b + 
9d and 6e + 9c, respectively. Overall, these results indicate that 6-chlorotacrine amine 
with linkers plus mefenamic acid with linkers 6b,d,e + 9b-d are generally more potent 
than the linked counterparts 13f-h, 13j-l, 13n-p in terms of IC50, but the linked 
counterparts 13f-h, 13j-l, 13n-p are generally more potent in terms of ROS IC50. 
 
3.4. Conclusion 
Three series of 6-chlorotacrine derivatives were synthesized and evaluated in AChE 
inhibition assays. These compounds, which differed in terminal functional groups (-NH2, 
-CH3, -OH) and length (n = 4-12), appeared to be acting as non-competitive EeAChE 
inhibitors in biochemical assays, creating some discrepancy with modeling studies. The 
amine group was determined to be the best terminal functional group in terms of IC50 
and ROS IC50. Compounds 6g-i (n = 9, 10, 12) were the most potent compounds tested 
as they had IC50 values <1 nM and ROS IC50 values <2.5 nM and were over 50-fold more 
potent than tacrine and 30-fold more potent than the 1:1/tacrine:mefenamic acid mixture 
in terms of IC50 and ROS IC50 values, respectively. The linker length of the most potent 
compounds in the amine and methyl series was determined to be around 8-12 atoms, 
which is consistent with our previous studies of tacrine-mefenamic acid hybrids. 
 
The 6-chlorotacrine with linkers were also evaluated in a 1:1 equimolar mixture with 
mefenamic acid or mefenamic acid linkers, and results indicated little difference in terms 
of IC50 and ROS IC50 when compared to the 6-chlorotacrine with linkers themselves. 6-
Chlorotacrine derivatives with terminal amines alone and in a 1:1 mixture with mefenamic 
acid or mefenamic acid linkers were found, in general, to be equally potent or, in many 




IC50. In terms of ROS IC50, linked compounds 13f-h, 13j-l, 13n-p outperformed their 
unlinked counterparts. However, in general the ROS IC50 trend was less well defined, 
and no generalization could be made. These results indicate that the mefenamic acid 
moiety in an amine-linked tacrine-mefenamic acid hybrid may not contribute to AChE 
inhibition in the absence of ROS, and the linker alone may be responsible for the increase 
in potency relative to tacrine. However, in the presence of ROS, there may be some 
advantage to amine-linked tacrine-mefenamic acid hybrids. While these results do not 
present an overwhelming advantage to the linked compounds, they do not discount the 
benefit of linking tacrine with an additional moiety to create tacrine hybrids, a strategy 
that has been widely used in the literature. 
 
An essential characteristic of any AD drug is the ability to cross the blood-brain barrier 
(BBB). The parallel artificial membrane permeation assay (PAMPA-BBB) described by 
Di et al.36 provides a high-throughput, high success means of predicting passive BBB 
permeation. Using this assay, tacrine-melatonin, tacrine-8-hydroxyquinoline, and 
pyrano[3,2-c]quinoline-6-chlorotacrine hybrids have all been predicted to cross the 
BBB.17,23,37 Based on these results, we predict that our structurally similar tacrine-
mefenamic acid hybrids and tacrine linkers will show comparable PAMPA-BBB results, 
and experiments to verify this will be performed in the near future. We also envision 
future mutational and structural studies aimed to confirm the interactions of our 
inhibitors with AChE predicted by our molecular modeling. There is literature precedent 
for purification and crystallization of TcAChE in complex with tacrine and other 
compounds.26,38-44 We therefore expect to use molecular replacement for our future 
structural work. In addition, studies aimed at synthesizing and further exploring the 
importance of covalent linkage in multifunctional compounds with AChE inhibition, ROS 
scavenging, metal chelation, and prevention of A aggregation properties are currently 
underway in our laboratory. 
 
3.5. Materials and instrumentation 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without 




prepared as previously described.18 Reactions were monitored by TLC (Merck, Silica gel 
60 F254). Visualization was achieved using one or more of the following methods: UV 
absorption by fluorescence quenching, a cerium-molybdate stain ((NH4)2Ce(NO3)6 (5 g), 
(NH4)6Mo7O24•4H2O (120 g), H2SO4 (80 mL), H2O (720 mL)), a ninhydrin stain 
(ninhydrin (1.5 g), n-butanol (100 mL), AcOH (3 mL)), a KMnO4 stain (KMnO4 (1.5 g), 
K2CO3 (10 g), NaOH (1.25 mL 10%), H2O (200 mL)), a bromocresol green stain 
(bromocresol green (0.04 g), EtOH (100 mL, absolute), slowly drip NaOH (0.1 M) until 
the solution just turns pale blue), or Dragendorff’s reagent (solution A: BiNO3 (0.17 g) in 
AcOH (2 mL), H2O (8 mL); solution B: KI (4 g) in AcOH (10 mL) and H2O (20 mL). 
Solutions A and B were mixed and diluted to 100 mL with H2O). Compounds were purified 
by SiO2 flash chromatography (Dynamic Adsorbents Inc., Flash Silica Gel 32-63u). 
1H 
NMR and 13C NMR spectra were recorded on a Varian 400 or 500 MHz spectrometer. 
Liquid chromatography mass spectrometry (LCMS) was performed on a Shimadzu LCMS-
2019EV equipped with a SPD-20AV UV-Vis detector and a LC-20AD liquid 
chromatograph. Analyses by UV-Vis assays were done on a multimode SpectraMax M5 
plate reader using 96-well plates (Fisher Scientific). Molecular modeling was performed 
using AutoDock 4.2 and Cygwin 1.7. 
 
3.6. Methods 
3.6.1. Chemical methods 
3.6.1.1. Preparation of N1-(6-chloro-1,2,3,4-
tetrahydroacridin-9-yl)pentane-1,5-diamine (6c). 6,9-
Dichloro-1,2,3,4-tetrahydroacridine (4) (300 mg, 1.19 mmol, 1 
eq), cadaverine (0.56 mL, 4.76 mmol, 4 eq), and 1-pentanol (2.5 mL) were combined and 
heated to reflux for 48 h. The reaction was cooled to rt, diluted with CH2Cl2 (50 mL), and 
washed with 10% aq. KOH (2x50 mL), H2O (2x50 mL), and brine (50 mL). The organic 
layer was dried (MgSO4), filtered, and concentrated under reduced pressure to afford the 
crude product, which was purified by flash column chromatography (SiO2; 
7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.12) to afford 6c (338 mg, 89%) 
as a yellow oil: 1H NMR (CDCl3, 400 MHz) 7.77 (d, 1H, J = 2.2 Hz), 7.76 (d, 1H, J = 




2.91 (br t, 2H), 2.61 (br s, 2H), 2.53 (br t, 2H), 2.24 (br s, 2H), 1.79 (p, 4H, J = 3.3 Hz), 
1.54 (p, 2H, J = 7.3 Hz), 1.35-1.42 (m, 2H), 1.26-1.33 (m, 2H) (Fig. 3.4); 13C NMR (CDCl3, 
100 MHz) 159.5, 150.5, 148.1, 133.7, 127.5, 124.5, 124.0, 118.3, 115.7, 49.3, 41.6, 34.0, 
32.7, 31.5, 24.5, 24.1, 22.8, 22.6 (Fig. 3.5); m/z calcd for C18H24ClN3: 317.17; found 318.05 
[M+H]+. 
 
3.6.1.2. General procedure for attachment of alkyl amine linkers to 6-chlorotacrine 
6-Chloro-N-pentyl-1,2,3,4-tetrahydroacridin-9-amine (14a). 6,9-
Dichloro-1,2,3,4-tetrahydroacridine (4) (410 mg, 1.625 mmol, 1 eq), 
pentylamine (750 L, 6.5 mmol, 4 eq), and 1-pentanol (1 mL) were 
combined and heated to reflux for 24 h. The reaction was cooled to rt, diluted with CH2Cl2 
(50 mL), and washed with 10% aq. KOH (2x50 mL), H2O (2x50 mL), and brine (50 mL). 
The organic layer was dried (MgSO4), filtered, and concentrated under reduced pressure to 
afford the crude product, which was purified by flash column chromatography (SiO2; 
9.9:0.1/EtOAc:MeOH with NH4OH (7 mL/L of solvent), Rf 0.33 (EtOAc)). Further 
purification by flash column chromatography (SiO2; 19:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent)) removed remaining impurities and gave 14a (250 mg, 51%) as a brown 
oil: 1H NMR (CDCl3, 400 MHz)  7.86 (d, 1H, J = 9.0 Hz), 7.85 (d, 1H, J = 2.2 Hz), 7.23 
(dd, 1H, J1 = 9.0 Hz, J2 = 2.2 Hz), 3.91 (br s, 1H), 3.44 (td, 2H, J1 = 7.0 Hz, J2 = 3.2 Hz), 
3.00 (br t, 2H), 2.63 (br t, 2H), 1.89 (p, 4H, J = 3.5 Hz), 1.63 (p, 2H, J = 7.2 Hz), 1.39-1.28 
(m, 4H), 0.88 (t, 3H, J = 7.2 Hz) (Fig. 3.6); 13C NMR (CDCl3, 100 MHz)  159.6, 150.9, 
148.4, 133.9, 127.7, 124.7, 124.2, 118.5, 115.8, 49.7, 34.2, 31.6, 29.2, 24.6, 23.0, 22.8, 




Compound 14b was prepared as described for the synthesis of 14a. 
The reaction of 6,9-dichloro-1,2,3,4-tetrahydroacridine (4) (361 mg, 
1.4 mmol, 1 eq), hexylamine (750 L, 5.7 mmol, 4 eq), and 1-pentanol (1 mL) yielded, 
after purification by flash column chromatography (SiO2; 9.9:0.1/EtOAc:MeOH with 
NH4OH (7 mL/L of solvent), Rf 0.32 (EtOAc)) and further purification by flash column 




mg, 42%) as a light brown solid: 1H NMR (CDCl3, 400 MHz)  7.86 (d, 1H, J = 8.5 Hz), 
7.85 (d, 1H, J = 2.5 Hz), 7.22 (dd, 1H, J1 = 9.0 Hz, J2 = 2.2 Hz), 3.92 (br s, 1H), 3.44 (t, 
2H, J = 7.2 Hz), 3.00 (br t, 2H), 2.63 (br t, 2H), 1.88 (p, 4H, J = 3.2 Hz), 1.62 (p, 2H, J = 
7.6 Hz), 1.40-1.21 (m, 6H), 0.86 (t, 3H, J = 6.8 Hz) (Fig. 3.8); 13C NMR (CDCl3, 100 MHz) 
 159.5, 150.8, 148.2, 133.8, 127.5, 124.6, 124.0, 118.4, 115.6, 49.6, 34.0, 31.7, 31.5, 26.5, 




Compound 14c was prepared as described for the synthesis of 14a. 
The reaction of 6,9-dichloro-1,2,3,4-tetrahydroacridine (4) (95 
mg, 0.375 mmol, 1 eq), heptylamine (178 L, 1.3 mmol, 3.5 eq), and 1-pentanol (1 mL) 
yielded, after purification by flash column chromatography (SiO2; 9.9:0.1/EtOAc:MeOH 
with NH4OH (7 mL/L of solvent), Rf 0.29 (EtOAc)) and further purification by flash 
column chromatography (SiO2; 19:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent)), 
14c (50 mg, 41%) as a light brown solid: 1H NMR (CDCl3, 400 MHz)  7.89 (d, 1H, J = 
9.0 Hz), 7.88 (d, 1H, J = 1.8 Hz), 7.26 (dd, 1H, J1 = 9.0 Hz, J2 = 2.2 Hz), 3.48 (t, 2H, J = 
7.2 Hz), 3.02 (br t, 2H), 2.66 (br t, 2H), 1.91 (p, 4H, J = 3.3 Hz), 1.65 (p, 2H, J = 7.2 Hz), 
1.44-1.23 (m, 8H), 0.88 (t, 3H, J = 6.8 Hz) (Fig. 3.10); 13C NMR (CDCl3, 100 MHz)  
159.4, 150.8, 148.1, 133.9, 127.5, 124.6, 124.1, 118.4, 115.6, 49.6, 34.0, 31.8, 31.7, 29.0, 




Compound 14d was prepared as described for the synthesis of 
14a. The reaction of 6,9-dichloro-1,2,3,4-tetrahydroacridine (4) 
(384 mg, 1.51 mmol, 1 eq), octylamine (1 mL, 6.1 mmol, 4 eq), and 1-pentanol (1 mL) 
yielded, after purification by flash column chromatography (SiO2; 9.9:0.1/EtOAc:MeOH 
with NH4OH (7 mL/L of solvent), Rf 0.36 (EtOAc)) and further purification by flash 
column chromatography (SiO2; 19:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent)), 




2.2 Hz), 7.79 (d, 1H, J = 9.3 Hz), 7.15 (dd, 1H, J1 = 9.0 Hz, J2 = 2.2 Hz), 3.88 (br s, 1H), 
3.37 (t, 2H, J = 7.2 Hz), 2.93 (br t, 2H), 2.56 (br t, 2H), 1.82 (p, 4H, J = 3.1 Hz), 1.55 (p, 
2H, J = 7.2 Hz), 1.34-1.15 (m, 10H), 0.84 (t, 3H, J = 6.7 Hz) (Fig. 3.12); 13C NMR (CDCl3, 
100 MHz)  159.4, 150.7, 148.1, 133.7, 127.5, 124.6, 123.8, 118.3, 115.5, 49.5, 34.0, 
31.69, 31.66, 29.2, 29.1, 26.8, 24.5, 22.9, 22.54, 22.48, 14.0 (Fig. 3.13); m/z calcd for 




(14e). Compound 14e was prepared as described for the 
synthesis of 14a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (55 mg, 0.22 mmol, 1 eq), nonylamine (160 L, 0.88 mmol, 4 eq), 
and 1-pentanol (1 mL) yielded, after purification by flash column chromatography (SiO2; 
9.9:0.1/EtOAc:MeOH with NH4OH (7 mL/L of solvent), Rf 0.38 (EtOAc)) and further 
purification by flash column chromatography (SiO2; 19:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent)), 14e (37 mg, 46%) as a light brown solid: 1H NMR (CDCl3, 500 MHz) 
 7.90 (d, 1H, J = 9.1 Hz), 7.88 (d, 1H, J = 2.0 Hz), 7.27 (dd, 1H, J1 = 9.1 Hz, J2 = 2.0 Hz), 
3.95 (br s, 1H), 3.48 (t, 2H, J = 7.2 Hz), 3.03 (br t, 2H), 2.67 (br t, 2H), 1.92 (br p, 4H, J = 
3.1 Hz), 1.65 (p, 2H, J = 7.4 Hz), 1.38 (p, 2H, J = 7.3 Hz), 1.32-1.26 (m, 10H), 0.88 (t, 3H, 
J = 6.8 Hz) (Fig. 3.14); 13C NMR (CDCl3, 100 MHz)  158.5, 151.3, 134.5, 126.3, 124.7, 
124.3, 118.3, 117.7, 114.8, 49.4, 33.1, 31.8, 31.7, 29.4, 29.3, 29.2, 26.8, 24.4, 22.8, 22.6, 




(14f). Compound 14f was prepared as described for the 
synthesis of 14a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (400 mg, 1.59 mmol, 1 eq), decylamine (1.3 mL, 6.4 mmol, 4 eq), 
and 1-pentanol (1 mL) yielded, after purification by flash column chromatography (SiO2; 
9.9:0.1/EtOAc:MeOH with NH4OH (7 mL/L of solvent), Rf 0.45 (EtOAc)) and further 
purification by flash column chromatography (SiO2; 19:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent)), 14f (328 mg, 55%) as a light brown solid: 1H NMR (CDCl3, 400 MHz) 




3.84 (br s, 1H), 3.29 (t, 2H, J = 7.4 Hz), 2.87 (br t, 2H), 2.47 (br t, 2H), 1.74 (br p, 4H), 
1.48 (p, 2H, J = 7.4 Hz), 1.24-1.12 (m, 14H), 0.76 (t, 3H, J = 6.4 Hz) (Fig. 3.16); 13C NMR 
(CDCl3, 100 MHz)  159.2, 150.6, 148.0, 133.6, 127.3, 124.5, 123.7, 118.2, 115.3, 49.4, 
33.9, 31.8, 31.6, 29.41, 29.39, 29.23, 29.18, 26.8, 24.4, 22.8, 22.6, 22.5, 14.0 (Fig. 3.17); 
m/z calcd for C23H33ClN2: 372.23; found 375.15 [M+H]
+. 
 
3.6.1.3. General procedure for attachment of amino alcohol linkers to 6-chlorotacrine 
5-((6-Chloro-1,2,3,4-tetrahydroacridin-9-yl)amino)pentan-1-
ol (15a). 6,9-Dichloro-1,2,3,4-tetrahydroacridine (5) (252 mg, 1 
mmol, 1 eq), 5-amino-1-pentanol (310 mg, 3 mmol, 3 eq), and 1-
pentanol (1 mL) were combined and heated to reflux for 24 h. The reaction was cooled to 
rt, diluted with CH2Cl2 (50 mL), and washed with 10% aq. KOH (2x50 mL), H2O (2x50 
mL), and brine (50 mL). The organic layer was dried (MgSO4), filtered, and concentrated 
under reduced pressure to afford the crude product, which was purified by flash column 
chromatography (SiO2; 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.34) to 
give 15a (261 mg, 80%) as a brown solid: 1H NMR (CDCl3, 400 MHz)  7.859 (d, 1H, J 
= 9.0 Hz), 7.856 (d, 1H, J = 2.2 Hz), 7.21 (dd, 1H, J1 = 9.0 Hz, J2 = 2.2 Hz), 4.15 (very br 
s, 1H), 3.65 (t, 2H, J = 6.3 Hz), 3.48 (t, 2H, J = 7.2 Hz), 3.05 (very br s, 1H), 2.99 (br t, 
2H), 2.62 (br t, 2H), 1.87 (p, 4H, J = 3.4 Hz), 1.68 (p, 2H, J = 7.4 Hz), 1.59 (p, 2H, J = 7.1 
Hz), 1.47 (p, 2H, J = 6.8 Hz) (Fig. 3.18); 13C NMR (CDCl3, 100 MHz)  159.0, 151.3, 
147.4, 134.4, 126.8, 124.8, 124.4, 118.1, 115.5, 62.3, 49.5, 33.6, 32.4, 31.5, 24.6, 23.3, 




ol (15b). Compound 15b was prepared as described for the 
synthesis of 15a. The reaction of 6,9-dichloro-1,2,3,4-
tetrahydroacridine (4) (252 mg, 1 mmol, 1 eq), 6-amino-1-hexanol (352 mg, 3 mmol, 3 eq), 
and 1-pentanol (1 ml) yielded, after purification by flash column chromatography (SiO2; 
9:1 CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.40), 15b (172 mg, 52%) as a 
brown solid: 1H NMR (CDCl3, 400 MHz)  7.870 (d, 1H, J = 2.2 Hz), 7.867 (d, 1H, J = 




Hz), 3.47 (t, 2H, J = 7.4 Hz), 3.01 (br t, 2H), 2.64 (br t, 2H), 2.48 (very br s, 1H), 1.89 (p, 
4H, J = 3.2 Hz), 1.66 (p, 2H, J = 7.1 Hz), 1.56 (p, 2H, J = 6.7 Hz), 1.40 (p, 4H, J = 3.9 Hz) 
(Fig. 3.20); 13C NMR (CDCl3, 100 MHz)  158.7, 151.3, 147.1, 134.4, 126.4, 124.7, 124.3, 
117.9, 115.2, 62.4, 49.3, 33.3, 32.5, 31.6, 26.6, 25.5, 24.4, 22.8, 22.4 (Fig. 3.21); m/z calcd 
for C19H25ClN2O: 332.17; found 333.10 [M+H]
+. 
 
3.6.2. Biochemical and computational methods 
3.6.2.1. In vitro AChE assay 
Compounds were dissolved in sodium phosphate (dibasic) buffer ((125 L), 0.1 M, pH 8.0 
(adjusted at rt)), and a five-fold dilution was performed. To the solution of inhibitors was 
added AChE cocktail (50 L, containing 0.08 U/mL (~0.29 nM) AChE (final 
concentration) (Sigma-Aldrich cat #C2888 from eel) in sodium phosphate (dibasic) buffer 
(0.1 M, pH 8.0 (adjusted at rt)). The mixture of inhibitor and enzyme was incubated for 10 
min before initiation with 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) (50 L, 0.25 mM 
final concentration) and acetylthiocholine (ATC) (0.5 mM final concentration) in 
phosphate buffer. The reaction was monitored at 412 nm taking measurements every 30 s 
for 30 min. Data was corrected with the negative control (no ATC) and normalized to the 
positive control (no inhibitor) using the initial rates (first 2-5 min). All assays were 
performed at least in triplicate. The resulting curve rate versus concentration of inhibitor 
was fitted to a sigmoidal curve, and IC50 values were calculated using KaleidaGraph 4.1.1. 
Four representative examples of IC50 curves are provided in Fig. 3.3A-D. All IC50 values 
are provided in Tables 3.1 and 3.2. 
 
3.6.2.2. Studies of the mode of inhibition 
Non-competitive inhibition was determined by incubating four concentrations of inhibitor 
(0, 0.2, 1, and 5 M) with AChE (as described above). The enzymatic reaction was then 
initiated by the addition of various concentrations of ATC (62.5, 250, 500, and 1000 M). 
The rates of the reactions were calculated using the first 2 min of the reaction and plotted 
on a Lineweaver-Burk plot. Separate lines were drawn for each concentration of inhibitor, 
and observation of intersection on the negative side of the x axis indicated non-competitive 





3.6.2.3. In vitro AChE ROS inactivation assay 
In the wells of a 96-well plate, horseradish peroxidase (0.25 M), H2O2 (100 M), AChE 
(0.08 U/mL, ~0.29 nM), compound (25 M – 13 pM), and diethylenetriaminepentaacetic 
acid (DETAPAC) (100 M) were dissolved in acetate buffer (pH 6.0) (50 mM) and 
incubated at 37 °C for 30 min. Note: all concentrations are reported as final concentrations. 
To the above solution, a mixture of ATC (0.5 mM) and DTNB (0.25 mM) in sodium 
phosphate (dibasic) buffer (50 mM, pH 7.4 (adjusted at rt)) was added. Reaction rates were 
monitored at 25 °C for 20 min taking measurements every 30 s, and rates were calculated 
using the initial rate (first 2-5 min). Total reaction volume was 200 L. Rates were 
normalized to the reaction without compounds and plotted in KaleidaGraph 4.1.1 to 
calculate the IC50. Four representative examples of IC50 curves are provided in Fig. 3.3A-
D. All IC50 values are provided in Tables 3.1 and 3.2. 
 
3.6.2.4. Molecular modeling 
Molecular docking studies were run on an Intell Premium 4 CPU (3.19 GHz, 0.99 GB of 
RAM, Windows XP Professional (Version 2002)) using the modeling program AutoDock 
4.2 (2009. The Scripps Research Institute. 10550 North Torrey Pines Road, La Jolla, CA 
92037. http://autodock.scripps.edu). Additionally, the program Cygwin (version 1.7. 
http://www.cygwin.com) was used to properly run the Autogrid and AutoDock 
applications. The crystal structure of AChE from Torpedo californica in complex with 
tacrine (PDB ID: 1ACJ, 2.8 Å resolution) was first edited in PyMOL 
(http://www.pymol.org, (PyMOL Molecular Graphics System, version 1.1r1, Schrödinger, 
LLC)) by manually removing all H2O molecules. The tacrine molecule was also removed 
from the active site. The enzyme was then loaded into AutoDock where all polar hydrogens 
were added and Kollman charges were assigned. The various ligands were prepared in 
ChemBio3D Ultra 12.0 (http://www.cambridgesoft.com), and then loaded into AutoDock. 
The scoring grid for AutoDock was centered approximately in between the CAS and PAS 
(x-center: 4.795, y-center: 66.845, z-center: 72.226). The grid size was selected to be 
606060 points with a spacing between grid points of 0.375 Å. A Lamarckian genetic 




energy evaluations of 2,500,000, while the rest of the docking study parameters were kept 
at their default quantity. After the docking was finished, conformations that were shown to 
be the in the largest cluster or most thermodynamically stable were examined in PyMOL. 
All docking figures were made in PyMOL (Fig. 3.2). 
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A novel hybrid of 6-chlorotacrine and metal-amyloid- modulator for inhibition of 
acetylcholinesterase and metal-induced amyloid- aggregation 
 
4.1. Abstract 
The number of people suffering from Alzheimer's disease (AD) is expected to increase 
dramatically in the coming decades. Currently, acetylcholinesterase inhibitors (AChEis) 
provide some relief of cognitive symptoms, while newer approaches, such as amyloid- 
(A)-targeted metal chelation, offer potential hope for slowing and/or reversing disease 
progression. This work details the synthesis and biochemical evaluation of a novel hybrid 
of 6-chlorotacrine and a metal-A modulator that chemically combines an AChEi and an 
A-targeted metal chelator into a single molecule. This hybrid shows potent inhibition of 
AChE under various conditions, interaction with Cu2+ and Zn2+, control of metal-free and 
metal-induced A aggregate assembly, and disaggregation of preformed metal-free and 
metal-associated A aggregates. As such, the hybrid described herein represents a 
promising, new multifunctional compound for AD studies. 
 
4.2. Introduction 
Alzheimer's disease (AD) is an age-related, neurodegenerative disorder estimated to affect 
over 5 million people in the United States alone.1 AD is progressive and ultimately fatal 
with symptoms ranging from cognitive dysfunction to psychiatric and behavioral 
disturbances. As the population ages, the prevalence of AD is expected to increase 
dramatically in the coming years and place an increasing burden on society. Many 
pathological hallmarks of the disease have been documented, yet the exact cause remains 
unknown. Current treatments for AD act mainly by inhibiting acetylcholinesterase (AChE). 
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While these acetylcholinesterase inhibitors (AChEis) are moderately effective in treating 
cognitive symptoms, they are incapable of stopping or reversing disease progression.2 
 
Tacrine was the first AChEi approved by the FDA.3 Though its clinical use has been limited 
by hepatotoxicity,4 tacrine remains an important starting point in research towards 
developing new drugs for AD due to its straightforward synthesis and comparatively low 
cost.5,6 In fact, tacrine hybrids, bifunctional molecules where tacrine has been chemically 
linked to another molecule with beneficial anti-AD properties, have been well 
characterized in the literature. For example, tacrine-8-hydroxyquinoline hybrids, tacrine-
ferulic acid hybrids, and tacrine-mefenamic acid hybrids have all shown promising 
results.7-11 The role of the linker in inhibitory activity of these hybrids towards AChE 
has also been investigated.12 
 
The presence and possible role of amyloid- (A) peptide aggregates in the brains of AD 
patients has been well documented.13-17 These aggregates provide an interesting 
pharmacological target in that drugs capable of disrupting already formed A 
aggregates or preventing A aggregation may be capable of halting or inverting the 
progression of AD.14,16 While AChE and butyrylcholinesterase (BChE) are important in 
AD because they control acetylcholine (ACh) levels, they also interact with A.18-20 
Structurally, AChE consists of a catalytic active site (CAS) and a peripheral anionic site 
(PAS) connected by a 20 Å gorge.21-23 AChE is known to promote A aggregation through 
interaction at the PAS, and it is often found entangled in A plaques along with BChE.18,24 
Thus, tacrine hybrids with the ability to simultaneously bind to the CAS and PAS by virtue 
of a chemical linker spanning the active site gorge have the potential to disrupt A 
aggregation.25,26 
 
Metal ions, such as Cu2+ and Zn2+, are known to interact with A peptides and promote 
their aggregation, which has been suggested to be involved in neurotoxicity.27-33 Given 
this fact, small molecules for modulation of metal-A interaction and reactivity have been 
developed. For example, N1,N1-dimethyl-N4-(pyridin-2-yl-methyl)benzene-1,4-diamine 
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(17, Fig. 4.1) has shown the ability to chelate Cu2+ and Zn2+ and interact with A, 
effectively regulating metal-induced A aggregation and neurotoxicity in vitro and in 
human neuroblastoma cells.34 We reasoned that chemically linking an AChEi with the 
metal-A modulator 17 would create a hybrid molecule (19, Fig. 4.1) potentially capable 
of multifunctionality (inhibition of AChE at the CAS, prevention of AChE-A 
interaction by blocking the PAS, as well as alteration of the interaction between metal 
ions and A with subsequent moderation of the reactivity of metal-associated A 
species). Herein, we describe the design, synthesis, and initial biochemical evaluation 
of such a hybrid (19, Fig. 4.1). 
 
4.3. Results and discussion 
4.3.1. Hybrid design and 
synthesis 
Hybrid 19 (Fig. 4.1) was designed 
to contain an AChEi moiety 
(blue), a linker region (black), and 
a metal-A modulating moiety 
(red). 6-Chlorotacrine (16), which 
was chosen as the AChEi moiety, 
has shown potent inhibition of 
AChE5 and has been incorporated 
into other AChE-directed hybrid 
molecules with favorable results.9 For comparison in biochemical studies, compound 16 
was prepared by heating 2-amino-4-chlorobenzonitrile and cyclohexanone in the 
presence of anhydrous ZnCl2 (Fig. 4.2A), as previously reported.
5,6 A decamethylene 
linker region was chosen due to its appropriate length to span the gorge of AChE and 
produce a compound capable of simultaneously interacting with the CAS and PAS.9 
This linker moiety was attached to 6-chlorotacrine to give analog 6h as previously 
reported.9 Compound 17 was chosen as the metal-A modulating moiety because of its 
ability to chelate metal ions (i.e., Cu2+ and Zn2+) as well as effectively interact with A, 
and i t  was prepared as established in previous procedures.34 For comparison in 
 
Fig. 4.1. Structures of 6-chlorotacrine (16), 6-chlorotacrine 
linker (6h), N1,N1-dimethyl-N4-(pyridin-2-ylmethyl)benzene-
1,4-diamine, metal-A modulator (17), metal-A modulator 




biochemical studies, metal-A modulator linker 18 was prepared from 6-bromo-2-
pyridinecarboxaldehyde via reductive amination with N,N-dimethyl-p-phenylenediamine 
followed by subsequent nucleophilic displacement of the bromo substituent by 1,10-
diaminodecane (Fig. 4.2B). Hybrid 19 was prepared using a copper-catalyzed Ullmann-
type reaction between 6h and the cyclic ethylene acetal-protected form of 6-bromo-2-
pyridinecarboxaldehyde. Subsequent deprotection and reductive amination with N,N-




Fig. 4.2. Synthetic schemes for the preparation of A. 6-chlorotacrine (16), B. metal-A modulator linker 
(18), and C. hybrid of 6-chlorotacrine-metal-A modulator (19). Reagents and conditions: (i) ZnCl2 (2.2 
eq), Δ. (ii) a) EtOH, Δ. b) NaBH4 (5.4 eq), Δ. (iii) 1-pentanol, Δ. (iv) MsOH (0.33 eq), toluene, Δ. (v) CuI 
(0.05 eq), L-proline (0.10 eq), K2CO3 (0.15 eq), 10:1/DMSO:H2O, 90 °C. (vi) 2:1/MeCN:aq. HCl, 60 °C. 





4.3.2. Biochemical evaluation 
4.3.2.1. AChE inhibition 
The AChE inhibitory properties of compounds 6h and 16-19 were assessed against AChE 
from Electrophorus electricus (EeAChE) using the well-established Ellman method35 to 
determine IC50 (Table 4.1). We previously tested tacrine with AChE (Table 4.1).
9 
However, since 6-chlorotacrine (16) is 25-fold more potent than tacrine itself, herein, we 
used it as the standard against which we compare all compounds. 6-Chlorotacrine (16) 
presented potent inhibition of AChE with an IC50 = 2.41 ± 0.48 nM, which is in good 
agreement with the literature value.36 The IC50 of compound 6h has recently been 
reported,12 and it also exhibited potent AChE inhibition. Metal-A modulator 17 showed 
very poor inhibition (IC50 > 200 M), which was expected given that it was not originally 
designed to interact with AChE. Introduction of the 1,10-diaminodecane moiety to 17, 
however, provides a remarkable increase (>200-fold) in potency (IC50 = 757 ± 279 nM 
for 18). Hybrid 19 was observed to have an IC50 = 2.37 ± 0.29 nM, identical to that of 16. 
Many tacrine hybrids reported in the literature showed an increase in potency compared to 
their parent compound. While this is not the case for 19 because the parent 6-chlorotacrine 
(16) is already highly potent, this compound is still of interest given its potential for 
metal chelation and A interaction. In addition, the IC50 value of 19 is within the range 
reported for structurally similar metal/A-targeted tacrine hybrids in the literature.37-40  
 
The AChE inhibitory properties of compounds 6h and 16-19 were also assessed using a 
method described by Muraoka and Miura41 to determine IC50 in the presence of reactive 
oxygen species (ROS IC50,  Table 4.1). Inflammation and oxidative stress from ROS are 
thought to play a role in AD, and tacrine-mefenamic acid hybrids have shown an increase 
in potency towards AChE in the presence of ROS, which may be beneficial for anti-AD 
compounds.9 As such, we aimed to establish if the compounds of interest in this study 
displayed similar results. Unfortunately, only metal-A modulator 17 showed a significant 
increase in potency in the presence of ROS. Although, even with this increase, 17 
remains a relatively poor inhibitor. In the case of 18 and hybrid 19, there was actually a 
reduction in potency. Compounds 16 and 6h indicated virtually no change between IC50 
and ROS IC50. To investigate the effect on enzyme inhibition of covalent linkage between 
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the AChEi, linker, and metal-A modulating moieties of hybrid 19, we examined 
combinations of molecules (6h + 17, 16 + 18 in 1:1 equimolar mixtures) in our inhibition 
assays (Table 4.1). Results indicate that covalent linkage is not essential for hybrid 19 in 
terms of IC50 as the values for 19, 6h + 17, and 16 + 18 were nearly identical. Similar results 
have been observed for tacrine-mefenamic acid hybrids.9,12 Interestingly, in terms of ROS 
IC50, covalent linkage may actually be detrimental for hybrid 19 as it was outperformed by 
both mixtures in this assay. However, covalent linkage may still be beneficial for 
simultaneous delivery of all components of the hybrid to the same location in the brain. 
 
4.3.2.2. BChE inhibition 
BChE is also commonly associated with characteristic A plaques. Thus, inhibition of 
BChE from equine serum (esBChE) by compounds 6h and 16-19 was also tested (Table 
4.1). With an IC50 = 2.41 ± 0.52 nM against BChE, 6-chlorotactine (16) showed inhibitory 
effect identical to that of AChE (2.41 ± 0.48 nM). Compounds 6h and 18 were found to be 
less active towards BChE than AChE with IC50 values of 13.6 ± 3.0 nM (13-fold 
diminution) and >200 M, respectively. Meanwhile, as observed with AChE, compound 
17 exhibited no inhibitory activity with BChE, and hybrid 19 demonstrated similar 
inhibition towards BChE (IC50 = 2.01 ± 0.12 nM) and AChE (IC50 = 2.37 ± 0.29 nM). 
 
As with AChE, the inhibitory effect of compounds 6h and 16-19 on BChE was also 
examined under a ROS environment (Table 4.1). With the exception of compounds 16 
and 18, the introduction of ROS seemed to have little effect on the inhibition of BChE. 
Compound 16 showed ca. 75-fold reduction in activity, while compound 18 displayed 
vastly improved inhibitory properties (IC50 = 0.162 ± 0.049 nM) suggesting that, in the 
absence of the tacrine moiety, the oxidized form(s) of compound 18 may block enzymatic 
turnover of BChE with an increased efficiency compared to other compounds. As with 
AChE, the covalent bond linkage requirement for inhibitory activity was investigated. 
While an equimolar combination of compounds 16 + 18 showed no improvement in 
inhibitory activity for BChE, an equimolar mixture of compounds 6h + 17 presented a 
59-fold increase in activity over hybrid 19. In the presence of ROS, equimolar mixtures 
of compounds 16 + 18 and 6h + 17 yielded values 2.5-fold and 125-fold better, 
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respectively, than those observed for the covalently linked hybrid 19. Although the 
covalent link seems to have an adverse effect upon the inhibitory activity of BChE, it 
still may be purposeful in transporting both components to the same site in the brain. It 
is important to note that the current linker has been optimized for AChE and not BChE. 
 
Table 4.1. Inhibition of EeAChE and esBChE activity by compounds 6h and 16-19 and effect of M2+ and A on IC50 
of hybrid 19 under various conditions. 
 EeAChE esBChE 
Compounda IC50 (nM) ROS IC50 (nM) IC50 (nM) ROS IC50 (nM) 
Tacrineb 52.4 ± 7.3 183 ± 21 NDf ND 
16 2.41 ± 0.48 1.86 ± 0.37 2.41 ± 0.52 188 ± 43 
6hc 0.932 ± 0.220 2.18 ± 0.27 13.6 ± 3.0 2.18 ± 0.27 
17 >200 M 1858 ± 235 >200 M >200 M 
18 757 ± 279 1906 ± 490 >200 M 0.162 ± 0.049 
19 2.37 ± 0.29 96.5 ± 24.3 2.01 ± 0.12 1.51 ± 0.18 
6h + 17d 0.544 ± 0.123 1.13 ± 0.33 0.034 ± 0.007 0.012 ± 0.003 
16 + 18d 1.61 ± 0.19 1.93 ± 0.24 2.85 ± 0.71 0.604 ± 0.223 
Conditionse EeAChE esBChE 
Effect of M2+ on IC50 (nM) of hybrid 19 
 CuCl2 ZnCl2 CuCl2 ZnCl2 
a 75.4 ± 12.4 2.46 ± 0.55 1.78 ± 0.22 0.713 ± 0.065 
b 144 ± 11 2.08 ± 0.37 8.14 ± 1.00 1.28 ± 0.08 
c 4.14 ± 0.43 6.99 ± 2.26 6.09 ± 0.54 2.76 ± 0.22 
Effect of A on IC50 (nM) of hybrid 19 
d 14.4 ± 5.2  0.554 ± 0.138  
e 2003 ± 647  1.02 ± 0.21  
f 7.26 ± 2.40  3.70 ± 0.48  
Effect of M2+ and A on IC50 (nM) of hybrid 19 
 CuCl2 ZnCl2 CuCl2 ZnCl2 
g 82.8 ± 8.3 8.80 ± 0.84 4.52 ± 1.54 2.38 ± 0.49 
h 8.87 ± 1.22 9.42 ± 1.49 23.0 ± 3.2 4.70 ± 0.94 
i 182 ± 66 111 ± 30 65.4 ± 6.7 41.5 ± 8.4 
a See Fig. 4.1 for chemical structures. b,c These values were previously reported and are used here for comparison.9,12 
d Tested as 1:1 equimolar mixture. e Conditions: (a) Dilute hybrid 19, add AChE (or BChE), wait 10 min, add M2+, 
wait 10 min, and initiate reaction. (b) Dilute hybrid 19, add M2+, wait 10 min, add AChE (or BChE), wait 10 min, and 
initiate reaction. (c) Dilute hybrid 19, add mixture of AChE (or BChE) and M2+, wait 10 min, and initiate reaction. (d) 
Dilute hybrid 19, add AChE (or BChE), wait 10 min, add A, wait 10 min, and initiate reaction. (e) Dilute hybrid 19, 
add A, wait 10 min, add AChE (or BChE), wait 10 min, and initiate reaction. (f) Dilute hybrid 19, add mixture of 
AChE (or BChE) and A, wait 10 min, and initiate reaction. (g) Dilute hybrid 19, add AChE (or BChE), wait 10 min, 
add A treated with M2+ for 2 min, wait 10 min, and initiate reaction. (h) Dilute hybrid 19, add A treated with M2+ 
for 2 min, wait 10 min, add AChE (or BChE), wait 10 min, and initiate reaction. (i) Dilute hybrid 19, add mixture of 




4.3.2.3. Effect of metals and A on AChE inhibition 
As previously mentioned, AChE is often found to be entangled in A plaques, and 
aggregation of A is promoted through binding at the PAS of AChE.18,24 Additionally, 
metal ions, such as Cu2+ and Zn2+, have been observed to interact with A and promote 
peptide aggregation.27-31 Composed of tacrine and a metal-A modulating moiety, hybrid 
19 was envisioned to interact with AChE, A, and Cu2+/Zn2+ simultaneously within the 
complex environment of an AD brain. However, interaction with A and Cu2+/Zn2+ could 
potentially be detrimental to the ability of 19 to function as an AChEi. The ability of hybrid 
19 to inhibit AChE in the presence of M2+ (Cu2+ or Zn2+) and A was examined (Table 4.1). 
It is important to note that, although other tacrine-derived hybrids have been shown to 
successfully coinhibit cholinesterases and A aggregation,37-40 to our knowledge, the 
effects of metals and A on cholinesterase inhibition have not been studied for these 
compounds. Various conditions (a-i, Table 4.1) were tested as it was anticipated that the 
order of interaction with AChE, A, and M2+ could affect the IC50 of 19. For example, 19 
could potentially interact with AChE before being exposed to M2+ (condition a), with 
M2+ before being exposed to AChE (condition b), or with AChE and M2+ simultaneously 
(condition c). Similarly, 19 could interact with AChE before being exposed to A 
(condition d), with A before being exposed to AChE (condition e), or with AChE and A 
simultaneously (condition f). Finally, 19 could interact with AChE before being exposed to 
A treated with M2+ (condition g), with A treated with M2+ before being exposed to AChE 
(condition h), or with AChE, A, and M2+ simultaneously (condition i). 
 
In general, hybrid 19 retained good inhibition of AChE in the presence of M2+ and A. With 
only one exception, 19 showed an IC50 < 200 nM under all conditions tested. The lone 
exception (condition e, Table 4.1) occurred when 19 was exposed to A for 10 min before 
introduction of AChE. Under these conditions, 19 indicated a nearly 850-fold reduction 
in potency (IC50 = 2003 ± 647 nM), which was not unexpected given that interaction of 
19 with A could likely lead to a complex that simply cannot fit into the AChE binding 
site as before. Only slight increases in IC50 were seen in the presence of A in other cases 
(conditions d and f). 
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Hybrid 19 showed moderate reduction in  potency in the presence of Cu2+ in two cases 
(conditions a and b, Table 4.1) but virtually no change under condition c. Similar to the 
case seen with A, the largest reduction in potency was seen when 19 was exposed to Cu2+ 
for 10 min before introduction of AChE (condition b). However, in contrast to the case 
seen with A, the reduction was only around 60-fold (IC50 = 144 ± 11 nM). Interestingly, 
19 presented essentially no change in IC50 in the presence of Zn
2+ under the conditions 
tested (conditions a-c, Table 4.1). 
 
Hybrid 19 exhibited varying IC50 values in the presence of M
2+ and A simultaneously 
(conditions g-i, Table 4.1). A moderate reduction in potency was indicated when 19 
interacted with AChE before being exposed to Cu2+-treated A (IC50 = 82.8 ± 8.3  nM),  
but  this  effect  was  not  seen  with  Zn2+-treated  A samples (condition g). Only slight 
increases in IC50 were visible when 19 interacted with Cu
2+/Zn2+-treated A before being 
exposed to AChE (condition h). These results are interesting given the observation for 
condition e (described above) and may indicate that compound 19 interacts differently with 
A and M2+-treated A. Moderate reductions in potency were observed when 19 interacted 
with AChE, A, and M2+ simultaneously (condition i). In the presence of AChE/A/Cu2+, 
hybrid 19 showed a nearly 80-fold reduction (IC50 = 182 ± 66 nM). In the presence of 
AChE/A/Zn2+, the reduction was nearly 50-fold (IC50 = 111 ± 30 nM). The case of 
AChE/A/Zn2+ should be noted in that, of all the conditions tested with Zn2+ present, it was 
the only one that showed a significant change in IC50. 
 
The fact that 19 maintains much of its inhibition potential when exposed to M2+-treated 
A prior to AChE, but not when exposed to A prior to AChE, may have implications for 
future in vivo studies. However, it is difficult to predict the order of interaction between 
these components in complex living systems. Regardless, the results described above 
indicate that hybrid 19 remains a relatively potent AChEi when interacting with M2+ and 
A. 
 
4.3.2.4. Effect of metals and A on BChE inhibition 
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The effects of Cu2+, Zn2+, A, and M2+-treated A on BChE inhibition were also tested 
(Table 4.1). In general, hybrid 19 maintained good inhibition of BChE, never losing 
more than 32-fold activity when compared to compound alone. Interestingly, with BChE, 
Cu2+ never increased the IC50 value by more than 4-fold (conditions a-c), while with AChE, 
the presence of Cu2+ increased the IC50 value by up to 60-fold. On the other hand, Zn
2+ 
actually improved the inhibitory activity by ca. 3-fold (IC 5 0  = 0.713 ± 0.065) when 
added to the inhibitor-BChE complex (condition a). Similarly, the addition of A to the 
inhibitor-BChE complex (condition d) resulted in a 4-fold increase in inhibitory activity 
(IC50 = 0.554 ± 0.138 nM) when compared to hybrid 19. In addition, a slight increase in 
inhibitory activity was seen when BChE was added to the Zn2+-inhibitor or A-inhibitor 
complex (conditions b and e), but no relative change was observed when Zn2+ and BChE 
or A and BChE were added simultaneously (conditions c and f). 
 
Larger shifts in BChE IC50 values were seen when hybrid 19 was tested in the presence of 
M2+ and A simultaneously (conditions g-i, Table 4.1). While the effect on inhibition was 
minimal when Cu2+/Zn2+-treated A was added to the inhibitor-BChE complex (condition 
g), the inhibitory activity of hybrid 19 was decreased 11-fold (IC50 = 23.0 ± 3.2 nM) when 
it interacted with Cu2+-treated A before being exposed to BChE (condition h). However, 
this same effect was not seen when 19 interacted with Zn2+-treated A before being 
exposed to BChE. The worst perturbation of activity arose when hybrid 19 interacted with 
BChE, A, and M2+ simultaneously (condition i). In the presence of BChE/A/Cu2+, hybrid 
19 showed a 32-fold reduction in inhibitory activity (IC50 = 65.4 ± 6.7 nM). In the 
presence of BChE/A/Zn2+, the reduction was 21-fold (IC50 = 41.5 ± 8.4 nM). Overall, while 
the inhibition of BChE by hybrid 19 is disturbed in the presence of A and metal species, 
the resulting change is less severe than that observed with AChE. 
 
4.3.2.5. Metal binding 
The ability of compounds 16, 6h, 18, and 19 to bind Cu2+ and Zn2+ was studied by UV-




Fig. 4.3. Metal binding studies of A. cpd 16, B. cpd 6h, C. cpd 18, and D. cpd 19 with CuCl2 (left) or 
ZnCl2 (middle) by UV-Vis. Conditions: [compound] = 40 M; [CuCl2 or ZnCl2] = 20-800 M; 30 min 
incubation (4 h for Zn2+ binding for cpd 18); rt. C and D. right panel = Zn2+ binding of 18 or 19 by 1H 
NMR. NMR spectra of 18 or 19 (black, 2.0 mM) with ZnCl2 (red, 3.2 mM) in CD3OD at rt. 
 
The Cu2+ and Zn2+ binding properties of compound 17 were previously reported.34,42 New 
optical bands were observed in the UV-Vis spectra of compounds 16 and 6h upon the 
addition of CuCl2 or ZnCl2, suggesting that these compounds were able to interact with 
Cu2+/Zn2+ (Fig. 4.3A and B). More importantly, compound 18 and hybrid 19, which were 
designed as metal chelators, showed promising metal binding properties. Upon incubation 
of CuCl2 with ligand (18 or 19) in EtOH, new optical bands (ca. 450 nm and 440 nm for 
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18 and 19, respectively) were indicated, implicating complex formation via metal 
chelation (Fig. 4.3C and D). Moreover, 18 or 19 treated with ZnCl2 displayed a new 
optical band at ca. 440 nm suggesting Zn2+ binding (Fig. 4.3C and D). In addition, 1H NMR 
investigation was used to examine possible interaction between compound 18 or 19 and 
Zn2+. Distinguishable downfield chemical shifts of the pyridyl, methylene, and aromatic 
protons were seen in the resulting spectrum of 18 or 19 when incubated with Zn2+ (Fig. 
4.3C and D, right panel). This suggests that both compounds are able to bind Zn2+ 
through the N-donor atoms on the pyridine ring and amino group. 
 
 
Fig. 4.4. Metal binding studies of 19 with A. CuCl2 or B. ZnCl2 in the absence and presence of A and/or 
AChE at pH 6.6 (Cu2+) and 7.4 (Zn2+), monitored by UV-Vis. Spectra of A, 19, [A + 19], [A + MCl2], 
[MCl2 + 19], and [A + MCl2 + 19 ± AChE] are depicted in black, light blue, orange, red, dark blue, and 
purple, respectively. Conditions: [A] = 10 M; [CuCl2 or ZnCl2] = 10 M; [AChE] = 10 M; [19] = 10 
M (5% v/v DMSO); 20 mM HEPES, pH 6.6 (Cu2+) and 7.4 (Zn2+), 150 mM NaCl; rt. 
 
Furthermore, the interaction of hybrid 19 with Cu2+/Zn2+ was examined by UV-Vis in the 
presence of A with or without AChE (Fig. 4.4A and B). For solutions containing A and 
Cu2+ or Zn2+ with or without AChE, optical changes upon addition of 19 were similar to 
those observed from the samples containing 19 incubated with Cu2+ or Zn2+ alone, which 
123 
 
implies that 19 has the ability to interact with Cu2+ or Zn2+ in the presence of A and AChE. 
While other metal/A-targeted tacrine hybrids have shown the ability to bind 
biometals,8,37 this is the first instance where a tacrine-metal chelator hybrid has been 
shown to bind Cu2+ or Zn2+ in the presence of A and AChE. Overall, the UV-Vis and 
NMR results demonstrate Cu2+ and Zn2+ interaction of compounds 16, 6h, 18, and 19, as 
well as the potential interaction of 19 with Cu2+ and Zn2+ surrounded by A and AChE. 
These results may correlate to the reactivity of the compounds towards metal-A species 
in vitro (vide infra). 
 
4.3.2.6. A aggregation inhibition 
In addition to examining the AChE inhibitory activity and metal binding properties of 
hybrid 19, its influence, compared to compounds 6h and 16-18, on metal-free and metal-
induced A1-40 aggregation in the absence and presence of AChE was studied in vitro. 
Two different A aggregation studies were carried out: inhibition (Fig. 4.5A) and 
disaggregation (Fig. 4.6A). The distribution of various-sized A species in both 
experiments was analyzed by gel electrophoresis followed by Western blotting with an 
anti-A antibody (6E10), and morphologies of the resulting A species were identified 
by transmission electron microscopy (TEM). 
 
The inhibition experiment was conducted to determine whether compounds 6h and 16-19 
were able to control the formation of metal-free and metal-associated A aggregates in 
the absence and presence of AChE (Fig. 4.5A-C). A species having a dispersion of 
molecular weight (MW) were observed with both metal-free and metal-treated conditions 
with and without AChE upon treatment with hybrid 19 (Fig. 4.5B, lanes 6). Noticeable 
differences in the MW distribution of the generated A species were indicated between 
Cu2+-treated and Zn2+-treated samples with and without AChE upon incubation with 19 
(Fig. 4.5B, lanes 6). In addition, TEM analysis of metal-free and metal-induced A 
species with and without AChE upon treatment with hybrid 19 displayed a mixture of 
amorphous and structured peptide species distinct from those of untreated samples (Fig. 
4.5C). Metal/ A-targeted tacrine hybrids have been shown to inhibit self-induced and 
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AChE-induced A aggregation in previous studies.37-39,43,44 However, there exists little 
precedent for demonstrating modulation of metal-associated A species among these 
hybrids making the results seen with 19 unique. 
 
 
Fig. 4.5. In vitro studies of the influence of 6h and 16-19 on metal-free and metal-associated A1-40 
aggregation with and without AChE. A. Scheme of the inhibition experiment. B. Visualization of various-
sized A species in the absence (left) and presence (right) of AChE by gel electrophoresis with Western 
blot (anti-A antibody, 6E10). C. TEM images of the 24 h incubated samples. Conditions: [A] = 25 M; 
[CuCl2 or ZnCl2] = 25 M; [AChE] = 25 M; [compound] = 50 M; pH 6.6 (for Cu2+ samples) or 7.4 (for 
metal-free and Zn2+ samples); 24 h incubation; 37 C; constant agitation. 
 
The reactivity of metal-A modulator linker 18, which has the same metal chelation 
moiety and linker region as 19 minus the AChEi moiety, towards both metal-free and 
metal-involved A aggregation with and without AChE was similar to that of 19 (Fig. 
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4.5B, lanes 5 and 6). However, metal-A modulator 17, which lacks the linker region and 
AChEi moiety, showed distinguishable reactivity with metal-treated samples with and 
without AChE compared to metal-free samples resulting in A species that have MW 
≤ 32 kDa (Fig. 4.5B, lanes 4).34 Comparing the results across all compounds of interest, 
the presence of the linker region in compounds 6h, 18, and 19 gave greater reactivity 
towards metal-free and metal-associated A species with and without AChE (Fig. 4.5B, 
6h/19 versus 16 and 18/19 versus 17). These results suggest the importance of the linker 
region, possibly by virtue of the increased hydrophobicity that it lends, for A reactivity. 
Overall, hybrid 19 displayed the desired multifunctionality by presenting varying degrees 
of regulatory activity towards metal-free and metal-mediated A aggregation with and 
without AChE in vitro. This activity may result from combined properties of metal 
chelation, A interaction, and hydrophobicity. 
 
4.3.2.7. Disaggregation of A aggregates 
Disaggregation of preformed A aggregates by other tacrine-derived hybrids has, to our 
knowledge, not been reported. Here, the disaggregation experiment was performed to 
assess the ability of compounds 6h and 16-19 to disassemble preformed metal-free and 
metal-associated A1-40 aggregates in the absence and presence of AChE (Fig. 4.6A and 
B). Similar to the results from the inhibition experiment, a wide array of both metal-free 
and metal-induced A species in the absence of AChE were observed upon treatment with 
hybrid 19 (Fig. 4.6B, lanes 6). However, in the presence of AChE, diverse-sized A species 
generated by incubation with 19 were only visualized under metal-involved conditions. 
Also, as before, A species having variable MW were detected between Cu2+- and Zn2+-
treated samples with and without AChE upon treatment with 19 (Fig. 4.6B, lanes 6). The 
overall reactivity of 18 towards preformed metal-free and metal-mediated A aggregates 
with and without AChE was similar to that of 19 (Fig. 4.6B, lanes 5). Relative to 19, samples 
containing A and 17 presented a smaller range of MW in both metal-free and metal-
treated cases with and without AChE. (Fig. 4.6B, lanes 4). Analogous to the inhibition 
results, compounds containing the linker region were shown to have greater reactivity 
towards metal-free and metal-associated A aggregates in the absence and presence of 
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AChE (Fig. 4.6B, in particular, 17 versus 18). Taken together, these results suggest that 
hybrid 19, in addition to being able to modulate the formation of metal-free and metal-
induced A aggregates with and without AChE, has the ability to impact preformed metal-
free and metal-triggered A aggregates with and without AChE to different extents. 
 
 
Fig. 4.6. Disaggregation studies using 6h and 16-19 with and without AChE. A. Scheme of the 
disaggregation experiment. B. Visualization of various-sized A1-40 species in the absence (left) and 
presence (right) of AChE by gel electrophoresis with Western blot (anti-A antibody, 6E10). Conditions: 
[A] = 25 M; [CuCl2 or ZnCl2] = 25 M; [AChE] = 25 M [compound] = 50 M; pH 6.6 (for Cu2+ 
samples) or 7.4 (for metal-free and Zn2+ samples); 24 h incubation; 37 C; constant agitation. 
 
4.3.2.8. Molecular modeling 
Molecular modeling was performed in an effort to visualize the interactions of hybrid 19 
with AChE and A. Modeling was performed with GOLD45 using AChE from Torpedo 
californica (TcAChE) and A1-40 (PDB codes: 1ACJ
46 and 2LFM,47 respectively). Hybrid 
19 was docked into the tacrine binding site of an energy optimized A1-40-TcAChE 
complex, and the first-ranked conformation is shown (Fig. 4.7A and B). 
 
The energy optimized A1-40-TcAChE complex showed a close association between the 
two components (Fig. 4.7A). As expected, the 6-chlorotacrine moiety of 19 was positioned 
in the CAS of the enzyme with the quinoline ring system stacked between W84 and 
F330 and the nitrogen of the quinoline ring in close proximity to H440 (Fig. 4.7B). The 
linker region of 19 was positioned such that it extended from the CAS to the PAS of the 
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enzyme by spanning the gorge region. These modeling results are consistent with previous 
docking studies on tacrine-based linkers and hybrids with TcAChE.9,12,48,49 Of more 
interest is the predicted binding of the metal chelator moiety of 19 and its potential 
interactions with A. This moiety was predicted to bind near the PAS of AChE and in 
close proximity to H6, H13, and H14 of A1-40 (Fig. 4.7B). These residues are known to 
be important for interaction of M2+ with A.27-31,50 In addition, N-donor atoms from the 
pyridine ring and amino group of the metal chelator moiety of 19 were predicted to be in 
the correct geometry to coordinate M2+. 
 
4.3.2.9. Blood-brain barrier 
permeability 
An essential characteristic for any 
anti-AD compound is the ability 
to cross the blood-brain barrier 
(BBB) and gain access to the 
central nervous system (CNS). 
BBB permeability for compounds 
6h and 16-19 was first predicted 
based on the calculated values of 
Lipinski's rules and logBB (Table 
4.2), which suggested that they 
might be able to cross the 
BBB.30,51,52 Along with this 
theoretical prediction, the 
potential BBB penetration of 6h 
and 16-19 was verified by an in 
vitro parallel artificial membrane 
permeability-BBB (PAMPA-
BBB) assay (Table 4.2).34,53 
Permeability values (-logPe) of 
6h and 16-19 were measured to be 
 
Fig. 4.7. Hybrid 19 docked with A1-40-TcAChE complex. A. 
Interaction of 19 with TcAChE (grey) and A1-40 
(yellow/orange). B. Close-up of important interactions 
between 19 and W84, H440, and F330 (grey) from TcAChE 
and H6, H13, and H14 (yellow) from A1-40. Carbon and 
nitrogen atoms of 19 are shown in green and blue, respectively. 
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5.1 ± 0.1 (for 16, 6h, and 18), 4.0 ± 0.1 (for 17),34 and 4.8 ± 0.1 (for 19). Based on 
empirical classification of known BBB permeable molecules (e.g., verapamil), our chemical 
scaffolds (in particular, hybrid 19) could potentially be BBB permeable. Similar results 
have been seen in this type of assay with tacrine-8-hydroxyquinoline hybrids and 
pyrano[3,2-c]quinoline-6-chlorotacrine hybrids.8,38 However, the PAMPA-BBB prediction 
only takes into account passive diffusion across the BBB. Permeability is likely more 
complex given the enzymes and efflux transporters (e.g., P-glycoprotein) that are known 
to prevent xenobiotic entry into the CNS, and future studies will aim to elucidate how 
hybrid 19 interacts with these biochemical barriers. 
 
Table 4.2. Values (MW, clogP, HBA, HBD, PSA, logBB, and -logPe) for compounds 6h and 16-19. 
Calculationa Cpd 16 Cpd 6h Cpd 17b Cpd 18  Hybrid 19 Lipinski’s rules and others 
MW 233 388 227 398 613 500 
clogP 4.08 7.76 1.76 5.10 10.7 ≤ 5.0 
HBA 2 3 3 5 6 ≤ 10 
HBD 2 3 1 4 3 ≤ 5.0 
PSA 38.9 50.9 28.2 66.2 65.1 ≤ 90 
logBB 0.174 0.555 -0.0197 -0.0744 0.785 > 0.3 (readily cross the BBB) 
< -1.0 (poor brain distribution) 
-logPec 5.1 ± 0.1 5.1 ± 0.1 4.0 ± 0.1 5.1 ± 0.1 4.8 ±0.1  
CNS+/- 
predictiond 
CNS+ CNS+ CNS+ CNS+ CNS+ -logPe < 5.4 (CNS+) 
-logPe > 5.7 (CNS-) 
a MW: molecular weight; clogP: calculated logarithm of the octanol-H2O partition coefficient; HBA: 
hydrogen bond acceptor; HBD: hydrogen bond donor; PSA: polar surface area; logBB: -0.0148 x PSA + 
0.152 x clogP + 0.130. b The values for cpd 17 were previously reported.34 c The values of -logPe were 
obtained using the parallel artificial membrane permeability assay adapted for blood-brain barrier 




In conclusion, a novel hybrid 19 of 6-chlorotacrine and metal-A modulator has been 
synthesized and evaluated in vitro. This compound showed potent inhibition of both 
AChE and BChE, and this potent inhibition was largely retained in the presence of ROS, 
M2+, and A. Additionally, 19 showed the ability to bind Cu2+ and Zn2+, and it was able 
to effectively modulate the assembly of metal-free and metal-induced A aggregates in the 
presence and absence of AChE. Furthermore, this compound presented the ability to 
transform preformed metal-free and metal-associated A aggregates with and without 
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AChE. Molecular modeling predicted that 19 was able to simultaneously interact with 
the CAS and PAS of AChE and with histidine residues known to be involved in M2+ 
binding in the A peptide. A PAMPA-BBB assay predicted the BBB penetrability of 19. 
Together, these results make hybrid 19 a worthy candidate for additional studies. As both 
a tacrine-8-hydroxyquinoline hybrid and a tacrine-melatonin hybrid have shown the 
ability to decrease A deposits using an in vivo mouse model,11,54 similar results would 
be anticipated for hybrid 19. However, due to the hepatotoxicity associated with tacrine, 
the next generation of hybrids capable of disaggregating metal-free and metal-triggered 
preformed A aggregates as well as inhibiting cholinesterases and A aggregation for 
in vivo studies will be composed of other currently used AD treatments, such as 
donepezil and galantamine. The synthesis and in vitro studies of such hybrids are 
currently underway in our laboratories. 
 
4.5. Materials and instrumentation 
Compounds 6h9 and 1734 were prepared as previously reported. A1-40 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) was purchased from 
Anaspec (Fremont, CA). All reagents for chemical synthesis were purchased from Sigma-
Aldrich (St. Louis, MO) and used without further purification. Reactions were 
monitored by TLC (Merck, Silica gel 60 F254). Visualization was achieved using the 
following methods: UV absorption by fluorescence quenching or a ninhydrin stain 
(ninhydrin (1.5 g), n-butanol (100 mL), AcOH (3 mL)). Compounds were purified by SiO2 
flash chromatography (Dynamic Adsorbents Inc., Flash Silica Gel 32-63u). 1 H and 1 3 C 
NMR spectra were recorded on a Bruker AvanceTM DPX 500 or Varian 400 MHz 
spectrometer. Liquid chromatography mass spectrometry (LCMS) was performed on a 
Shimadzu LCMS-2019EV equipped with a SPD-20AV UV-Vis detector and a LC-20AD 
liquid chromatograph. HRMS was performed on a Micromass AutoSpec Ultima 
Magnetic sector mass spectrometer. Optical spectra for metal binding studies were 
obtained using an Agilent 8453 UV-Vis spectrophotometer. Analyses by UV-Vis assays 
(determination of IC50 values and parallel artificial membrane permeability assay for 
blood-brain barrier penetration (PAMPA-BBB)) were carried out on a multimode 
SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) using 96-well plates 
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(Fisher Scientific). Transmission electron microscopy (TEM) images were recorded on 
a Philips CM-100 transmission electron microscope (Microscopy and Image Analysis 
Laboratory, University of Michigan, Ann Arbor, MI). Molecular modeling was performed 
using Sybyl-X and GOLD.45 
 
4.6. Methods 
4.6.1. Chemical methods 
4.6.1.1. Preparation of 6-chloro-1,2,3,4-tetrahydroacridin-9-amine 
(16). The known compound 16 was prepared in a manner similar to those 
previously established in the literature.5,6 Briefly, 2-amino-4-chlorobenzonitrile (382 mg, 
2.5 mmol, 1 eq), cyclohexanone (1.26 mL, 12.2 mmol, 4.9 eq), and anhydrous ZnCl2 (750 
mg, 5.5 mmol, 2.2 eq) were combined and heated at 125 °C for 3 h. The reaction mixture 
was cooled to rt and treated with H2O (50 mL). The remaining solid was collected by 
vacuum filtration, treated with 1 M aq. NaOH (50 mL), and heated to reflux for 16 h. The 
reaction mixture was then cooled to rt and extracted with CHCl3 (3 x 50 mL). The 
combined organic layers were washed with brine (50 mL), dried (MgSO4), filtered, and 
concentrated under reduced pressure to afford a crude yellow solid, which was purified by 
flash column chromatography (SiO2, 9:1/EtOAc:MeOH, Rf 0.15) to yield 16 (135 mg, 
23%) as an off-white solid: 1H NMR ((CD3)2SO, 400 MHz)  8.18 (d, 1H, J = 9.0 Hz), 
7.62 (d, 1H, J = 2.0 Hz), 7.28 (dd, 1H, J1 = 9.0 Hz, J2 = 2.0 Hz,), 6.48 (s, 2H), 2.81 (t, 2H, 
J = 5.4 Hz), 2.53 (t, 2H, J = 5.5 Hz), 1.81 (m, 4H); 13C NMR ((CD3)2SO, 100 MHz)  
158.8, 148.3, 147.0, 132.4, 126.4, 124.2, 122.7, 115.6, 109.4, 33.5, 23.6, 22.5, 22.4; LRMS 
m/z calcd for C13H13ClN2: 232.08; found 233.00 [M+H]
+. 
 
4.6.1.2. Preparation of N1-((6-bromopyridin-2-yl)methyl)-N4,N4-
dimethylbenzene-1,4-diamine (20). 6-Bromo-2-
pyridinecarboxaldehyde (1 g, 5.38 mmol, 1 eq), N,N-dimethyl-p-
phenylenediamine (733 mg, 5.38 mmol, 1 eq), and EtOH (40 mL) 
were combined and heated to reflux for 1 h. The reaction was cooled to rt, and NaBH4 (1.1 
g, 28.8 mmol, 5.4 eq) was added. The reaction was again heated to reflux for 1 h before 
being cooled to rt, quenched with H2O (100 mL), and extracted with Et2O (3 x 50 mL). 
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The combined organic layers were washed with brine (100 mL), dried (MgSO4), filtered, 
and concentrated under reduced pressure to afford a crude brown oil, which was purified 
by flash column chromatography (SiO2, 1:1/hexanes:EtOAc, Rf 0.43) to yield 20 (1.5 g, 
91%) as a brown solid: 1H NMR (CDCl3, 400 MHz)  7.48 (t, 1H, J = 7.7 Hz), 7.35 (d, 1H, 
J = 7.8 Hz), 7.32 (d, 1H, J = 7.6 Hz), 6.76-6.58 (m, 4H), 4.41 (br s, 2H), 2.83 (br s, 6H); 
13C NMR (CDCl3, 100 MHz)  161.5, 144.3, 141.6, 139.9, 139.1, 126.3, 120.3, 115.8, 
114.5, 50.1, 42.2; LRMS m/z calcd for C14H16BrN3: 305.05; found 305.75 [M+H]
+. 
 
4.6.1.3. Preparation of N1-((6-((10-aminodecyl)amino)pyridin-
2-yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine (18). 
Compound 20 (136 mg, 0.443 mmol, 1 eq), 1,10-diaminodecane 
(305 mg, 1.77 mmol, 4 eq), and 1-pentanol (2 mL) were combined 
and heated to reflux for 14 h. The reaction was cooled to rt, diluted with CH2Cl2 (50 mL), 
and washed with 10% aq. KOH (2 x 50 mL), H2O (2 x 50 mL), and brine (50 mL). The 
organic layer was dried (MgSO4), filtered, and concentrated under reduced pressure to 
afford a crude yellow oil, which was purified by flash column chromatography (SiO2, 
7:3/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 0.76). Further purification by 
flash column chromatography (SiO2, 9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), 
Rf 0.23) removed remaining impurities and gave 18 (47 mg, 27%) as a dark yellow solid: 
1H NMR (CDCl3, 400 MHz)  7.36 (t, 1H, J = 7.9 Hz), 6.73 (d, 2H, J = 8.8 Hz), 6.65 (d, 
2H, J = 8.8 Hz), 6.58 (d, 1H, J = 7.3 Hz), 6.23 (d, 1H, J = 8.2 Hz), 4.56 (br t, 1H, J = 5.1 
Hz), 4.19 (s, 2H), 3.22 (q, 2H, J = 6.6 Hz), 2.80 (s, 6H), 2.68 (t, 2H, J = 7.0 Hz), 1.61 (p, 
2H, J = 7.2 Hz), 1.46-1.36 (m, 4H), 1.29 (s, 10H) (Fig. 4.8); 13C NMR (CDCl3, 100 MHz) 
 158.8, 157.4, 144.2, 141.0, 138.1, 116.0, 114.6, 110.4, 104.1, 50.4, 42.5, 42.4, 42.2, 33.5, 
29.7, 29.63, 29.62, 29.53, 29.49, 27.2, 27.0 (Fig. 4.9); HRMS m/z calcd for C24H39N5: 
397.3205; found 398.3260 [M+H]+. 
 
4.6.1.4. Preparation of 2-bromo-6-(1,3-dioxolan-2-yl)pyridine (21). The 
known compound 21 was prepared by following a modified protocol of 
previously reported procedures.55,56 A solution of 6-bromo-2-pyridinecarboxaldehyde (2.0 
g, 10.8 mmol, 1 eq), ethylene glycol (1.2 mL, 21.5 mmol, 2 eq), and methanesulfonic acid 
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(230 L, 3.55 mmol, 0.33 eq) in toluene (65 mL) was heated to reflux in a Dean-Stark 
apparatus for 24 h prior to being cooled to rt and neutralized with saturated aq. NaHCO3. 
The organic layer was separated and the aqueous phase was extracted with Et2O (3 x 50 
mL). The combined organic layers were washed with H2O (3 x 50 mL) and brine (50 mL), 
dried (MgSO4), filtered, and concentrated under reduced pressure to afford a crude yellow 
oil, which was purified by flash column chromatography (SiO2, 1:1/hexanes:EtOAc, Rf 
0.66) to yield 21 (1.81 g, 73%) as a pale yellow oil: 1H NMR (CDCl3, 500 MHz)  7.49 (t, 
1H. J = 7.7 Hz), 7.38 (d, 1H, J = 7.3 Hz), 7.35 (d, 1H, J = 7.9 Hz), 5.68 (s, 1H), 4.06-3.99 
(m, 2H), 3.97-3.90 (m, 2H); 13C NMR (CDCl3, 125 MHz)  158.3, 141.3, 139.0, 128.2, 
119.3, 102.5, 65.4. 
 
 4.6.1.5. Preparation of N1-(6-(1,3-dioxolan-2-yl)pyridin-2-yl)-
N10-(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)decane-1,10-
diamine (22). Compound 21 (500 mg, 2.17 mmol, 1 eq), 
compound 6h (1.25 g, 3.23 mmol, 1.5 eq), CuI (21 mg, 0.109 
mmol, 0.05 eq), L-proline (25 mg, 0.217 mmol, 0.10 eq), K2CO3 (45 mg, 0.326 mmol, 0.15 
eq), DMSO (8 mL), and H2O (800 L) were combined and stirred at 90 °C for 47 h. The 
reaction was cooled to rt, diluted with H2O (150 mL), and extracted with CH2Cl2 (3 x 50 
mL). The combined organic layers were washed with H2O (3 x 50 mL) and brine (50 mL), 
dried (MgSO4), filtered, and concentrated under reduced pressure to afford a crude brown 
oil, which was purified by flash column chromatography (SiO2, 49:1/CH2Cl2:MeOH with 
NH4OH (7 mL/L of solvent) to 19:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent), Rf 
0.41 (9:1/CH2Cl2:MeOH with NH4OH (7 mL/L of solvent))) to yield 22 (249 mg, 21%) as 
a yellow oil: 1H NMR (CDCl3, 400 MHz)  7.84 (d, 1H, J = 9.0 Hz), 7.83 (s, 1H), 7.39 (t, 
1H, J = 7.8 Hz), 7.20 (dd, 1H, J1 = 9.0 Hz, J2 = 1.4 Hz), 6.73 (d, 1H, J = 7.3 Hz), 6.29 (d, 
1H, J = 8.4 Hz), 5.63 (s, 1H), 4.65 (br t, 1H, J = 5.0 Hz), 4.13-4.05 (m, 2H), 4.02-3.96 (m, 
2H), 3.94 (br s, 1H), 3.42 (br t, 2H), 3.15 (q, 2H, J = 6.6 Hz), 2.97 (br t, 2H), 2.60 (br t, 
2H), 1.85 (br p, 4H), 1.59 (p, 2H, J = 7.0 Hz), 1.54 (p, 2H, J = 7.3 Hz), 1.32-1.29 (m, 4H), 
1.23 (br s, 8H); 13C NMR (CDCl3, 100 MHz)  159.4, 158.8, 155.4, 150.8, 148.1, 138.0, 
133.8, 127.5, 124.6, 124.0, 118.4, 115.6, 108.9, 106.0, 103.6, 65.3, 49.6, 42.3, 34.0, 31.7, 
29.42, 29.38, 29.27, 29.26, 27.0, 26.8, 24.5, 22.9, 22.6; LRMS m/z calcd for C31H41ClN4O2: 
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536.29; found 537.35 [M+H]+. 
 
 4.6.1.6. Preparation of 6-((10-((6-chloro-1,2,3,4-
tetrahydroacridin-9-yl)amino)decyl)amino)picolinaldehyde 
(23). A solution of compound 22 (91 mg, 0.170 mmol) in MeCN 
(2.2 mL) and 2 M aq. HCl (1.1 mL) was stirred at 60 °C for 23 h. 
The reaction was cooled to rt, slowly quenched with saturated aq. NaHCO3, and extracted 
with CH2Cl2 (3 x 25 mL). The combined organic layers were washed with brine (50 mL), 
dried (MgSO4), filtered, and concentrated under reduced pressure to yield 23 (81 mg, 96%) 
as a yellow oil, which was used without any further purification: 1H NMR (CDCl3, 400 
MHz)  9.82 (s, 1H), 7.85 (d, 1H, J = 9.1 Hz), 7.84 (s, 1H), 7.48 (t, 1H, J = 7.8 Hz), 7.20 
(dd, 1H, J1 = 9.1 Hz, J2 = 1.9 Hz), 7.15 (d, 1H, J = 7.2 Hz), 6.53 (d, 1H, J = 8.4 Hz), 4.86 
(br t, 1H), 4.03-3.97 (m, 1H), 3.43 (t, 2H, J = 7.2 Hz), 3.27 (q, 2H, J = 6.7 Hz), 2.98 (br t, 
2H), 2.61 (br t, 2H), 1.85 (br p, 4H), 1.62 (p, 2H, J = 7.2 Hz), 1.57 (p, 2H, J = 7.4 Hz), 
1.34-1.30 (m, 4H), 1.24 (br s, 8H); 13C NMR (CDCl3, 100 MHz)  193.8, 159.4, 159.1, 
151.3, 150.9, 148.0, 137.8, 133.9, 127.4, 124.7, 124.1, 118.3, 115.6, 112.0, 111.5, 49.6, 
42.1, 34.0, 31.8, 29.5, 29.4, 29.31, 29.28, 27.0, 26.9, 24.6, 22.9, 22.6; LRMS m/z calcd for 
C29H37ClN4O: 492.27; found 493.20 [M+H]
+. 
 
 4.6.1.7. Preparation of N1-((6-((10-((6-chloro-1,2,3,4-
tetrahydroacridin-9-yl)amino)decyl)amino)pyridin-2-
yl)methyl)-N4,N4-dimethylbenzene-1,4-diamine (19). To a 
solution of compound 23 (64 mg, 0.129 mmol, 1 eq) in EtOH 
(2.5 mL) was added N,N-dimethyl-p-phenylenediamine (18 mg, 0.129 mmol, 1 eq). The 
reaction mixture was heated to reflux for 1 h and cooled to 0 °C prior to addition of NaBH4 
(33 mg, 0.864 mmol, 6.7 eq). The reaction mixture was stirred at 0 °C for 5 min, warmed 
to rt, and stirred for an additional 30 min before quenching with H2O (10 mL) and 
extracting with Et2O (3 x 10 mL). The combined organic layers were dried (MgSO4), 
filtered, and concentrated under reduced pressure to afford a crude yellow oil, which was 
purified by flash column chromatography (SiO2, 19:1/CH2Cl2:MeOH with NH4OH (7 
mL/L of solvent), Rf 0.20) to yield 19 (41 mg, 52%) as a yellow oil: 
1H NMR (CDCl3, 400 
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MHz)  7.888 (d, 1H, J = 1.5 Hz), 7.886 (d, 1H, J = 8.8 Hz), 7.35 (t, 1H, J = 7.7 Hz), 7.25 
(dd, 1H, J1 = 8.8 Hz, J2 = 1.5 Hz), 6.73 (d, 2H, J = 8.6 Hz), 6.64 (d, 2H, J = 8.6 Hz), 6.58 
(d, 1H, J = 7.3 Hz), 6.22 (d, 1H, J = 8.3 Hz), 4.56 (br t, 1H, J = 4.9 Hz), 4.19 (s, 2H), 3.97 
(br s, 1H), 3.47 (t, 2H, J = 7.0 Hz), 3.22 (q, 2H, J = 6.6 Hz), 3.02 (br t, 2H), 2.80 (s, 6H), 
2.65 (br t, 2H), 1.90 (br p, 4H), 1.64 (p, 2H, J = 7.1 Hz), 1.61 (p, 2H, J = 7.4 Hz), 1.39-
1.35 (m, 4H), 1.29 (s, 9H) (Fig. 4.10); 13C NMR (CDCl3, 100 MHz)  159.5, 158.7, 157.4, 
150.9, 148.2, 144.1, 141.0, 138.1, 134.0, 127.6, 124.7, 124.2, 118.5, 115.9, 115.7, 114.6, 
110.4, 104.1, 50.3, 49.7, 42.44, 42.36, 34.1, 31.9, 29.7, 29.5, 29.44, 29.39, 27.2, 27.0, 24.6, 
23.0, 22.7 (Fig. 4.11); HRMS m/z calcd for C37H49ClN6: 612.3707; found 613.3600 
[M+H]+. 
 
4.6.2. Biochemical, biophysical, and computational methods 
4.6.2.1. In vitro AChE and BChE assay 
Compounds of interest were dissolved in sodium phosphate (dibasic) buffer ((100 L), 0.1 
M, pH 8.0 adjusted at rt). AChE was added to the solution of inhibitors (50 L, containing 
0.08 U/mL (~0.29 nM) AChE (final concentration) (Sigma-Aldrich cat #C2888 from eel) 
in sodium phosphate (dibasic) buffer (100 mM, pH 8.0 adjusted at rt)). The mixture of 
inhibitor and enzyme was incubated for 10 min before initiation with a 
DTNB:acetylthiocholine (ATC) (0.25 mM:0.5 mM final concentration, respectively) 
mixture (50 L) in phosphate buffer (100 mM, pH 8.0 adjusted at rt). The reaction was 
monitored at 412 nm taking measurements every 30 sec for 20 min on a SpectraMax M5 
plate reader. Data was corrected with the negative control (no ATC) and normalized to the 
positive control (no inhibitor) using the initial rates (first 2-5 min). All assays were 
performed in triplicate. The data was fitted to a Hill-plot and IC50 values calculated using 
KaleidaGraph 4.1.1. All IC50 values are reported in Table 4.1. All butyrylcholinesterase 
(BChE) experiments were performed using identical conditions substituting 
butyrylthiocholine (BTC) for ATC. 
 
4.6.2.2. In vitro AChE and BChE ROS inactivation assay 
In the wells of a 96-well plate, horseradish peroxidase (0.25 M), H2O2 (100 M), AChE 
(0.08 U/mL, ~0.29 nM), inhibitors (25 M to 13 pM), and DETAPAC (100 M) were 
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dissolved in sodium acetate buffer (50 mM, pH 6.0 adjusted at rt) and incubated at 37 °C 
for 30 min. Note: all concentrations are reported as final concentrations. A 
DTNB:acetylthiocholine (ATC) (0.25 mM:0.5 mM final concentration, respectively) 
mixture in sodium phosphate (dibasic) buffer (50 mM, pH 7.4 adjusted at rt) was added to 
the AChE/inhibitor solution to initiate the reactions. The crude data was processed to obtain 
IC50 values as described in section 4.6.2.1. All IC50 values are reported in Table 4.1. BChE 
experiments were done in an identical manner substituting BTC for ATC. 
 
4.6.2.3. Metal binding studies by UV-Vis and NMR spectroscopy 
The interaction of compounds 6h and 16-19 with 0.5-2 eq of Cu2+ or Zn2+ in EtOH was 
monitored by UV-Vis ([compound] = 40 M (1% v/v final DMSO concentration); 
incubation for 30 min (4 h for Zn2+ binding for cpd 18); rt) (Fig. 4.3). Metal binding 
properties of compound 19 in the presence of A and/or AChE were also studied by UV-
Vis (Fig. 4.4). A (10 M) was treated for 2 min with CuCl2 or ZnCl2 (10 M) in HEPES 
(20 mM, pH 6.6 (for Cu2+) or pH 7.4 (for Zn2+)) and NaCl (150 mM). AChE (10 M) was 
added to the solution containing A and Cu2+ or Zn2+. The resulting sample was incubated 
for 5 min at rt and treated with compound 19 (10 M, 5% v/v final DMSO concentration) 
followed by 5 min incubation. For comparison, optical spectra of the samples generated 
from incubation of compound 19 (10 M) with CuCl2 or ZnCl2 (10 M) for 5 min were 
measured. The interaction of compounds 18 and 19 with ZnCl2 was observed by 
1H NMR 
(Fig. 4.3C,D). Compound 18 or 19 (2 mM) was dissolved in CD3OD and treated with 1 eq 
of ZnCl2. The resulting solution was incubated for 30 min prior to NMR measurement. 
Sequentially, 0.2 eq of ZnCl2 was added to this solution until no further change in the NMR 
spectrum or precipitation was observed. 
 
4.6.2.4. A peptide experiments 
To aliquot the A1-40 (1 mg), it was completely dissolved with the NH4OH provided by the 
supplier, split into 5 aliquots, lyophilized, and stored at -80 °C. For assays, A1-40 solutions 
were prepared by addition of NH4OH (10 L, 1% v/v, aq) to the above aliquots followed 
by dilution with ddH2O to obtain ca. 200 M as determined by UV-Vis (280 nm, rt). For 
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both inhibition and disaggregation experiments (Fig. 4.5A and 4.6A), the buffer solution 
(20 M HEPES, pH 6.6 (for Cu2+) or pH 7.4 (for metal-free and Zn2+), 150 M NaCl) was 
used. For the inhibition experiment, A (25 M) was first treated with either CuCl2 or 
ZnCl2 (25 M) for 2 min at rt followed by addition and incubation of AChE (25 M) for 5 
min (only for AChE-indicated samples). The resulting samples were then incubated with 
compounds 6h and 16-19 (50 M, 1% v/v final DMSO concentration) at 37 °C for 24 h 
with constant agitation. For the disaggregation experiment, A (25 M) was first incubated 
with CuCl2 or ZnCl2 (25 M) at 37 °C for 24 h with constant agitation. The samples were 
then treated sequentially with AChE (25 M, only for AChE-indicated samples) for 5 min 
followed by addition of compounds 6h and 16-19 (50 M; 1% v/v final DMSO 
concentration). These resulting solutions were incubated for an additional 24 h at 37 °C 
with constant agitation. 
 
4.6.2.5. Gel electrophoresis with Western blotting 
The A peptide experiments (described in section 4.6.2.4) were analyzed by gel 
electrophoresis with Western blotting using anti-A antibody (6E10) (Fig. 4.5B and Fig. 
4.6B).34,57 Various A species generated by both inhibition and disaggregation experiments 
were separated by a 10-20% Tris-tricine gel (Invitrogen). The gel was transferred to a 
nitrocellulose membrane and blocked for 2 h with BSA (Sigma, 3% w/v) dissolved in Tris-
buffered saline (TBS, Fisher) containing 0.1% Tween-20 (TBS-T, Sigma). The membrane 
was treated with 6E10 (1:2000; 2% BSA in TBS-T, Covance, Princeton, NJ) overnight at 
4 °C with gentle agitation and probed with a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:5000; Cayman Chemical, Ann Arbor, MI) in 2% BSA in 
TBS-T solution for 1 h at rt. The protein bands were visualized by using the 
ThermoScientific Supersignal West Pico Chemiluminescent Substrate (Fisher). 
 
4.6.2.6. Transmission electron microscopy (TEM) 
TEM samples were prepared following a previously reported method.34,57 Glow-discharged 
grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA) were 
treated with the samples (5 L) from either the inhibition or disaggregation experiment for 
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2 min at rt. Excess sample was removed with filter paper. The grids were washed five times 
with ddH2O, stained with uranyl acetate (1% w/v, ddH2O, 5 L) for 1 min, and dried for 
15 min at rt. A Philips CM-100 transmission electron microscope (80 kV, 25000x 
magnification) was used for obtaining TEM images of the samples (Fig. 4.5C). 
 
4.6.2.7. Effect of metals and A peptide on AChE and BChE inhibition 
The AChE inhibitor 19 (10 M to 5 pM) was dissolved in phosphate buffer (100 L, 100 
mM final concentration, pH 8.0 adjusted at rt), and one of three conditions was followed. 
Conditions (a), (d), and (g): AChE (25 L, 0.08 U/mL final concentration) was added to 
the inhibitor solutions (100 L) and incubated for 10 min prior to addition of CuCl2 or 
ZnCl2 or A peptide (25 L, 10 M final concentration). After 10 min, the reactions were 
initialized with a DTNB:ATC (0.25 mM:0.5 mM final concentration, respectively) mixture 
(50 L) in phosphate buffer (100 mM final concentration, pH 8.0 adjusted at rt). Conditions 
(b), (e), and (h): CuCl2 or ZnCl2 or A peptide (25 L, 10 M final concentration) was 
added to the inhibitor solutions (100 L) and incubated for 10 min prior to addition AChE 
(0.08 U/mL final concentration). After 10 min, the reactions were initialized with a 
DTNB:ATC (0.25 mM:0.5 mM final concentration, respectively) mixture (50 L) in 
phosphate buffer (100 mM final concentration, pH 8.0 adjusted at rt). Conditions (c), (f), 
and (i): A mixture (50 L) of AChE (0.08 U/mL final concentration) and CuCl2 or ZnCl2 
or A peptide (10 M final concentration) (50 L total) was added to the inhibitor solutions 
(100 L). After 10 min, the reactions were initialized with a DTNB:ATC (0.25 mM:0.5 
mM final concentration, respectively) mixture (50 L) in phosphate buffer (100 mM final 
concentration, pH 8.0 adjusted at rt). IC50 values were determined as previously described 
(section 4.6.2.1) and are reported in Table 4.1. Outside of using BTC in lieu of ATC, all 
BChE experiments were performed as AChE experiments. 
 
4.6.2.8. Molecular modeling 
Compound 19 was built using the Sybyl-X software and minimized to 0.01 kcal/mol by 
the Powell method, using Gasteiger-Hückel charges and the Tripos force fields. The 
coordinates of AChE from Torpedo californica (TcAChE) and A1-40 were downloaded 
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from the Protein Data Bank website (PDB codes: 1ACJ and 2LFM, respectively). The H2O 
molecules and all other ligands were removed from the two proteins. Hydrogen atoms were 
added, and the energy of both proteins was minimized separately using the Amber force 
fields with Amber charges. The energy-optimized ligand (compound 19) was then docked 
into the tacrine binding site in the energy minimized tacrine-free TcAChE using GOLD.45 
The parameters were set as the default values for GOLD. The maximum distance between 
hydrogen bond donors and acceptors for hydrogen bonding was set to 3.5 Å. After docking, 
the first-ranked conformation of compound 19 was merged into the corresponding tacrine-
free TcAChE (to determine the proper binding area for A1-40 binding). 
 
The energy-optimized A was then docked close to the surface of TcAChE using GOLD. 
A distance constraint was applied between the H6 residue of A1-40 and the Q74 of TcAChE 
(that was chosen due to its vicinity to the metal-chelator portion of compound 19 in the 
compound 19-TcAChE complex). Here again, the parameters were set as the default values 
for GOLD. The maximum distance between hydrogen bond donors and acceptors for 
hydrogen bonding was set to 3.5 Å. After docking, the first-ranked conformation of A1-40 
was merged into the corresponding tacrine-free TcAChE. The new A1-40-TcAChE 
complex was subsequently subjected to energy minimization using the Amber force fields 
with Amber charges. During the energy minimization, the structure of A1-40 and residues 
within a 7 Å radius were allowed to move. The remaining residues were kept frozen in 
order to save calculation time. The energy minimization was performed using the Powell 
method with a 0.05 kcal/mol energy gradient convergence criterion and a distance 
dependent dielectric function.  
 
Finally, compound 19 was docked into the tacrine binding site in the obtained energy 
optimized A1-40-TcAChE complex as described above. The first-ranked conformation of 






4.6.2.9. Parallel artificial membrane permeability assay adapted for blood-brain 
barrier (PAMPA-BBB) 
Previously reported protocols with modification using the PAMPA Explorer kit (Pion, Inc.) 
were applied to our PAMPA-BBB experiment.34,53,58,59 Each stock solution of the 
compounds was diluted to a final concentration of 10 M (1% v/v final DMSO 
concentration) with pH 7.4 Prisma HT buffer (Pion). The resulting solution (200 L) was 
added to each of the wells of the donor plate (number of replicates per sample = 12). The 
BBB-1 lipid (Pion formulation, 5 L) was used to coat the polyvinylidene fluoride (PDVF, 
0.45 μM) filter membrane on the acceptor plate. The acceptor plate was placed on the top 
of the donor plate generating a “sandwich,” and each well of the acceptor plate was filled 
with the brain sink buffer (200 L, Pion). The sandwich was incubated at rt for 4 h without 
stirring. A microplate reader was used to obtain the optical spectra (250-500 nm) of the 
solutions in the reference, acceptor, and donor plates. The –logPe for each compound was 
calculated using the PAMPA Explorer software c. 3.5 (Pion). CNS+/– assignment was 
determined in comparison to compounds identified previously.53,58,59 Compounds 
categorized as CNS+ have the ability to permeate through the BBB and target the CNS. 
Compounds categorized as CNS– have poor permeability through the BBB, and, therefore, 
their bioavailability into the CNS is considered to be minimal. All values (MW, clogP, 




(1) Thies, W.; Bleiler, L. Alzheimers Dement 2013, 9, 208-245. 
(2) Schliebs, R.; Arendt, T. J Neural Transm 2006, 113, 1625-1644. 
(3) Davis, K. L.; Powchik, P. Lancet 1995, 345, 625-630. 
(4) Ames, D. J.; Bhathal, P. S.; Davies, B. M.; Fraser, J. R. E. Lancet 1988, 331, 887. 
(5) Recanatini, M.; Cavalli, A.; Belluti, F.; Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; 
Valenti, P.; Andrisano, V.; Bartolini, M.; Cavrini, V. J Med Chem 2000, 43, 2007-
2018. 
(6) da Costa, J. S.; Pisoni, D. S.; da Silva, C. B.; Petzhold, C. L.; Russowsky, D.; Ceschi, 
M. A. J Braz Chem Soc 2009, 20, 1448-1454. 
(7) Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Bioorg Med 
Chem Lett 2008, 18, 2905-2909. 
140 
 
(8) Fernandez-Bachiller, M. I.; Perez, C.; Gonzalez-Munoz, G. C.; Conde, S.; Lopez, M. 
G.; Villarroya, M.; Garcia, A. G.; Rodriguez-Franco, M. I. J Med Chem 2010, 53, 
4927-4937. 
(9) Bornstein, J. J.; Eckroat, T. J.; Houghton, J. L.; Jones, C. K.; Green, K. D.; Garneau-
Tsodikova, S. Med Chem Commun 2011, 2, 406-412. 
(10) Chen, Y.; Sun, J.; Fang, L.; Liu, M.; Peng, S.; Liao, H.; Lehmann, J.; Zhang, Y. J 
Med Chem 2012, 55, 4309-4321. 
(11) Antequera, D.; Bolos, M.; Spuch, C.; Pascual, C.; Ferrer, I.; Fernandez-Bachiller, M. 
I.; Rodriguez-Franco, M. I.; Carro, E. Neurobiol Dis 2012, 46, 682-691. 
(12) Eckroat, T. J.; Green, K. D.; Reed, R. A.; Bornstein, J. J.; Garneau-Tsodikova, S. 
Bioorg Med Chem 2013, 21, 3614-3623. 
(13) Hardy, J. A.; Higgins, G. A. Science 1992, 256, 184-185. 
(14) Wang, Y. J.; Zhou, H. D.; Zhou, X. F. Drug Discov Today 2006, 11, 931-938. 
(15) Haass, C.; Selkoe, D. J. Nat Rev Mol Cell Biol 2007, 8, 101-112. 
(16) Jakob-Roetne, R.; Jacobsen, H. Angew Chem Int Ed Engl 2009, 48, 3030-3059. 
(17) Kurz, A.; Perneczky, R. J Alzheimers Dis 2011, 24 Suppl 2, 61-73. 
(18) Inestrosa, N. C.; Alvarez, A.; Perez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; 
Casanueva, O. I.; Soto, C.; Garrido, J. Neuron 1996, 16, 881-891. 
(19) Alvarez, A.; Alarcon, R.; Opazo, C.; Campos, E. O.; Munoz, F. J.; Calderon, F. H.; 
Dajas, F.; Gentry, M. K.; Doctor, B. P.; De Mello, F. G.; Inestrosa, N. C. J Neurosci 
1998, 18, 3213-3223. 
(20) De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. 
C. Biochemistry 2001, 40, 10447-10457. 
(21) Dvir, H.; Silman, I.; Harel, M.; Rosenberry, T. L.; Sussman, J. L. Chem Biol Interact 
2010, 187, 10-22. 
(22) Rydberg, E. H.; Brumshtein, B.; Greenblatt, H. M.; Wong, D. M.; Shaya, D.; 
Williams, L. D.; Carlier, P. R.; Pang, Y. P.; Silman, I.; Sussman, J. L. J Med Chem 
2006, 49, 5491-5500. 
(23) Bourne, Y.; Radic, Z.; Kolb, H. C.; Sharpless, K. B.; Taylor, P.; Marchot, P. Chem 
Biol Interact 2005, 157-158, 159-165. 
(24) Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. Biochem Pharmacol 2003, 65, 
407-416. 
(25) Musial, A.; Bajda, M.; Malawska, B. Curr Med Chem 2007, 14, 2654-2679. 
(26) Mehta, M.; Adem, A.; Sabbagh, M. Int J Alzheimers Dis 2012, 2012, 728983. 
(27) Pithadia, A. S.; Lim, M. H. Curr Opin Chem Biol 2012, 16, 67-73. 
(28) Faller, P.; Hureau, C. Dalton Trans 2009, 1080-1094. 
(29) Drew, S. C.; Barnham, K. J. Acc Chem Res 2011, 44, 1146-1155. 
(30) Scott, L. E.; Orvig, C. Chem Rev 2009, 109, 4885-4910. 
(31) Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem Biol 2013, 8, 856-865. 
(32) Hureau, C. Coord Chem Rev 2012, 256, 2164-2174. 
(33) Hureau, C.; Dorlet, P. Coord Chem Rev 2012, 256, 2175-2187. 
(34) Choi, J. S.; Braymer, J. J.; Nanga, R. P.; Ramamoorthy, A.; Lim, M. H. Proc Natl 
Acad Sci U S A 2010, 107, 21990-21995. 
(35) Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Feather-Stone, R. M. Biochem 
Pharmacol 1961, 7, 88-95. 
141 
 
(36) Gregor, V. E.; Emmerling, M. R.; Lee, C.; Moore, C. J. Bioorg Med Chem Lett 1992, 
2, 861-864. 
(37) Mao, F.; Huang, L.; Luo, Z.; Liu, A.; Lu, C.; Xie, Z.; Li, X. Bioorg Med Chem 2012, 
20, 5884-5892. 
(38) Camps, P.; Formosa, X.; Galdeano, C.; Munoz-Torrero, D.; Ramirez, L.; Gomez, E.; 
Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; 
Andrisano, V.; Arce, M. P.; Rodriguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, 
F. J. J Med Chem 2009, 52, 5365-5379. 
(39) Luo, W.; Li, Y. P.; He, Y.; Huang, S. L.; Tan, J. H.; Ou, T. M.; Li, D.; Gu, L. Q.; 
Huang, Z. S. Bioorg Med Chem 2011, 19, 763-770. 
(40) Fernandez-Bachiller, M. I.; Perez, C.; Monjas, L.; Rademann, J.; Rodriguez-Franco, 
M. I. J Med Chem 2012, 55, 1303-1317. 
(41) Muraoka, S.; Miura, T. Life Sci 2009, 84, 272-277. 
(42) Braymer, J. J.; Merrill, N. M.; Lim, M. H. Inorg Chim Acta 2012, 380, 261-268. 
(43) Wang, Y.; Wang, F.; Yu, J. P.; Jiang, F. C.; Guan, X. L.; Wang, C. M.; Li, L.; Cao, 
H.; Li, M. X.; Chen, J. G. Bioorg Med Chem 2012, 20, 6513-6522. 
(44) Pi, R.; Mao, X.; Chao, X.; Cheng, Z.; Liu, M.; Duan, X.; Ye, M.; Chen, X.; Mei, Z.; 
Liu, P.; Li, W.; Han, Y. PLoS One 2012, 7, e31921. 
(45) Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Proteins 
2003, 52, 609-623. 
(46) Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, 
P. H.; Silman, I.; Sussman, J. L. Proc Natl Acad Sci U S A 1993, 90, 9031-9035. 
(47) Vivekanandan, S.; Brender, J. R.; Lee, S. Y.; Ramamoorthy, A. Biochem Biophys Res 
Commun 2011, 411, 312-316. 
(48) Fernandez-Bachiller, M. I.; Perez, C.; Campillo, N. E.; Paez, J. A.; Gonzalez-Munoz, 
G. C.; Usan, P.; Garcia-Palomero, E.; Lopez, M. G.; Villarroya, M.; Garcia, A. G.; 
Martinez, A.; Rodriguez-Franco, M. I. ChemMedChem 2009, 4, 828-841. 
(49) da Silva, C. H.; Campo, V. L.; Carvalho, I.; Taft, C. A. J Mol Graph Model 2006, 25, 
169-175. 
(50) Alies, B.; Bijani, C.; Sayen, S.; Guillon, E.; Faller, P.; Hureau, C. Inorg Chem 2012, 
51, 12988-13000. 
(51) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv Drug Deliv Rev 
2001, 46, 3-26. 
(52) Clark, D. E.; Pickett, S. D. Drug Discov Today 2000, 5, 49-58. 
(53) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. Eur J Med Chem 2003, 
38, 223-232. 
(54) Spuch, C.; Antequera, D.; Isabel Fernandez-Bachiller, M.; Isabel Rodriguez-Franco, 
M.; Carro, E. Neurotox Res 2010, 17, 421-431. 
(55) Landa, A.; Minkkila, A.; Blay, G.; Jorgensen, K. A. Chemistry 2006, 12, 3472-3483. 
(56) Hamon, F.; Largy, E.; Guedin-Beaurepaire, A.; Rouchon-Dagois, M.; Sidibe, A.; 
Monchaud, D.; Mergny, J. L.; Riou, J. F.; Nguyen, C. H.; Teulade-Fichou, M. P. 
Angew Chem Int Ed Engl 2011, 50, 8745-8749. 
(57) Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y.; Vivekanandan, S.; 
Ramamoorthy, A.; Lim, M. H. J Am Chem Soc 2009, 131, 16663-16665. 
(58) Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. J 
Pharm Sci 2007, 96, 2893-2909. 
142 
 




This chapter is adapted from a published article: Kochi, A.*; Eckroat, T. J.*; Green, K. 
D.; Mayhoub, A. S.; Lim, M. H.; Garneau-Tsodikova, S. Chem Sci 2013, 4, 4137-4145. 
*Denotes equal contribution. 
 
Authors’ contribution: 
TJE synthesized all compounds. 
AK performed all metal binding, A, and blood-brain barrier experiments. 
KDG performed all enzyme inhibition assays. 
ASM performed molecular modeling. 























































The worked described in this dissertation represents a significant contribution to the 
multifunctional hybrid approach for the treatment of AD. In chapter 2, novel series of 
tacrine- and 6-chlorotacrine-mefenamic acid hybrids were synthesized and evaluated for 
AChE inhibition under standard conditions and in the presence of ROS. Several highly 
potent AChEis with low nanomolar IC50 values were identified. As intended, many 
compounds from these series showed improvement in IC50 in the presence of ROS. These 
results have never been seen in a tacrine hybrid before, and the improved IC50 in the 
presence of ROS may have unique in vivo implications. The most potent compound 
identified was 13m (IC50 = 0.418 ± 0.025 nM, ROS IC50 = 0.009 ± 0.003 nM), which 
exhibited >100-fold increase in potency under standard conditions and >20,000-fold 
increase in the presence of ROS when compared to tacrine (1). This compound represents 
one of the most potent tacrine hybrids described to date. 
 
Further study of tacrine-mefenamic acid hybrids is warranted. It was hypothesized the 
formation of a nitrogen radical on the mefenamic acid moiety was responsible for the 
increases in potency in the presence of ROS. To further test this idea, analogs could be 
synthesized that prevent the formation of this radical. It is anticipated that such analogs 
would not show the dramatic increases in potency in the presence of ROS. Initial synthesis 
of several N-methylated analogs has already been accomplished. Surprisingly, these 
analogs still remain highly potent in the presence of ROS (data not shown) indicating that 
factors other than formation of a nitrogen radical on the mefenamic acid moiety may be 





Additional studies of 13m, the most potent tacrine-mefenamic acid hybrid identified, are 
needed to further explore its potential as an anti-AD compound. For example, it remains to 
be seen if 13m is also a potent inhibitor of BChE, which may be important for an anti-AD 
compound as described in chapter 4. Also, while modeling studies suggested that 13m was 
capable of interacting with and blocking with the PAS, this remains to be proven 
experimentally. The propidium displacement assay, which has been successfully used to 
determine the ability of tacrine-melatonin hybrids to interact with the PAS,1 could be used 
for this purpose. Additionally, because of its suspected ability to block the PAS, 13m could 
be tested for its ability to inhibit AChE-induced A aggregation using an assay that has 
been well-established in the literature.1-4 Beyond that, 13m could be tested for drug-like 
properties, such as BBB permeability and metabolic stability, and optimized as needed. An 
optimized version of 13m could then be evaluated in whole cell viability and 
neuroprotection assays to determine toxicity, therapeutic safety range, and ability to protect 
cells from oxidative stress and A-induced toxicities. Ultimately, favorable results in these 
assays may lead to studies using animal models of AD. 
 
In chapter 3, three series of 6-chlorotacrine with linkers varying in terminal functional 
group and length were synthesized, evaluated for AChE inhibition, and compared to tacrine 
and 6-chlorotacrine-mefenamic acid hybrids. Several highly potent molecules (low 
nanomolar IC50 values) comprised of linkers with terminal amines were identified. 
Additionally, the need for covalent linkage of mefenamic acid in regards to AChE 
inhibition was investigated. Results suggest that the mefenamic acid moiety in an amine-
linked tacrine-mefenamic acid hybrid may not contribute to AChE inhibition under 
standard conditions, and the linker moiety alone may be responsible for the increase in 
potency relative to tacrine. However, in the presence of ROS, there may be some advantage 
to covalent linkage of the mefenamic acid moiety in amine-linked tacrine-mefenamic acid 
hybrids. This study represents the first extensive study of the linker moiety and requirement 
for covalent linkage in tacrine hybrids. The methodology used in this study will be 
employed in future work to more fully elucidate the need for covalent linkage in other 
multifunctional hybrids for AD. 
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In chapter 4, 6-chlorotacrine-metal-A modulator hybrid 19 was synthesized and evaluated 
in vitro. Hybrid 19 displayed potent inhibition of AChE (IC50 = 2.37 ± 0.29 nM) and BChE 
(IC50 = 2.01 ± 0.12 nM). Potent inhibition was largely retained in the presence of ROS, 
Cu2+/Zn2+, and A. Testing of inhibition in the presence of ROS, Cu2+/Zn2+, and A has 
never been previously reported for a tacrine hybrid. Additionally, 19 showed remarkable 
multifunctionality through interaction with Cu2+/Zn2+, control of metal-free and metal-
induced A aggregate assembly, and disaggregation of preformed metal-free and metal-
associated A aggregates, while PAMPA-BBB predicted the BBB penetrability of 19. 
Hybrid 19 represents one of the few tacrine hybrids designed to specifically target the 
interplay of AChE/A/metals, and no other tacrine hybrids have been tested in the 
aggregation and disaggregation assays described in this work. Together, these results make 
hybrid 19 a worthy candidate for additional studies, and future directions will largely focus 
on further understanding and improving the properties of this compound. 
 
First, the length of the linker in 19 will be optimized for AChE inhibition and 
AChE/A/metal interaction. As mentioned in chapter 4, the linker length was chosen based 
on the results seen with tacrine-mefenamic acid hybrids. However, it remains to be seen if 
the decamethylene linker gives optimal results for 19 in the biochemical assays used. 
Analogs with shorter and longer linker lengths will be synthesized and tested for this 
reason. Also, the structure activity relationship (SAR) between 19 and A will be 
established. The -N(CH3)2 group of 19 will be replaced with -NHCH3, -NH2, and -H groups 
to determine how the degree of methylation affects the interaction of the hybrid with A 
species. It has been previously established in the literature that the -N(CH3)2 group is 
essential for A interaction when the metal-A modulating moiety 17 is tested alone.5 
However, it remains to be established if the same is true in the hybrid molecule, but it is 
anticipated that analogs with greater degrees of methylation will show greater interaction 
with A peptide. It is also remains to be seen how the degree of methylation affects 
AChE/BChE inhibition, although it is anticipated that the effects will be minimal given the 
predicted binding of the compound. Syntheses of the required hybrids are in various stages 
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of completion, and similar biochemical, biophysical, and computational methods as 
employed previously will be used to determine this SAR.
 
Additionally, the drug-like properties of hybrid 19 will be improved. For example, it is 
anticipated that replacing the polymethylene linker with a polyethylene glycol linker of 
similar length will decrease lipophilicity and increase overall aqueous solubility of the 
compound. Replacement of the pyridine ring of 19 with a pyrimidine ring is another 
possible modification with anticipated similar effects. Increased aqueous solubility may 
provide better performance in biochemical assays (e.g. quantifying interaction of 19 with 
Cu2+/Zn2+) in the short-term, and better performance in whole cell or animal studies in the 
long-term. Syntheses of these hybrids are in preliminary and planning stages. As another 
example, through collaboration with Dr. Mayland Chang (University of Notre Dame), we 
have found that 19 is susceptible to metabolism primarily through N-dealkylation (data not 
shown). Chemical strategies to combat this metabolism are currently being devised. In 
addition, while PAMPA-BBB predicted 19 should be BBB permeable via passive 
diffusion, it remains to be established whether 19 is a substrate for active transport into or 
P-glycoprotein efflux from the CNS. Hybrid 19 will be assessed in cell-based in vitro 
assays for BBB permeability to more accurately predict access to the CNS and chemical 
modifications will be made as needed. An optimized version of 19 could then be evaluated 
in whole cell viability and neuroprotection assays, ultimately progressing to animal studies 
if favorable results are obtained. 
 
Another possible direction includes replacement of the 6-chlorotacrine moiety of hybrid 
19 with donepezil. While the initial biochemical characterization of 19 was very promising, 
this hybrid may ultimately fail in more advanced studies because it contains 6-chlorotacrine 
as the core AChEi, which, as described previously, is hepatotoxic and clinically irrelevant. 
It is anticipated that replacement of the 6-chlorotacrine moiety of hybrid 19 with a 
donepezil moiety will create a second generation hybrid with similar biochemical 
properties and multifunctionality that might ultimately be better suited for future in vivo 
studies. The synthesis of a donepezil moiety with a suitable linkage point has been 
completed. However, chemically linking this moiety with the metal-A modulating moiety 
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17 has posed some synthetic difficulties, and various strategies are being tested. Similar 
biochemical, biophysical, and computational methods as employed previously will be used 
to determine proper linker length and overall properties of this donepezil-metal-A 
modulator hybrid. 
 
Finally, if the donepezil hybrid proposed above is successful, metal-A modulator moieties 
distinct from 17 will be sought for incorporation into novel donepezil-metal-A modulator 
hybrids. One such metal-A modulator is myricetin, a naturally occurring flavonoid with 
multiple metal chelation sites that has been shown to modulate production of metal-
triggered Aβ aggregates, disassemble structured metal-Aβ aggregates, and modulate metal-
Aβ toxicity in human neuroblastoma cells.6 It is anticipated that a donepezil-myricetin 
hybrid may show additional beneficial properties for AD, among them AChE/BChE 
inhibition. Synthesis of this hybrid is in preliminary and planning stages. Similar 
biochemical, biophysical, and computational methods as employed previously will be used 
to determine proper linker length and overall properties of this donepezil-myricetin hybrid.  
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